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1 Introduction 
1.1 Motive and aim of the study 
"Every four hours, day in, day out, a jumbo jet crashes and all on board are 
killed. The 250 passengers are all women... They are all either pregnant or 
have recently given birth to a child". 
This shocking statement was given by Malcolm Potts at the World Health 
Organization's (WHO) interregional Meeting on the prevention of maternal 
mortality, November 1985 (Anonymous 1986). This statement is the more 
intolerable because most of these deaths are theoretically preventable with 
present knowledge and equipment. The majority of maternal deaths occurs in 
developing countries (Royston & Armstrong 1989). It shows the poignant 
inequality in maternal health between the rich and the poor. Postpartum 
haemorrhage is one of the most important causes of maternal mortality in 
developing countries (Kwast, 1991b). 
A Technical Working Group on the prevention and management of postpar-
tum haemorrhage was convened by WHO in Geneva, 3-6 July 1989. A 
consensus was reached on the active management of the third stage of labour 
for all parturients, in particular for those for whom the access to hospital 
services is difficult or time-consuming. The major drawback was to find a drug 
to be used as prophylactic oxytocic that was easy to administer and stable 
(WHO 1990). During the working group, one of the midwives, Barbara Kwast, 
suggested giving oral ergometrine. From that day on the project on oral 
ergometrine began. The core of the ergot-taskgroup was formed by Pieter van 
Dongen (PhD, obstetrician, University Hospital Nijmegen, The Netherlands), Jos 
van Roosmalen, a member of the Technical Working Group in Geneva (PhD, 
obstetrician University Hospital Leiden, The Netherlands), Yechiel Hekster 
(PhD, clinical pharmacist), and Tom Vree (PhD, chemist), both from the 
department of clinical pharmacy, University Hospital Nijmegen, The Nether-
lands. 
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The research project consisted of 3 studies, oriented toward the following 
questions: 
• Pharmaceutical study: Is oral (methyl)ergometrine in contrast to intravenous 
(methyl)ergometrine stable under tropical conditions? 
• Pharmacological study: Are the pharmacokinetic and pharmacodynamic 
properties of (methyl)ergometrine tablets favourable enough to use them as 
prophylactic drugs in the third stage of labour? 
• Clinical study: Do ergometrine tablets have effect on blood loss after 
childbirth, in spite of the answers on the questions mentioned above? 
The three questions are related, but were answered independently. Assuming 
that the pharmacological and clinical study would lead to possitive results, the 
pharmaceutical study was started first as there was doubt about the stability of 
the tablets under tropical conditions. While this stability study was being set up 
and started, the pharmacological and clinical parts of the project were started 
simultaneously. This set up of the research project had been chosen to underline 
the three-fold question, each related to the completely different grounds for 
which an answer had to be given before an answer could be given to the 
principle question: "Is oral (methyl)ergometrine a suitable alternative 
prophylactic drug to prevent postpartum haemorrhage?". Such an approach to 
the question would also detect which aspect (pharmaceutical, pharmacological 
or clinical) might need to be ameliorated. 
This thesis starts with an introduction on prevention of postpartum 
haemorrhage (Chapter 1). It then compares the process of menstruation and 
placental separation, as in the pharmacodynamic study menstruating non-
pregnant women were examined to simulate the process of placental separation. 
Chapter 2 describes the history of ergot alkaloids and summarizes their chemical 
background, pharmacological properties and adverse drug reactions. Chapters 
3, 4, 5 and 6 describe the studies performed with oral and intravenous 
(methyl)ergometrine. Chapter 7 summarizes the results of the separate studies 
and presents the overall conclusions of the complete research project. 
The research project was supported by WHO (Technical Services Agreement 
MHR-0145) and the Dutch "Praeventiefonds" grant no. 28.2196. 
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1.2 Prevention of postpartum haemorrhage* 
Each year at least half a million women die world wide from causes related 
to pregnancy and childbirth. All but about 6000 occur in developing countries, 
which account for 86% of the world's birth. In the USA and Europe the 
maternal mortality rate is very low in contrast to that in developing countries: 
less than 10 deaths per 100,000 live births versus 600-1500 per 100,000 live 
births (Royston & Armstrong 1989). 
Obstetric haemorrhage claims the lives of 150,000 women annually (Kwast 
1991a). It is the most important cause of maternal mortality in the developing 
world (Royston & Armstrong 1989; Kwast 1991b). Obstetric haemorrhage can 
be divided into antepartum (ΑΡΗ) and postpartum haemorrhage (PPH): the 
latter causes most maternal deaths. 
Death from PPH invariably occurs within a few hours after birth. In 
hospitals, where facilities for the prevention and management of PPH are often 
available, the consequences of PPH are possibly less dramatic than elsewhere 
in the health-care system. However, even in developed countries, e.g., the 
Netherlands, PPH causes 13% of all recorded maternal deaths (Schuitemaker et 
al. 1991). Proper management and better prevention are necessary at all levels 
of obstetric care because emergency referral is often difficult to arrange, 
especially in many third world countries. 
This Chapter deals with the prevention of PPH. It elucidates the international­
ly accepted WHO definition (Royston & Armstrong 1989), assesses risk factors 
for PPH and discusses recent trials on management of the third stage of labour. 
All these aspects help to set priorities and delineate strategies to prevent PPH 
and reduce its incidence and the subsequent morbidity and mortality. Guidelines 
for clinical practice of primary prevention are given in the conclusion. 
Based upon: Prevention of postpartum haemorrhage. In: Baillière's Clinical Obstetrics 
and Gynaecology, international practice and research. Preventive care in obstetrics. 
Steegers EAP, Eskes TKAB, Symonds EM, editors. London: Baillière Tindall, 1995a; 
9: 619-631. 
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1.2.1 Definition of PPH 
PPH, defined by the WHO (Royston & Armstrong 1989) as postpartum blood 
loss > 500 ml, is a clinical diagnosis that encompasses excessive blood loss 
after delivery and, if untreated, may result in shock and death of the mother. 
The choice of 500 ml is arbitrary but is a loss that most mothers can tolerate 
without risk. Women who are at risk are those with severe anaemia, eclampsia, 
antepartum haemorrhage, intrapartum blood loss or those who have had a 
difficult instrumental delivery. In countries where many women have severe 
anaemia, maternal blood loss of even 250 ml may be fatal (Lawson 1967). 
Another reason for the 500 ml criterion is that blood loss is often underesti-
mated: accurately measured loss is usually about twice the estimated loss. This 
is particularly so when an estimation of "moderate" blood loss is made; 
estimation of very small or large amounts of blood are more accurate (Brant 
1967; Duthie et al. 1990). The clinical consequences of postpartum blood loss 
depend on both the amount and rate of blood loss and whether the mother's 
health is good, a factor included in part in the definition of PPH. 
Gilbert et al. (1987) reported an incidence of about 10% for PPH in all 
vaginal births in Britain. It is, however, difficult to compare figures on PPH, 
because of large variations in management protocols, different populations 
studied -for instance home deliveries or high risk deliveries in hospital- and 
because blood loss is often estimated rather than measured. These factors are 
important when using the incidence of PPH as a measurement and evaluation 
for care in the third stage of labour. 
1.2.2 Physiology of postpartum bleeding 
The mechanism by which the uterine bleeding stops after placental separation 
is not clearly understood. In fact, concepts of the physiology of the postpartum 
uterus are scarce. 
At least three processes can be discriminated: placental separation, uterine 
activity before and after placental separation and coagulation cascade, 
fibrinolysis after placental separation. Chapter 1.3.3 describes these processes 
extensively. Uterine activity after placental separation can be described by 
retraction and contractions. Retraction is the start of the involution of the uterus, 
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characterized by shortening of the uterine musculature, despite relaxation of 
individual muscle fibres and increasing intra-uterine tone (Knaus 1948). 
Contractions are characterized by the short period in which the muscle fibres 
contract and which are followed by relaxation of the muscle fibres. 
Disturbances in postpartum bleeding (PPH) may be explained by interference 
with retraction, a retained placenta or a full bladder (to be diagnosed by a high 
positioned or flaccid uterus), disturbances of uterine contractility or intra-uterine 
coagulation, as will be explained in Chapter 1.3. 
Prevention of PPH includes facilitating retraction, which means preventing 
a full bladder and reassurance of the absence of retained placental fragments. 
When the bladder is empty and the placenta is completely born, oxytocic drugs 
enhancing uterine contractility lower further blood loss. 
1.2.3 Primary prevention of PPH 
"Risk factors" for PPH and the use of the risk approach in primary 
prevention of PPH 
Primary prevention includes the prophylactic treatment of those women at risk 
for PPH. The main causes of PPH are (Kapernick 1991): 
1. Disturbance of uterine retraction (often called uterine atony) 
(frequency > 50%); 
2. Vaginal/ cervical lacerations (frequency ± 20%); 
3. Retained placenta (or placenta fragments) (frequency ± 5-10%); 
4. Coagulation defects (low frequency). 
Risk factors for PPH, are given in Table 1.2.3.1. There are two categories of 
risk factors: those predisposing a woman to be at "moderately" or "very high" 
risk for developing PPH. All the risk factors in Table 1.2.3.1 predispose mainly 
to disturbance of uterine contraction, the prime cause of PPH. Vaginal or 
cervical lacerations may occur after any delivery, although they usually result 
from precipitate, uncontrolled or instrumental deliveries. In case of PPH, the 
doctor or midwife should always check that excessive bleeding is not also 
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caused by lacerations since PPH may result from a combination of causes. 
Retention of placental fragments may be due to placental abnormalities or 
mismanagement of the third stage and this often leads to disturbance of uterine 
contraction. The recurrence risk (RR) of retained placenta is 2.4 and of PPH 3.3 
(Hall et al. 1985). 
There is no uniform definition of risk factors for PPH. Management differs 
according to the factor. Data on their relative importance or frequency are rare 
(Combs et al. 1991; Stones et al. 1993). If a woman has a risk factor, this does 
not immediately imply that she should not have her baby at home or that intra­
venous treatment facilities have to be available during labour. For instance, 
nulliparity is a risk factor, but, in the Netherlands, nulliparity is no contra­
indication for a home delivery. When the nulliparous woman has her baby at 
home, she will not get routine active management of the third stage, as this is 
(still) not the standard management protocol. Factors given in Table 1.2.3.1 are 
generally accepted as risk factors for PPH, but their relative risk on PPH varies. 
This may explain why the third stage is managed in different ways. 
Women with one of the factors in Table 1.2.3.1 are judged to be at "high" 
risk for PPH. The group at "very high" risk should deliver in a hospital with 
proper facilities for managing PPH. Appropriate referral only occurs if risk 
factors are easily identified an almost unrealistic goal. 
Table 1 2.3.1 Risk factors for PPH stratified in "moderately" and "very" high risk 
Moderately high risk for PPH 
- nulliparity, grand multiparity > 5 г м 
- priming; induction or augmentation 
of labour11' 
- long 1 st and/or 2nd stage' ' * 
- instrumental deliveries'3' 
- tocolysis prior to delivery' 
Very high risk for PPH 
- history of PPH ( К І ^ З . З ) 1 4 ' 
- history of retained placenta (RR=2.4)'" 
- anticoagulant therapy ' 
- uterine fibroids ! 
- antepartum haemorrhage" 
- polyhydramnios" 
- multiple pregnancies'" 
1 = Stones et al 1993 3 = Gilbertetal 1987 5 = van Dongen et al 1991 
2 = Kwast, 1991b 4 = Halletal 1985 6 = Begley, 1990 
RR = recurrence risk 
14 
Moreover, women at low risk for PPH are not excluded from excessive loss 
of blood after delivery. Therefore, implementation of the risk approach in 
preventing PPH will not be suitable in circumstances where a woman's 
immediate referral to a hospital is logistically impracticable, as is the case in 
many third world countries. In these circumstances preventive measures against 
PPH are required for all women, not only for those at "high" risk for PPH. This 
has also been recommended by a WHO Technical Working group on prevention 
and management of PPH (1990). It has been suggested that PPH should be 
prevented by active management of the third stage. Identification of women 
who are at "low" or "high" risk for PPH is only of use in those countries where 
pregnant women in the low risk group have immediate access to a hospital with 
facilities to manage PPH. 
Active management 
Active management of the third stage of labour includes prophylactic 
administration of any parenteral oxytocic drug, early clamping of the umbilical 
cord and controlled cord traction. It implies a "cascade of interventions" in 
managing the third stage of labour. Whether these interventions themselves 
cause complications in women at low risk for PPH has never been studied. 
Routine use of oxytocics and active management of the third stage still remains 
a controversial issue (Inch 1985; Thilaganathan et al. 1993). 
When analyzing trials to compare active versus expectant management 
procedures, we met several problems: 
• Management protocols for third stage of labour vary from hospital to hospital 
within a country; including: 
active management only in cases in which there is an increased 
risk for third stage complications (e.g. a history of previous third 
stage complications; prolonged labour, instrumental delivery, use 
of oxytocic drugs in the first or second stage of labour, multiple 
pregnancy) 
awaiting signs of placental separation, after which the placenta is 
delivered by the mother's own efforts or by fundal pressure or 
controlled cord traction by the birth attendant. 
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The term "expectant" management is confusing because it means different 
things to different people. For example, in the Netherlands, it means 
waiting for signs of placental separation, after which the placenta is 
delivered either by maternal effort alone, or maternal effort aided by 
fundal pressure. In some parts of Africa it means controlled cord traction 
without a prophylactic oxytocic. In the United Kingdom it usually means 
no intervention of any kind other than to stimulate the mother to deliver 
the placenta, as soon as signs of separation are present. Investigators are 
used to their own management protocols and thus are often unfamiliar 
with the "trial" policy, which influences the outcome of the trial. 
• The behaviour of the person responsible for the delivery might be influen-
ced by the knowledge that no oxytocic is given and therefore influences 
the results of the study, as was suggested in the Bristol trial (Prendiville 
et al. 1988b). At present, 98% of obstetric units in the United Kingdom 
routinely use active management and British obstetricians would now con-
sider management without the use of oxytocic drugs "unethical". 
• A proper double blind trial is not possible. The use of drugs (either 
medication or placebo) is always different from "expectant" management. 
• Inclusion criteria for the different trials are not equal, because there is no 
uniform definition of "high" and "low" risk groups for PPH. 
These practical difficulties give rise to different trial outcomes and to 
controversial opinions about management of the third stage. The evidence 
of the effectiveness of active management with an oxytocic was mainly 
based on a meta-analysis of controlled trials (Elbourne et al. 1988; 
Prendiville et al. 1988a) and on the outcome of the Bristol third stage trial, 
conducted by Prendiville, one of the WHO Working Group participants 
(Prendiville et al. 1988b). He advocates routine active management of the 
third stage of labour. 
Thilaganathan et al. (1993) on the other hand expressed disagreement with 
the need for active management in the group of women at low risk for 
PPH. 
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Effectiveness of active management with oxytocic drugs 
The effectiveness of active management with an oxytocic drug can be judged 
by examining the meta-analysis of controlled trials. After administration of any 
oxytocic drug an average decrease of 40% in the incidence of PPH was noted, 
from 10% to 6%. The incidence of PPH, defined as a postpartum blood loss 
>500 ml, was reduced to 5.9% as compared to 17.9% after expectant manage-
ment. Moreover, there was less need for additional oxytocic drugs after 
prophylactic administration (Prendiville et al. 1988b). 
Even women at low risk for PPH showed significant beneficial effects from 
active management: they had less blood loss and required less oxytocin (odds 
ratio 0.28 and 20 resp; 95% confidence interval: 0.20-0.39 and 0.15-0.26, resp. 
(Elboume et al. 1991)). The study populations included women at both low and 
high risks for PPH. Centres participating in the studies were accustomed to the 
"active" management protocol when the trial was started. The results of the 
Bristol (Prendiville et al. 1988b) and Dublin (Begley 1990) trials accorded with 
those of the two trials mentioned above, reported in the meta-analysis. However, 
in the Dublin trial (Begley 1990), the low risk women faced an increased risk 
of manual removal of the placenta after active management with ergometrine 
0.5 mg intravenously given. Recently it has been suggested that active manage-
ment does not reduce blood loss in women at low risk for postpartum haemor-
rhage (Thilaganathan et al. 1993). Therefore, we question the need for active 
management in the group of low risk women as a routine in countries where 
acute management of PPH in hospital is readily available. A randomised trial, 
investigating whether or not expectant management is preferable in women at 
low risk for PPH, is best conducted by midwives because they are used to this 
management protocol. 
However, in countries with difficult access to hospitals, the prophylactic use 
of an oxytocic drug is justifiable to reduce both the risk of PPH and the need 
for further oxytocic therapy. The main reason for this strategy is that the risk 
approach is not a practical tool for dividing women at the lowest level of 
obstetric care into a group for whom active management is mandatory and 
another group for whom "expectant" management can be allowed. 
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Table 12 3 2 Oxytocics used as prophylaxis for postpartum haemorrhage after vaginal 
delivery 
Drug 
• Ergot alkaloids 
ergometnne (E) 
methylergometnne 
synlometnne (sE) 
(0 5mg E+ 5IU ОТ) 
• Oxytocin (ОТ) 
• Prostaglandins 
sulprostone 
(ME) 
Route of administration 
oral· (M)E 
intramuscular· (M)E,sE 
intravenous. (M)E 
buccal 
intramuscular 
intravenous 
intramuscular 
lntramyometnal (25(^g) 
Remarks 
-> serious side effects 
-> drug of choice 5 IU 
-> not as prophylaxis 
modified from van Dongen el al, 1991 
Choice of an oxytocic 
Any oxytocic drug reduces the incidence of PPH by about 40%. The question 
is which one to choose. The decision depends on factors such as: effectiveness 
of the drug, its adverse side-effects, its route of administration and its stability 
under extreme (tropical) conditions. Oxytocic drugs can be divided in three 
pharmaceutically different groups (Table 1.2.3.2). 
Mechanism of action 
• (Methyl)ergometrine 
Methylergometrine and ergometrine maléate decrease the blood loss 
postpartum by enhancing the muscle tone of the uterus, superposed by fast 
rhythmic contractions of the myometrium, the so-called tetany. As a corollary 
the myometrial blood vessels are compressed resulting in the restriction of the 
loss of blood. The tetany continues for several hours; the mean terminal half life 
elimination is about 120 minutes (Anonymous 1988a). Recently, interindividual 
variation in pharmacokinetics have been described (de Groot et al. 1994a; 
1994b). 
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• Oxytocin 
The human myometrium contains oxytocin receptors. During labour the 
amount of oxytocin receptors in both the myometrium and decidua increases 
(Fuchs & Fuchs 1984). Therefore, an injection with oxytocin will result in fast 
and long lasting contractions, upon the basal tone of the myometrium (Brindlye 
& Sokol 1988). The plasma half-life of oxytocin in vitro is 3 to 5 minutes. This 
short half life often necessitates an intravenous infusion to produce sustained 
activity. Syntometrine (5 IU oxytocin + 0.5 mg ergometrine) has been designed 
to take advantage of the rapid onset of action of oxytocin, with the longer 
action of ergometrine. Recently, a long-acting synthetic analogue of oxytocin 
(carbetocin) has been developed with a rapid onset of action and a prolonged 
duration of action relative to oxytocin. Its half life is about 40 minutes (Sweeny 
et al. 1990). The effectiveness of carbetocin compared with oxytocin awaits 
further studies. 
* Prostaglandins 
The uterotonic action of prostaglandins is independent of gestational age. 
After both local and systemic administration it gives a strong myometrial 
contraction resulting in an increased uterine tone. The use of prostaglandins as 
prophylaxis in third stage is not widely practised (Hayashi 1990; Poeschmann 
et al. 1991). Because of its fast and strong effect on the uterus its role in 
management of atonic uterine bleeding, however, is quite promising (Hayashi 
1990, van Dongen et al. 1991). van Dongen et al. (1991) advocate intra-
myometrial administration of 250 μg (Table 1.2.3.2). However 250 μg 
sulprostone costs 50 times as much as 0.2 mg metherginR. 
Effectiveness 
A randomised controlled trial of oxytocin versus Syntometrine showed that 
intramuscular oxytocin 10 IU was as effective as Syntometrine in preventing 
PPH. The latter caused more nausea and vomiting and had a greater 
hypertensive effect than oxytocin (McDonald et al. 1993). Therefore, oxytocin 
is the oxytocic of choice when used as an intramuscular or intravenous 
preventive treatment for PPH (Prendiville et al. 1988b; Begley 1990; van 
Dongen et al. 1991; Hogerzeil et al. 1994). Whether the usual 5 IU oxytocin 
will also have similar effects remains to be settled. 
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Adverse side-effects 
• (Methyl)ergometrinc 
The prophylactic use of ergometrine in the management of third stage was 
criticized in 1962 by Ringrose. In 1993 we also reported numerous side effects 
of intravenous (methyl)ergometrine (de Groot et al. 1993)(see Chapter 2.4). Due 
to its serious and unpredictable side-effects, its place among the oxytocics is 
controversial in prevention of PPH. 
• Oxytocin 
Oxytocin has less (severe) side-effects than ergometrine, though severe 
hypotension may occur after intravenous administration of 10 or even 2 IU 
oxytocin (Hendricks & Brenner 1970; Johnstone 1972; Anonymous 1988b). 
• Prostaglandins 
Gastrointestinal side effects after local intracervical/intramyometrial adminis-
tration of sulprostone are reported (Fruzzetti et al. 1988). Fatigue, dizziness, and 
headache have been observed in some patients treated with sulprostone. Acute 
myocardial infarction is possibly associated with the spasmogenic properties of 
sulprostone after intramuscular administration (Ulmann et al. 1992). 
Route of administration 
Drugs used for the prophylaxis of PPH at the most peripheral level of 
obstetric care should be easy to administer. In most countries traditional birth 
attendants (TBA's), even after training, either do not have the skills to give 
injections or are not allowed to use oxytocic drugs. Therefore, different routes 
of administration are advisable, preferably one by mouth. (Methyl)ergometrine 
is the only oral oxytocic available. The feasibility of oral (methyl)ergometrine 
as prophylaxis for PPH has been tested in a trial in our department. 
Stability 
Instability of oxytocics during transport and storage in hot climates is a major 
problem (Walker et al. 1988; Hogerzeil et al. 1994). Oxytocin is the most stable 
injectable oxytocic. 
• The best choice of oxytocics for prophylactic use in third stage is 
oxytocin 5 IU given intramuscularly. 
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1.2.4 Conclusion 
Primary prevention of PPH is advocated at all levels of obstetric care. This 
implies active management of the third stage also at the first and most 
peripheral levels of obstetric care, where access to hospital services is difficult 
or time-consuming. Women at "very" high risk for PPH should deliver in 
hospital. In these women prevention and anticipatory management includes 
availability of intravenous treatment as well as active management with an 
oxytocic. This is summarized in the flowchart: "Guidelines for clinical practice" 
(Figure 1.2.4.1). 
Guidelines for clinical practice 
women at high risk 
for PPH 
very high 
hospital delivery 
active management 
management third 
stage of labour 
moderately high 
active management 
women at low risk 
for PPH 
> 20 mm from hospital 
active management 
< 20 min from hospital 
'expectant" 
management 
Figure 1.2.4 1 Flowchart illustrating guidelines for clinical practice 
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1.3 The process of menstruation and 
placental separation 
A model has been constructed to assess the pharmacodynamic properties of 
methylergometrine on the uterus. A comparison between the menstruating uterus 
and the postpartum uterus is described. Because of the similarities between the 
non-pregnant and pregnant situation, it was thought that studies during 
menstruation would be also valid during the phases of placental separation. 
1.3.1 Uterine structure, vascularisation, and contractions 
The uterine wall consists of three parts, from outside to inside. There are the 
perimetrium, the myometrium and the endometrium. The perimetrium is a 
modification of the peritoneum. The myometrium is the contractile element 
which however is not a uniform muscle. It is composed of smooth muscle cells 
from mesodermal origin, consisting of two layers having different structure and 
function: the archemyometrium (old inner layer of the uterus) and the para or 
neomyometrium (younger outer layer of the uterus) (Daels 1974). The en-
dometrium consists of a functional (lamina functionalis) and a basal (lamina 
basalis) layer. After conception the lamina functionalis is called decidua. 
Uterine structure 
The human uterus develops in the eighth week of embryonic life when the 
ends of the paramesonephric (Miillerian) ducts fuse. Between the fifth and the 
seventh month, the primordial musculature of the uterine body develops 
producing a modification of the circular musculature from the Miillerian ducts, 
which are connected by horizontal fibres at the midline. Even during pregnancy 
two sets of oblique spirals cross each other. This so-called circular layer is 
derived from primordial musculature forming the inner parts of the uterine body 
as well as most of the isthmic region. A longitudinal layer is formed between 
the circular layer and the peritoneum (Goerttler 1931; Fuchs & Fuchs 1991) 
(Figure 1.3.1.1). Renn (1970) described the structure of the myometrium 
differently. In his histologic studies he found that muscle bundles were arranged 
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in a three-dimensional network, running in all directions instead of having a 
strict structure. He emphasized the importance of the muscle sheaths around the 
arterial and venous vessels. However, whichever opinion is correct, the typical 
arrangement of the circular muscular layer provides a strong uterine wall, allows 
three-dimensional expansion without compromising wall strength during 
pregnancy, and causes a compression of arterial (and venous) blood vessels 
during contraction of muscle cells. This might explain the relative limited 
amount of blood loss during menstruation (Markee 1950) or at placental 
separation (Renn 1970). 
The muscular tissue of the uterus is responsible for the myometrial contractile 
activity. The fundal uterine part contains 80% musculature, gradually decreasing 
towards the cervix with approximately 15% muscular tissue. The muscular 
proportion of the cervix is not uniform; it decreases gradually towards the distal 
Figure 1.3.1 1 Typical arrangement of circular uterine muscle layer schematically 
showing its three-dimensional expansion. 
a. at rest: two sets of crossing spirals 
b. at term1 stretching of two crossing spirals 
(Reproduced with permission of Morphologischer Jahrbuch, Figure 21 from Goerttler 1931) 
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portion, from 30% in the isthmic region to 7% in the last third segment. In the 
third month of pregnancy, the isthmus lengthens and widens down to the level 
of the histologic internal os. This process is complete in the fifth month of 
pregnancy, and the isthmus is now part of the uterine wall. The anatomic 
ostium internum functions as a sphincter between the (thickening) upper uterine 
segment and the lower uterine segment. The cervical fibrous connective tissue 
is a determining factor in holding a pregnancy until term (Danforth 1974; van 
Dongen et al. 1991). 
Uterine vascularisation 
The uterus is supplied by two major vessels: the uterine and ovarian arteries. 
The most important blood supply is through the uterine arteries, both of which 
separate into ascending and descending (vaginal) branches. The ascending 
branch supplies the uterine body by the arcuate arteries, which course through 
the myometrium parallel to the lumen. Radial arteries split off and provide the 
myometrium with blood through myometnal flow. After passing the 
myoendometrial junctions, the radial arteries continue in the direction of the 
surface endothelium in a corkscrew appearance and are called spiral arteries. 
The vasculature of the endometrium is well summarized by Ramsey (1977). 
In the non-pregnant uterus, the coiling of the spiral artery increases during 
proliferation and secretion phases. It forms an arcade by turning back towards 
its origin, forming a subepithelial plexus. From the plexus the blood drains to 
the myometrial arcuate veins into the uterine vein. The spiral arteries are end-
arteries, and, therefore there are no arterio-venous shunts (Flowers & Wilbom 
1978; Christiaens 1981). Studies in non-pregnant women using two thermistor 
probes showed a reduction of endometrial blood flow at the onset of 
menstruation (Hansson 1987). 
During pregnancy, the composition of the spiral arteries changes by the 
altered endocrinologie conditions. The resulting "funnels" create a low resistance 
vascular bed in the intervillous space (IVS), which facilitates increased utero-
placental blood flow during pregnancy (Fuchs & Fuchs 1991). Pijnenborg 
(1994) recently reviewed morphological studies on endovascular trophoblast 
invasion in humans. He describes a first wave of trophoblast invasion at 8 
weeks and a second, at 14-15 weeks. During the second wave, the disruption 
of smooth muscle layers in the inner myometrium takes place. After this 
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process, the invasion normally stops, and as this is a strictly controlled process 
staying within physiological limits, it does not lead to haemorrhage or 
thrombosis in physiological circumstances (Kliman 1994). Although the 
mechanisms are still not fully understood, the role of the trophoblast is crucial 
in keeping this process within physiological barriers (Pijnenborg 1994). 
The uterus has no auto-regulation which means that uterine vascular 
resistance is not adjusted to sustain a uniform blood flow when the flow 
changes (Moll 1974; Low 1977). Maternal blood enters the intervillous space 
from the endometrial spiral arterioles as systolic "spurts" (Ramsey 1977). The 
word "spurt" suggests a head of pressure, close to normal arterial pressure 
values. For obvious reasons these values are not known. It is noteworthy to 
know that the pressures measured in the placental spiral arteries of the rhesus 
monkey did not exceed 20 mmHg (Moll et al. 1974). If this is also the case in 
the human, one must conclude that the architecture of the spiral arteries with 
their wide nozzles at the end, invaded by trophoblast, markedly reduces the 
head of arterial pressure in blood flow to the placenta. This would favour a 
marsh-like intervillous blood flow, a low pressure medium at the placental bed, 
and a low-pressure arterial "flow" in the remaining uterine bed when the 
placenta is expelled. Blood pressure in utero-placental arteries drops from 70-80 
mmHg to a mean value of 10 mmHg in the IVS in a relaxed uterus and to 30-
50 mmHg during uterine contractions; the maternal blood then passes into the 
utero-venous plexus (< 8 mmHg) (Hendricks 1959; Hamilton & Hamilton 
1977). Utero-placental flow is affected by muscular activity. In studies using 
an electromagnetic flow probe in ewes, flow reduction is observed with each 
uterine contraction. During delivery uterine blood flow decreased minimally; a 
second diminution followed placental expulsion (Greiss 1965). Lees et al. 
(1971) demonstrated with radio-nuclide microspheres a diminution of blood 
flow to the maternal placenta during contractions. In pregnant women, a 
decreased utero-placental blood flow (with vast inter-individual differences) 
was observed by radio-angiographic methods after each uterine contraction 
independent of the level of intra-uterine pressure elevation (Borell et al. 1964). 
The passive constriction of spiral arteries by increasing intra-uterine pressure 
during contraction, the rise in IVS-resistance secondary to IVS-compression, 
and possible hormonal factors influencing vascular activity are said to decrease 
utero-placental flow during contraction (Low 1977). Myometrial blood flow is 
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essential in supplying the uterine muscle with its nutrients. Only a small part 
from the uterine blood flow is distributed to myometrium. Experiments in 
rhesus monkeys showed that the myometrial blood flow is hardly affected by 
uterine contractions. This was shown in both the non-pregnant uterus and the 
uterus at term (Lees et al. 1971). Rosenfeld (1980) performed studies 
immediately postpartum in chronically instrumented ewes with radio-nuclide 
microspheres and could not demonstrate significant changes in myometrial 
blood flow. 
Uterine contraction 
Excitation of myometrial smooth muscle cells 
The myometrial smooth muscle cell consists of contractile proteins which are 
organized in a contraction-relaxation model, as are other smooth muscle cells. 
Their typical intracellular organization enables the smooth muscle to develop 
force over a broad range of operating length (Fuchs & Fuchs 1991). The 
smooth muscle cell can be activated by either electrical or hormonal stimulus. 
Hormone binding to a receptor at the cell surface, called pharmacomechanical 
coupling, can activate a chain of events which eventually leads to muscle 
contraction (Wray 1993). Unique for the myometrium is the hormonal influence 
on the biosynthesis of contractile proteins and other cellular constituents of 
importance for excitability of the cell and propagation of excitation from cell 
to cell (Fröhlich 1974). The presence of gapjunctions in the uterine smooth 
muscle cell leads to simultaneous and co-ordinated muscular contractions at 
time of parturition. The formation of gapjunctions, a steroid dependent 
phenomenon, plays an important role in the onset of co-ordinated uterine 
activity (Garfield 1977; Ramondt 1991). Experiments in rats show that the 
amount of gapjunctions depends on time of gestation. A maximum of 
gapjunctions was seen 3-6 hours after onset of delivery. During the postpartum 
period, a rapid, i.e. within 12 hours, resolution of gapjunctions was observed in 
Raymondt's study. The sudden decline in oestrogen-receptors, the rise in 
progesterone concentration and progesterone receptors, and the decline in 
mechanical uterine muscle tension have been proposed as a possible explanation 
(Saito et al. 1985). 
The current opinion is that myosine light-chain kinase activated by the Ca2" 
calmodulin complex, results in phosphorylation of the myosine light-chain 
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which leads to smooth muscle contraction (Fuchs & Fuchs 1991). Ca2* enters 
the cell through either a voltage or hormone controlled Ca2'-channel (Carsten 
& Miller 1987). Experiments with skinned muscle tissues of human 
myometrium suggest that in human myometrium both the amount of contractile 
proteins and the sensitivity to Ca2* may increase at term as compared with the 
non-pregnant state (Izumi et al. 1990). They recently suggested that calmodulin 
(intracellular receptor for Ca2*) increases the Ca2* sensitivity for contractile 
elements (Izumi et al. 1994). 
Cyclic activity 
The contractile function of the myometrium seems to depend merely on 
intrinsic factors (Fuchs & Fuchs 1984). The myometrium is known to have a 
(cyclic) characteristic repetitive activity-pattern, independent of whether it is a 
non-pregnant, a pregnant, or a postpartum uterus (Eskes 1962; Hein 1972). The 
contractions noted in the puerperium show about the same pattern as those 
present early in the menstrual period (Eskes 1962; Hein 1972) (Figure 1.3.1.2). 
There is no marked difference between the contractions of primiparous or 
muciparous women. The cyclic activity of the myometrium clearly shows 
interindividual differences. Patterns characteristic for the different phases of the 
menstrual cycle (menstrual, early pre-ovulatory, mid-pre-ovulatory, peri-ovulato-
ry, and late postovulatory (the late luteal phase) remain present during 
registration (Hendricks 1966; Hein 1972). This cyclic pattern might be caused 
by the different levels of progesterone and oestrogens. Acute withdrawal of 
oestrogen is associated with marked increase in the generation of spontaneous 
myometrial activity; this is also observed during the early postpartum period in 
the rat (Fuchs & Fuchs 1984; Fuchs & Poblete 1970). 
In addition to the cyclic changes of the myometrium, differences in 
innervation and concentration of oxytocin receptors exist between the non-
pregnant, pregnant, and puerperal uterus. Maternal endogenous hormonal 
circadian rhythms exist and may play a role in the sensitivity of the oxytocin 
receptors, myometrial activity and timing of delivery (Honnebier 1993). 
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Comparison intra-uterine pressure (IUP)-recordings during menstruation and 
immediately postpartum. 
IUPÎ 
m m Hg 
Time (minutes) 
Figure 1.3.1.2 
Top-trace: IUP-recording at 2nd day of menstruation; three little blocks represent 
one minute. (Reproduced with permission of Hein, figure 3 from Hein 1972) 
Bottom-trace: IUP-recording 1 hour postpartum; three little blocks represent one 
minute. (Reproduced with permission of Eskes, figure 23 from Eskes 1962) 
Factors influencing uterine contractility 
The following factors possibly influence contractility of the non-pregnant, 
pregnant and puerperal uterus although their contribution differs during various 
hormonal conditions (Hein 1972, Wray 1993). 
• Intrinsic activity of the uterus and uterine distension 
• Adrenergic autonomic nervous system 
• Progesterone and oestrogens 
• Prostaglandins and oxytocin 
• Metabolic factors 
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• Intrinsic activity of the uterus 
Both the structure of the uterine musculature and the muscular content of 
uterine body and cervix are essential determinants for the process of contraction 
power of the (non)-pregnant and postpartum uterus. The increase of uterine 
volume during pregnancy is an important stimulus for myometrial growth. 
Stretch in general, or distension in case of the uterus, stimulates smooth muscle 
contraction. It is not clear whether stretch leads to contraction directly or 
indirectly by stimulating other e.g. hormonal factors (Wray 1993). 
• Adrenergic autonomic nervous system 
The uterus is innervated by autonomic nerves, forming a dense plexus: the 
uterovaginal plexus. It contains a mixture of sympathie, parasympathic and 
afferent nerves. Adrenergic innervation is under hormonal control; in fact the 
role of external innervation is not clearly understood as the nerve endings do 
not have a close apposition to the separate smooth muscle cells. This 
corresponds with the knowledge that all separate smooth muscle cells can 
function as a single tissue. 
Adrenergic autonomic innervation diminishes during pregnancy (Sjöberg 
1967). Experimental studies in chronically instrumented oophorectomized ewes 
show that the autonomic nervous system or its receptors do not play a role in 
maintenance of spontaneous myometrial activity as the uterus can contract 
without an external nerve supply (Verhoeff 1985). Myometrial strips removed 
from the body will continue contracting rhythmically, without neuronal or 
hormonal stimuli, as shown in many in vitro studies (Wray 1993). 
• Progesterone and oestrogens 
Administration of oestradiol induces the formation of gapjunctions, which is 
associated with an increase in co-ordination of myometrial activity; on the other 
hand, progesterone inhibits formation of gapjunctions (Garfield 1977). In 
oophorectomized ewes, the concentration of estradiol rose sharply 12 hours 
before delivery, while plasma progesterone levels fell four days before delivery 
(Verhoeff 1985). Saito et al. (1985) suggest that it is not the estradiol-concen-
tration per se but its receptor-pharmacokinetics which determine the number of 
gapjunctions. Based on this study in rats, Saito et al. (1985) emphasize the 
importance of estradiol and progesterone nuclear receptors and their relation 
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with the number of gapjunctions. It is generally accepted that changes in 
hormone receptor-levels are related to an increase in gapjunction area. An 
increase in the gapjunction area improves the co-ordination of contractility of 
the uterus, and, thus the onset and process of labour (Fuchs & Fuchs 1991; 
Wray 1993). 
• Prostaglandins and oxytocin 
Prostaglandins give strong contractions (Frölich 1974) in a non-pregnant 
uterus and influence myometrial activity and contractions (Ramondt 1991). In 
oophorectomized ewes inhibition of prostaglandin synthesis interferes neither 
with an estradiol-induced increase in number of gapjunctions nor with the 
improvement in the co-ordination of myometrial activity (Verhoeff 1985; 
Ramondt 1991). Recently, Izumi et al. (1994) suggested that Prostaglandines 
induce contractile responses due to Ca2* release from store-sites while oxytocin 
can release Ca2h, only indirectly. 
Regulators for initiation of parturition are still not fully understood. An 
important role is attributed to oxytocin receptors, the concentrations of which 
increase 100 to 200 fold during pregnancy, similiar to concentration of oxytocin 
itself. Corticotrophin releasing factor (CRF) is produced in large quantities in 
the placenta and influences contractility by potentiating the effect of oxytocin 
as well as stimulating prostaglandin synthesis. Concentration of CRF strongly 
increases six weeks before labour, independent of gestational age, which 
suggests that it may play an important role in the onset of labour (Quartero 
1991). 
• Metabolic factors 
Uterine activity might change oxygen-supply as well as pH in the uterus. 
Until now little attention has been paid to the possible influence of these 
metabolic changes on uterine function. The role of metabolic changes in uterine 
activity might be of importance. In vitro studies are needed to show whether 
they influence the spontaneous rhythmical contractions of a myometrial strip 
(Wray 1993). 
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1.3.2 (Patho)physiology of menstrual bleeding 
Markee (1950) suggested that the rapid regression of endometrium (due to 
hormonal withdrawal) causes changes in the coiling of the spiral arteries which 
would lead to vascular stasis and result in tissue shedding and menstrual 
bleeding. 
Christiaens (1981) critized this "vascular" menstruation theory by reviewing 
studies which showed that the location of vasoconstriction is unclear and that 
beside vasoconstriction, other mechanisms may explain vascular narrowing. 
However, she agreed that a partial vessel occlusion might occur during 
menstruation. She described the haemostatic plug formation during menstruation 
based on histologic studies and showed differences between haemostasis in the 
endometrium and in skin wounds. In contrast to plugs elsewhere in the human 
body, the hemostatic plugs in the menstrual endometrium have a complete 
intravascular location. She suggested that as long as tissue shedding continues, 
plug formation is important for bleeding arrest. According to her, tissue 
regeneration and re-epithelization are the result and not the cause of 
haemostasis. 
Moreover, she demonstrated that menstrual blood contains fibrin and 
platelets. Christiaens (1981) demonstrated that during shedding of the 
endometrium (and despite loss of blood vessel continuity in the uterine cavity) 
the uterine bleeding stops due to haemostatic plug formation (platelet 
aggregation, fibrin formation), vasoconstriction and regeneration of the 
endometrium on one hand and vasodilatation, fibrinolysis and prostaglandins 
influenced platelet inhibition on the other hand. According to her, the high 
fibrinolytic capacity of the endometrium has a three-fold function. It promotes 
the emptying of the uterus by liquefaction of the shed tissue, it prevents 
implantation during menstruation and it improves the regeneration of the 
endometrium. She illustrated the importance of haemostatic plug formation for 
haemostasis in menstrual endometrium with the fact that in patients with platelet 
and coagulation disorders menorrhagia often occurs. The exact function of 
prostaglandins in menstrual haemostasis is not elucidated, but it is certain that 
they play a role in menstrual physiology (Christiaens 1981). 
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1.3.3 (Patho)physiology of postpartum bleeding 
The mechanism by which uterine bleeding stops after placental separation is 
not clearly understood. In fact, concepts of the physiology of the postpartum 
uterus are scarce. At least three processes can be discriminated: placental 
separation, uterine activity before and after placental separation, and the 
coagulation cascade and fibrinolysis after placental separation. 
Placental separation 
In the third stage of labour, two processes take place in regard to the 
placenta: 
• It separates from its insertion: the detachment takes place between the 
endometrium "functionalis" and the endometrium "basalis" (Friedländer 
1876). 
• It is expelled from the uterine body through the birth canal, passing the 
cervix and vagina. 
A few weeks before parturition, several degenerative and necrobiotic processes 
take place to create the circumstances for easy expel of the placenta. After 
parturition the vessels in the placental site are characterized by thrombosis, 
hyalinization, and obliterative fibrinoid endarteritis in the arteries. Many of the 
thrombosed and hyalinized veins are extruded with the slough of the necrotic 
placental site. Restoration of the endometrium occurs within 16 days. (Williams 
1931; Anderson & Davis 1968). 
Uterine activity after placental separation 
When the child is born, uterine activity can be described as follows: 
• Retraction 
Immediately after delivery, the position of the uterine fundus is lowered from 
the upper abdomen to the umbilicus, the so called "retraction" (Schwenzer 
1977). Retraction is the start of the involution of the uterus. Whereas contrac-
tions are characterized by the short period in which muscle fibre contracts and 
which is followed by relaxation of the muscle fibre, retraction is characterized 
by shortening of the uterine musculature, in spite of relaxation of the individual 
muscle fibres and increasing intrauterine tone (Knaus 1948). 
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Uterine activity during and after (placental) delivery. 
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Placenta delivered at arrow. (Reproduced with permission of American Journal 
of Obstetrics and Gynecology, figure 4 from Hendricks et al 1962). 
Retraction is probably facilitated by the typical arrangement of uterine muscular 
(circular) fibres (Goerttler 1931). 
• Contraction 
After approximately two to three minutes, the first postpartum contraction can 
be observed. The intensity or amplitude is two to three times higher than before 
delivery (Pascal's Law: pressure is force divided by area), and the uterine 
activity (product of frequency and intensity) decreases exponentially. This 
pattern is independent of the presence or absence of the placenta within the 
uterine cavity (Eskes 1962; Hendricks et al. 1968) (Figure 1.3.3.1). 
Coagulation cascade and fibrinolysis after placental separation 
Changes in coagulation factors during pregnancy, in particular at the time of 
delivery and in early puerperium, are summarized below. 
Coagulation and Fibrinolysis 
During an uncomplicated pregnancy, the concentration of most plasma pro-
coagulants is increased, with the exception of factors XI and XIII. In the first 
days after delivery, the plasma concentration of factors V, VII, and X increases 
(Wallenburg 1987). 
In the fibrinolytic system, the tissue-type plasminogen-activator inhibitors 
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type I (PAI-1) and type 2 (PAI-2) increase until the end of the thirty-eight 
gestational week, after which they all decrease except t-PA antigen (Lindoff et 
al. 1993). Fibrinolysis appears to be enhanced after placental separation 
(Shimada 1989; Gerbasi et al. 1990). Prostaglandins, involved in the initiation 
and maintenance of labour (Keirse et al. 1977) also have an effect on variables 
of fibrinolysis (Bertele et al. 1989). Bremer et al. (1994) found a rise in t-PA 
antigen as well as a fall in PAI-1 antigen and PAI activity in venous blood of 
electively induced women. The rise in t-PA antigen can be explained by 
physical exercise known to release t-PA from vascular endothelium (Rijken et 
al. 1983; Kruithof et al. 1987) or vascular damage in the utero-placental bed 
(Yoshimura et al. 1992). After placental separation the fibrinolytic potential of 
the maternal blood appears to increase. 
Platelets 
During normal pregnancy, platelet reactivity increases due to an enhanced 
activity of the cyclo-oxygenase pathway and an elevated sensitivity of the 
platelet membrane (Louden et al. 1992). 
Inflammation 
In contrast to former (histological) observations by Williams (1931), bioche-
mical studies show that a low-level inflammatory process may be a normal 
occurrence in the term placenta. A close interrelation was observed between the 
levels of the mediators released during inflammatory processes (Tumor Necrosis 
Factor, Interleukin 1,2, and 6). This process induces the production of cytokines 
playing a role in the regulation of parturition as well as local coagulation at the 
placental bed during expulsion (Halgunset et al. 1994). 
Haemostasis in the utero-placental bed 
In the uterine veins, morphologic changes are seen such as thrombosis, 
hyalinisation and endophlebitis. In the uterine arteries obliterative fibrinoid 
endarteritis has been observed (Anderson 1968). The infiltration of trophoblast 
cells in the arterial walls which occurs in early pregnancy could contribute 
towards the hyalin changes in these arteries (Pijnenborg 1994). 
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The precise mechanism of coagulation during and after placental separation 
is unknown; however, the following processes do play a part in local 
haemostasis. 
• The contraction of muscle sheaths around the spiral arteries, which leads to 
platelet plug formation (also described for menstrual bleeding in 1.3.2) (Renn 
1970). 
• Retraction of the uterus (1.3.3) causing mechanical occlusion of the arteries 
facilitating plug formation (Schwenzer 1977). 
• The activation of the coagulation cascade and fibrinolysis during and after 
placental separation as shown above. 
1.3.4 Discussion 
From a physiologic point of view, there are no big differences between the 
endometrium and the decidua. It is noteworthy that the differences in spiral 
arteries between the non-pregnant and pregnant state are mainly due to tropho-
blastic invasion into the vessels (1.3.1). 
The similarities between menstrual and postpartum bleeding are shown in Table 
1.3 4.1. 
Christiaens (1981) suggested that myometrial contractions have no major role 
during menstruation haemostasis. During the placental separation, the process 
of retraction (volume reduction) influences in particular uterine activity. 
Table 13 4 1 Comparison between menstrual bleeding and placental separation 
Menstrual bleeding Placental separation 
Endometrium Detachment between endometrium Detachment between decidua 
"functionalis" and "basalis" "functionahs" and "basahs" 
Blood vessels Spiral arteries Spiral arteries 
Myometrium Contractility in the menstrual Contractility in the postpartum 
period period 
Coagulation factors Coagulation cascade Coagulation cascade 
Fibrinolysis Fibrinolysis 
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It is reasonable to suppose that the retraction of the uterus compresses uterine 
vessels (including spiral arteries) and, therefore, plays a role in haemostatic plug 
formation. The exact mechanism, however, is unknown (Schwenzer 1977). As 
for the fibrinolytic and coagulation process, no systemic change of coagulation 
factors (as shown in the peripheral blood of pregnant and postpartum women) 
takes place during menstruation. At local uterine level, however, the changes in 
coagulation factors, the increasing fibrinolytic activity and the function of the 
platelets in the haemostatic plug formation are comparable. 
On the assumption that there are similarities between menstrual bleeding and 
postpartum bleeding, we have used the menstruating uterus as a model for the 
postpartum uterus in one of our studies (Chapter 5: Pharmacodynamics), while 
keeping in mind that by using this model we only partly simulated the process 
of placental separation. 
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2 Ergot alkaloids as uterotonics 
2.1 History of ergot alkaloids 
From ergotism to ergometrine* 
-, ι · ALE L V i V RI Л ч . 
Figure 2.1.1 The first illustration of ergot. Woodcut in Caspar Bauhin'sTheatrum 
Botanicum (1685) 
van Dongen PWJ, de Groot ANJA. History of Ergot alkaloids; From ergotism to 
ergometrine. Eur J Obstet Gynec Reprod Biol 1995; 60: 109-116. 
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Prim um non nocere 
Early history 
The very fertile crescent of Mesopotamia between the Euphrates and Tigris 
produced the first agricultural settlements around 9.000 ВС. The wild grasses 
were cultivated and yielded good harvests of grain from wheat and rye. Assyria 
and Babylonia could develop because of the stable supply of this staple food. 
However, grasses and especially rye can be contaminated by the fungus 
Claviceps purpurea during wet seasons, producing the typical ergot, i.e. the 
Sclerotium, in the ears of grain (Figure 2.1.1). 
Ergot is probably first mentioned around 600 ВС on an Assyrian cuneiform 
tablet as a "noxious pustule in the ear of grain". The Roman historian Lucretius 
(98 - 55 ВС) called erysipelas "Ignis sacer", i.e. Holy Fire, which name was 
given in the Middle Ages to ergotism. In one of the holy books of the Parsees 
in the 7th century ergotism was described as " noxious grasses that cause 
pregnant women to drop the womb and die in childbed" (Barger 1931; Clark 
1984). 
Ergotism 
Epidemics of ergotism occurred frequently in the Middle Ages. It was caused 
by eating rye bread contaminated with С purpurea, resulting in gangrene of 
limbs, disturbances in the function of the central nervous system and ultimately 
death. 
Ergot is derived from the old French word argot, meaning the cock's spur. 
The violet or black sclerotia consist of hyphae and are at least three times 
longer than the grains. Before or at harvest time the sclerotia fall on the ground 
and remain inactive till they germinate in the next warm and moist spring by 
developing 15 till 60 white spherical heads on stalks (hence the name claviceps; 
Figure 2.1.2). Ascospores are set free by rupture of the head and propelled into 
the air by several centimetres. Within eight days the infection of the flowering 
rye causes a secretion, the so-called honey-dew, in which the conidia (asexual 
spores) develop. This secondary infection leads to the production of the 
mycelium and then to the solid Sclerotium, closing the lifecycle of C. purpurea 
(Tulasne 1853; Bauer 1973; Luyendijk-Elshout 1983). 
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If bread was prepared without removing the black spurs, epidemics of ergotism 
sprang up. Rye was mainly eaten by the poor people, especially during famines. 
The suffering from ergotism was then doubled, because the spurs were also 
collected because of hunger. The Russians in the late Middle Ages considered 
the spurs as a necessity to produce good quality bread. The German mythology 
explained the "sudden" appearance of ergot by transgression of the 
"Kornmutter" (grain-mother) through fields during foggy weather (Barger 1931). 
The first mentioning of gangrenous ergotism can be found in the "Annales 
Xantenses" (Germany) in 857 AD: "A great plague of swollen blisters consumed 
the people by a loathsome rot so that their limbs were loosened and fell off 
before death" (Fuchs 1834). 
The first epidemic of convulsive ergotism is described in 945 in Paris, France 
(Barger 1931). It was accompanied by erythema, diarrhoea, vomiting, 
formication and agonizing burning sensations as if the limbs were burning, often 
Figure 2.1.2 Fully developed heads of the Claviceps purpurea 
magnification 12 times 
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Table 2 1 1 Symptoms of ergotism 
Gangrenous ergotism Convulsive ergotism 
• abortion · fatigue 
• amenorrhoea · giddiness 
• failure to lactate · paraesthesia 
• lassitude · formications 
• lumbar pain · nausea/vomiting 
• calf pain · burning sensation 
• feet/hands · clonic/tonic spasms 
- swollen · flexion of arms/hands 
- vesicles · paralysis, hemi(para)plegia 
- inflammation · maniacal excitement 
- alternating hot or cold · hallucinations 
- livid, black · visual disturbances 
- analgesia · delusional insanity 
- gangrene · psychosis 
- amputation · convulsions 
• jaundice · dullness 
• severe diarrhoea · cataract 
preceded by convulsions, catalepsy, dullness or maniacal excitement, hence the 
mentioning of "dancing epidemics". Most victims died, but some who fled to 
the church of St Mary or Martial survived, because most probably they got 
non-contaminated food as was seen in the epidemic of Aquitaine, France (994 
AD) in which 40,000 people perished (Barger 1931). 
The gangrenous type was mostly seen in France and the convulsive one in 
Germany The two distinct types of ergotism (gangrenous and convulsive) may 
be considered as acute and chronic varieties of ergotism. The different 
symptoms described are given in Table 2.1.1 As the formication is typical in 
the convulsive type, it was called "Kriebelkrankheit" in Germany. Mixed types 
were described as well, especially in other European countries. (Clark 1984). 
Holy Fire 
In 1095 the order of St. Anthony was founded in Vienne, France Especially 
in the twelfth and thirteenth centuries people flocked during epidemics to the 
hospitals of the Antonines. The bones of the Egyptian hermit St. Antony (251 -
356 AD) were sprinkled with holy water and wine and given to the sufferers of 
ergotism Soon the hospitals were called the "hôpitaux des démembrés" because 
at its entrance the spontaneously amputated limbs were exhibited as kinds of ex 
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Figure 2.1.3 Woodcut by Hans Wächtlin, Straßburg."Von der kalten Brandt" in: 
Feldtbuch der Wundartzney, Hanns von Gersdorff (1517) 
votos. Due to the good treatment by providing non-contaminated bread, the 
popular hospitals spread all over Europe till a zenith of 390 settlements (Bauer 
1973). 
The frequent epidemics were called St. Anthony's Fire, "Holy Fire" or Ignis 
Sacer because of the burning sensations in the limbs as is depicted in the art of 
the time (Dixon 1984; Crijns 1992; Sello 1992; van Dongen 1995). Victims of 
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ergotism could identify themselves easily with the lifelong tortured St. Anthony. 
In the woodcut from 1517 (Figure 2.1.3) a farmer who lost his right foot, 
extends his left arm engulfed in symbolic flames towards St. Anthony for help 
and protection. Medieval medicines were thought to restore the balance between 
hot and cold, wet and dry ailments. The Holy Fire was of course considered as 
a very hot disease, treatable with cooling elixirs, holy vintage with rare and 
costly ingredients, fish and water, thistle and mandrake (mandragora)-apple and 
-root. The juice of the mandragora-apple was also used for analgesia but 
overdoses caused often untimely death, hence the nickname of "devil's apple". 
It contains the two belladonna-alkaloids hyoscyamine and hyoscine with 
parasympathicolytic properties of mydriasis, bradycardia, reduced glandular 
secretions but also visual hallucinations, especially sensations of flying. The 
famous St. Anthony Tryptich (Lisbon, Museu Nacional de Arte Antiga) shows 
not only the temptations of St. Anthony, all "cold" treatments for ergotism 
including the mandragora-apple and -roots, suffering ergotants but also strange 
flying aircrafts. Jeroen Bosch (1452-1516) painted all three interior panels with 
outrageously strange and diabolic scenes as if seen by a hallucinating brain. 
Ergot when baked with dough may be transformed into lysergic acid 
diethylamine (LSD), a reknown hallucinogen. Ergotants were therefore twice 
afflicted by hallucinations: first by the transformed ergot-alkaloids and then 
from the belladonna-alkaloids from the mandragora (Bauer 1973; Dixon 1984; 
Sello 1992; van Dongen 1995). 
Use of ergot as an oxytocic drug 
The Renaissance in Europe may be defined as the transition from the medi-
eval, magical-religious society to the modern world. For ergotism, the Middle 
Ages ended in 1582 when Adam Lonicer in Germany mentioned for the first 
time the use of ergot to stimulate uterine contractions of labour ("pains of the 
womb") by administering three sclerotia (equals 0.5 mg ergot). 
The first accurate description of the ergot is also from his Kreuterbuch: ".... 
long black hard narrow com pegs, internally white, often protruding like long 
nails from between the grains in the ear" (Clark 1984). 
The honour of the first description in a medical journal is given to Paulizky in 
1787. Ergot as "pulvis ad partum" was prescribed by midwives and physicians 
alike. It showed an action which was " more rapid and powerful than any 
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other known drug" (Paulitzky 1787). John Steams from New York (1807) wrote 
in a famous letter to Mr. S. Akerly about the properties, dosage and side effects 
of ergot (Stearns 1807). The crude ergot was given in a dosage of 5-10 grams 
to parturients resulting in a rapid and sudden termination of labour with an 
induction delivery time of not more than three hours. However, this "pulvis 
parturiens" was not suitable for accurate therapeutic administration because of 
the large variation of active ingredients and the severe adverse events like 
violent nausea and vomiting. The period of administering ergot as means of 
quickening birth ended in 1822 when Hosack from New York stated that many 
stillbirths were due to uterine rupture with resulting maternal death. The "pulvis 
ad partum" was renamed "pulvis ad mortem" (Hosack 1824). By the end of the 
19lh century its use as an oxytocic was virtually abandoned. 
Cause and prophylaxis of ergotism 
The first suggestion that ergotism was caused by blighted grains was already 
mentioned in 1125. Caspar Schwenkfeldt (Poland, 1600) thought that the honey-
dew of the rye was the cause of the ergot epidemics (Bauer 1973). 
During an epidemic of gangrenous ergotism in Sologne (France, 1630), Tuilier 
Sr did animal research by giving "comicula nigra" to chickens, geese and pigs: 
they all died. Unfortunately, he did not publish his results. Only in 1676, Dodart 
with help from the son of Tuilier, solved the problems of the epidemiology and 
cause of the gangrenous ergotism. Likewise, Johann Brunner, described the 
cause of the convulsive type in 1695 in Leipzig, Germany (Bauer 1973). 
Although the cause of ergotism was known, it took more than a century to 
specify the first prophylactic measures by L'Abbé Tessier in 1778. A vast 
epidemic of gangrenous ergotism with more than 8000 victims in Sologne, 
France, was caused because the grains were not cleansed from ergot. He 
proposed drainageways, cultivation of potatoes in stead of rye and the enforced 
cleaning of grains (Percebois 1977). A second description of preventing 
ergotism by controlling the quality of bread in hospitals was elucidated by 
Johann Taube in his magnificent book "Die Geschichte der Kriebelkrankheit" 
(Göttingen, Germany, 1782). Moreover, his clinical pictures of the neurologic 
and psychiatric disorders are still valuable today. His recommended treatments 
of ergotism were waterbaths of 20°C, electrotherapy and anthelmintic drugs 
(Bauer 1973). 
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The last epidemic of convulsive ergotism in Germany (Oberhessen) was 
eloquently depicted by Siemens in 1879 (Siemens 1881). He noted that 
neurological symptoms, like painful tonic contractions of the flexors, ataxy of 
the limbs, instability and epilepsy, preceded always psychiatric disturbances like 
decreased awareness, delirium and hallucinations. Moreover, the damage proved 
to be irreversible (Table 2.1.1). 
Analysis and mode of action of ergot alkaloids 
Although the word alkaloids is a misnomer, it is still used widely. Originally, 
alkaloids were described in 1913 as " basic substances occurring in plants" 
(Henry 1913). Nowadays, nitrogenic constituents are included as well. One may 
say that ergot is a "treasure chest of valuable pharmaceuticals" (Table 2.1.2, 
Clark 1984). 
Table 2.1.2 
A choice of pharmaceutical constituents found in ergot alkaloids 
acetylcholine 
agmatine 
amino-sulphonic acid 
betaine 
cadaverine 
choline 
ergobasine 
ergochrysin 
ergoclavine 
ergocornine 
ergocristine 
ergokryptine 
ergoflavin 
ergometrine (= ergonovine) 
ergosterol 
ergotamine 
ergotaminine 
ergothioneine 
ergotinine 
ergotocin 
ergotoxine 
guanosine 
histamine 
histidine 
iso-amylamine 
iso-Ieucine 
leucine 
putrescine 
sclerocrystallin (= secalonic acid) 
secale cornutum 
sensibamine 
trimethylamine 
tyramine 
tyrosine 
uracil 
valine 
X-alkaloid (ergostetrin) 
The four alkaloids ergometrine, ergobasine, X-alkaloid and ergotocin are identical (see text) 
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The honour of the first person trying to analyze and isolate the active prin-
ciples of ergot goes to the pharmacist Heinrich Wiggers in 1835 in Göttingen, 
Germany (Dann 1953). However, after numerous systematic botanical and 
chemical investigations no fundamental discovery was made. 
The first pure alkaloid was described in 1875 by Tanret in France (Tanret 
1875). The crystallized ergotinine was, however, almost inert. Sollmann and 
Brown (Sollmann & Brown 1905) studied in 1905 the circulatory effects in 
mammals after both intravenous and intramuscular injections of crude ergot. 
The results varied considerably because of differences in the preparations and 
hence the dosages of ergot. Even after destruction of the spinal cord the same 
pattern of a rapid drop of blood pressure followed by a prompt recovery of the 
blood pressure was noted, but only after intravenous injection of ergot and not 
after oral administration. The response to epinephrine (hypertension) was 
decreased by ergot. The adrenergic blockade by ergot is therefore first described 
by Sollmann (Sollmann & Brown 1905) and not by Barger as stated in his 
extensive monograph (Barger 1931). Barger and Carr (1906) obtained two 
impure fractions from ergotinine. The uterotonic activity was attributed to a 
single alkaloid, the so-called ergotoxine. 
Ergotamine was developed as a new physiologically active agent in 1920 
(Stoll 1920; Spiro 1921). Its uterotonic properties are easily lost during storing 
(Thompson 1935). At present, ergotamine is only used in the treatment of 
migraine and other vascular headaches. When inadvertently given during 
pregnancy it may cause fetal stress. A review of all side-effects of ergot 
alkaloids during pregnancy has been published elsewhere (de Groot et al. 
1993b). 
Uterine action after oral administration of extract of ergot (according to the 
British Pharmacopoeia) was monitored externally in 1927. It was found to be 
wholly inert, as was the extract according to the U.S. Pharmacopoeia (Bourne 
& Burn 1927). Ergotamine or ergotoxine exerted a prolonged action and were 
therefore considered to be ideal agents for use after delivery. However, it took 
four to ten minutes after intravenous injection before any uterotonic action was 
noted, twenty minutes after intramuscular injection and by mouth even thirty-
five minutes or longer. 
In their classic paper of 1932, Moir and Dale used the same technique for 
intra-uterine pressure recording as Schatz in 1872 (Schatz 1872) and Bourne 
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and Burn in 1927 (Bourne & Burn 1927): a sterilized bag was inserted in the 
puerperal uterus, connected by tubing to a mercury manometer and to a rotating 
drum with a recording device (Moir & Dale 1932; MacDonald 1982). When an 
aqueous extract of ergot was given by mouth to a postpartum woman, the effect 
appeared not only in a remarkably short time of four minutes, but also 
strikingly different as was seen after administration of ergotamine or ergotoxine. 
The contractions were more frequent (two or three to the minute), more regular, 
with greater amplitude and rise of the basal intra-uterine pressure than observed 
after administration of any other drug. Therefore it was concluded that another 
and more powerful uterotonic agent must be present. Indeed a watersoluble 
alkaloid was isolated in 1935 by the same group and henceforth called 
ergometrine (Dudley & Moir 1935). 
The properties were described as follows: ".... the onset is sudden, and 
accompanied by pronounced uterine spasm, which appears to be caused by a 
succession of contractions so rapid that the organ as a whole has no time to 
relax. This stage lasts for about an hour, and is followed by a second stage, 
during which the uterus shows regular, vigorous, isolated contractions, 
continuing for an hour or more" Oral administration of 0.5 mg ergometrine 
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Figure 2 1 4 Tracing of uterine contractions made on sixth day of puerpenum by 
intra-uterine bag method, showing the effect of 0 5 mg ergometrine by 
mouth The arrow shows moment of administration (Is Figure 1 from 
Dudley and Moir 1935) Reproduced with permission of British 
Medical Journal 
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provoked, after an interval of 6/2-8 minutes, contractions identical with those 
produced by the watery extracts of ergot as described in 1932 (Moir & Dale 
1932) (Figure 2.1.4). Therefore, the active substance of ergot extract must be 
ergometrine. After intramuscular or intravenous administration of ergometrine 
the sudden action was recorded after four and two minutes, resp. 
Within a month, three other groups - two in the U.S.A. (Davis et al. 1935; 
Adair et al. 1935; Thompson 1935) and one in Switzerland (Stoll 1935) -
described the same alkaloid, although by different names: ergotocin (Davis et 
al. 1935; Adair et al. 1935) ergostetrin (Thompson 1935) and ergobasine (Stoll 
1935). The four alkaloids proved to be the same substance. In the United 
Kingdom it adopted the name ergometrine; a fifth name ergonovine was 
selected for use in the U.S.A. 
Chemistry of ergometrine, its derivatives and bromocriptine 
All naturally occurring alkaloids are derived from lysergic acid and contain 
a substituent at position 8 (Figure 2.2.1 ρ 52; Rail 1990). Two groups are 
described with different target organs, pharmacological properties and side-
effects. Ergometrine is the simplest compound with a single amine-group as 
substituent. Upon hydrolysis, ergometrine yields lysergic acid and an amine; 
consequently it is designated as amine alkaloid. Methylergometrine is a 
semisynthetic amide derivative of d-lysergic acid. It contains an extra methyl-
group in the substituent at position 8. (Methyl-)ergometrine has greater 
uterotonic than vasoconstrictive abilities (de Groot et al. 1993b) (see Chapters 
2.2 and 2.3). The partial synthesis of ergometrine by Stoll and Hofmann (1938) 
was followed by the synthesis of lysergic acid diethylamide (LSD) in 1943 by 
Hofmann. It proved to be more toxic and less uterotonic than ergometrine. 
Within forty minutes after swallowing an overdosage, Hofmann himself 
experienced dizziness, unrest, difficulty in concentration, visual disturbances and 
"delusional insanity", as was described in the old epidemics of ergotism (Table 
2.1.1). It was shown that the hallucinogenic activity resulted from serotonine (5-
hydroxy-tryptamine)-antagonism (Hofmann 1970). 
The amino acid alkaloids comprise the naturally occurring ergotamine and 
ergotoxine and the semisynthetic bromocriptine. Prolactin secretion inhibition 
is caused by the a-ergokryptine compound. The synthesis of bromocriptine (2-
bromo-a-ergokryptine) in 1965 heralded the new era of dopamine receptor 
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Stimulation. Interestingly, it is known that during epidemics of ergotism the 
milkproduction of nursing mothers and cows stopped. Ergot extracts were also 
used in the 19lh century to treat amenorrhoea (Rail 1990)! 
Management of the third stage of labour with ergot alkaloids 
The World Health Organization (WHO) estimates that each year at least half 
a million (500,000) women die from causes related to pregnancy and childbirth 
(Royston & Armstrong 1989). Postpartum haemorrhage (PPH) is one of the 
most common causes of maternal death, amounting to 13% of all maternal 
deaths in developed and 33% in developing countries (van Dongen et al. 1991). 
The calculated Maternal Mortality Rate (MMR) on the British Isles in the 18lh 
century was about 2,000 per 100,000 live births. William Smellie decribed PPH 
in 1751 as follows: "all women, when the placenta separates, and after it is 
delivered, lose more or less red blood from the quantity of half a pound to that 
of one pound or even two; but should it exceed this proportion and continue to 
flow without diminution, the patient is in great danger of her life" (Joyce & 
Lennon 1948). The MMR in the United Kingdom in 1930 was still 300/100,000 
live births. Nowadays, in Western Europe and North-America this figure is 
about 8/100,000 live births (Royston & Armstrong 1989). 
The tremendous decrease in MMR is due to improved socio-economic 
factors, introduction of antibiotics, blood transfusion facilities and oxytocic 
drugs. The active management of the third stage of labour and treatment of 
excessive blood loss in the so-called fourth stage of labour (period after 
expulsion of the placenta) by administering oxytocics has been described as " 
one of the enduring achievements of modern science" (Royston & Armstrong 
1989). 
After administering "secale luxurians" after birth, Schwenkfeldt in 1600 noted 
for the first time in history that ".... sanguinem sistere vulgus credit", i.e. ".... 
one believes it will stop the bleeding" (Bauer 1973). The "Guide to midwifery" 
from 1912 recommends an intramuscular injection of ergotine after the birth of 
the infant (Hart 1912). 
The first application of ergometrine as a prophylactic drug is attributed to 
Browne in 1935, but it was published in 1947 (Flew & Gibber 1947). 
Ergometrine 0.5 mg was given intramuscularly to 500 consecutive normal cases 
as soon as the head was delivered. Results of blood loss are, however, not 
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given. It is only stated that no cases of manual removal of the placenta were 
seen. 
Joyce and Lennon studied 156 cases with PPH between 1938-1947. They 
advocated that if PPH occurred before delivery of the placenta, 0.5 mg 
ergometrine should be given intramuscularly by ".... the midwife while awaiting 
the doctor's arrival" (Joyce & Lennon 1948). Shaw (1949) noted that the 
duration of the third stage was markedly reduced. Moreover, less blood 
transfusions were needed if a manual placental removal was done after 
prophylactic intravenous injection of ergometrine (54% vs 8%) (Shaw 1949). 
Daley (1951) is the first one who administered routinely 0.5 mg ergometrine 
intramuscularly in normal parturients (490 vs 510 controls) after crowning of 
the head. Blood loss was carefully measured. Significant reduction in duration 
of the third stage with four minutes and in blood loss of 70 mis was established. 
However, the most important finding was that the frequency of PPH -defined 
as blood loss > 560 mis- was significant less in the ergometrine group (9.2%) 
as compared to the control group (15.7%) (Daley 1951). 
At present, evidence of the effectiveness of active management with oxytocic 
drugs is based on meta-analysis of randomized controlled trials. Prescribing any 
oxytocic drug routinely for the prevention of PPH resulted in significantly 
decreased blood loss, less blood transfusions, lower incidence of PPH (from 10-
6%), shortened third stage of labour and decreased need of further 
administration of oxytocics (Prendiville et al. 1988a; 1988b; Elbourne 1988; 
McDonald 1993). No statistical differences in the incidence of PPH was found 
after administration of oxytocin, ergometrine or prostaglandins (Elbourne et al. 
1988; Poeschmann 1991; Mc Donald 1993). However, it is very clear that 
ergometrine may provoke unpredictably severe hypertension, nausea, vomiting 
and many more side-effects due to its vaso-constrictive effects (de Groot et al. 
1993b), sometimes leading to maternal deaths (Ringrose 1962). Moreover, there 
is ample evidence that both oral and parenteral ergometrine are not stable under 
humid, warm and light conditions (Walker et al. 1988; Hogerzeil et al. 1991; 
Hogerzeil et al. 1992; de Groot et al. 1994c; Hogerzeil et al. 1994). It was 
therefore concluded that the best choice for use in third stage of labour is not 
ergometrine but oxytocin (de Groot 1995a). 
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Conclusion 
We may have come full circle: from the accidental poisoning with ergot 
alkaloids (ergotism), acceleration of labour, prevention and treatment of PPH 
to the knowledge of the severe side-effects and instability of ergometrine. 
Perhaps the time has come to abandon oral ergometrine from obstetrics and 
intravenous MetherginR as prophylaxis in the third stage of labour. Primum non 
nocere. 
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2.2 Chemical background 
Ergot alkaloids can all be considered to be derivatives of the tetra-cyclic 
compound 6-methylergoline (Figure 2.2.1; Rail 1990). The naturally existing 
alkaloids of therapeutical interest are amide derivatives of d-lysergic acid, so 
called 9-ergolenes; they contain a substituent at position 8 and a double bond 
in ring D between C9 and CIO. The substituent at position 8 can either be in 
the ß-configuration or in the α-configuration. The 8 Η-atom is called 8a when 
it is trans to the 5-H and 8ß when it has a cis position in relation to the 5-H. 
Traditionally the α-isomer is distinguished from the ß-form by the prefix iso or 
by the suffix ¡nine. Thus, the 8ß-configuration is called d-lysergic acid and the 
8a-configuration, d-isolysergic acid. The substituent at position 8 forming d-
lysergic acid is the working compound. Optical isomerism is due to the 
presence of two asymmetrical carbon atoms (position 5 and 8) in the lysergic 
acid portion of the molecule. 
In combination with water and on exposure to light, in particular that of UV-
frequency, H20 can be added to the double bond between C-9 and C-10; 6-
hydroxy derivatives are then formed: Lumi-derivatives. An acid environment 
facilitates this reaction (Rail 1990; Glover & Halki 1991). Furthermore, the 
ergot alkaloids are easily oxidized, with the oxidation products being coloured 
(Rail 1990). 
Ergometrine(= ergonovine)(Figure 2.2.1) is an amide derivative of 
d-lysergic acid; it contains a double bond between C-9 and C-10 (ring D). 
Upon hydrolysis, ergometrine yields lysergic acid and an amine; consequently, 
it is designated as an amine alkaloid. 
Methylergometrine (= methylergonovine) is a semisynthetic amide derivative of 
d-lysergic acid. It contains an extra methyl-group in the substituent of the 
ß-configuration at position 8 (Rutschmann & Stadler 1978; Rail 1990). 
The enantiomers (optical isomers) are called ergometrinine and methylergo-
metrinine. The naturally existing enantiomers are always present due to 
spontaneous epimerisation about the asymétrie centre C8. However, the 8a-
configuration (-inine) forms only a small part of the mixture (Rail 1990). 
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Derivatives of 1-lysergic acid (epimere at position 5) and d-isolysergic acid 
display relatively little biological activity. None of the other products of 
ergometrine display any biological activity (Rutschmann & Stadler 1978; Rail 
1990). 
The presence of the OH-group in the substituent at C8 in both ergometrine 
and methylergometrine makes glucuronidation a plausible metabolic pathway 
(Correia & Castagnoli 1984) (Figure 2.2.2). Indications of this pathway of 
metabolisation were obtained, but have not yet been validated. As literature 
gives no further information on glucuronidation of (methyl)ergometrine, this is 
still an issue to be investigated. 
C H 3 
I 
C H 2 
Nat, 
H N -
Methylergometnne 
К 
coon 
с-сн,о - ¿ H — < „ . 
* OH ° " 
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-сн. 
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1 , сое« 
- - • з-^-Т—C~. H—с—CHjO-
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Methylergometnnine MeUiyleigomelrinineglucuronide 
Figure 2.2 2 Glucuronidation of methylergometrine and its enantiomer methylergo­
metnnine as possible metabolic pathway (TB Vree, personal communication) 
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2.3 Pharmacological properties 
In general, ergot alkaloids act as partial antagonists at α-receptors and give 
a direct vasoconstrictive action. They mainly affect the dilated arterioles, induce 
contractions of uterine musculature, and provide a central stimulation of 
dopamine receptors (Müller-Schweinitzer & Weidemann 1978). Activity profiles 
for the vasoconstrictive and uterotonic properties of peptide alkaloids, dihydro-
peptide alkaloids, lysergic acid amides, and lysergic acid alkaloids are given in 
Table 2.3.1 (Berde & Stürmer 1978; Leist & Grauwiler 1974). 
In obstetrics, ergot alkaloid derivatives with specific uterotonic action and 
without vasoconstrictive properties are used in the management of the third 
stage. The vasoconstrictive action of (methyl)ergometrine (=ergonovine) is less 
than that of other ergot alkaloids (Table 2.3.1). 
Ergometrine maléate and methylergometrine maléate are pharmacologically 
similar (Rail 1990; Glover & Halki 1991). Methylergometrine and ergometrine 
maléate decrease the postpartum blood loss by enhancing the muscle tone of the 
uterus, imposed by fast rhythmic contractions of the myometrium, the so-called 
tetany. As a by product, the myometrial blood vessels are compressed resulting 
in limited blood loss (van Dongen et al. 1991). Former studies have described 
the absorption rate of oral ergometrine and methylergometrine as rapid and 
complete (Rail 1990). Uterine action after oral administration of an ergot extract 
was described as early as 1927 (Bourne & Burn 1927). After oral 
administration of ergometrine a gradual ascent of the curve to the tetany level 
Table 2.3.1 Activity profile of structural groups of ergot alkaloids 
Activity profile Vasoconstriction Uterotonic Ergotism 
(systemic) Contraction 
Peptide alkaloids +++ ++ +++ 
[ergotamine] 
Dihydro-peptide alkaloids ++ ± ± 
[dihydro-ergotamme] 
Lysergic acid amides ± +++ ± 
[(methyl)ergometnne] 
Lysergic acid alkaloids ± ++ ++ 
[lysergic acid diethylamide (LSD)] 
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(during ¡ntra-uterine pressure recording) was seen after 10 minutes. The tetany 
continued for one hour. The intravenous injection of ergometrine caused an 
instantaneous response after 15 to 20 seconds with an abrupt rise of the curve; 
6.5 - 8 minutes after an intramuscular administration of ergometrine the same 
effect was seen (Moir & Dale 1932; Adair et al. 1935; Davis et al. 1935; 
Dudley & Moir 1935). A small dosage of ergometrine produced the fastest 
action when compared to other ergot alkaloids (Adair et al. 1935). Notwith-
standing these properties, no information was found regarding the oral applica-
tion of ergometrine or methylergometrine to prevent PPH (Prendiville et al. 
1988a). 
Although oral (methyl)ergometrine has been used for a long time, little 
pharmacokinetic data are available for both drugs (Kanto et al. 1976; Alionen 
et al. 1978; Mäntylä et al. 1978). A major reason for this has been the lack of 
analytical methods with sufficient sensitivity to measure low concentrations of 
both drugs in the plasma in the nanogram amounts which occur after the usual 
single therapeutic doses of 0.125-0.2 mg. No new data on the pharmacokinetics 
after oral administration for these drugs have been published since the late 
seventies (Mäntylä et al. 1978; Kanto et al. 1981). Chapter 4 describes 
pharmacokinetic data obtained with High Performance Liquid Chromatography 
(HPLC)-assay for oral (methyl)ergometrine in men and non-pregnant women. 
Pharmacologic action of methylergometrine 
Little is known about how (methyl)ergometrine achieves its oxytocic 
effect. Interaction with nifedipine suggests that the Ca++ channel of smooth 
muscle cells are of importance for this mechanism (Forman 1982). For oxytocin 
(ОТ), a receptor mechanism has been described. In contrast to ОТ, that has its 
own ОТ receptors on the uterus which increase during pregnancy, a specific 
(methyl)ergometrine receptor has never been described. Cibils and Hendricks 
(1969) studied the interaction between ОТ and (methyl)ergometrine by 
measuring the effect on pressure in postpartum uteri. They could not detect a 
major interference between these two drugs. They observed a relative lack of 
reaction to ОТ when the patients were premedicated with (methyl)ergometrine. 
Intra-amniotic infusion of methylergometrine did not show any uterine respons 
(Cibils & Hendricks (1969)). Daels (1974) described the existence of two 
different zones in the myometrium related to the embryologie origin of the 
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Uterus: The innerzone, the archemyometrium (= rudimentary corpus uteri -
oldest muscle layers) and the outerzone, para- or neomyometrium (see Chapter 
1.3). Daels showed that in myometrium strips of non-pregnant, pregnant, and 
postpartum women the different layers had different contractile characteristics 
and different reactions to adrenaline and oxytocin. Tonic contraction in the 
inner layer occurred in postpartum myometrial strips after administration of 
adrenaline, whereas oxytocin affected the spontaneous motility of the 
postpartum inner layer only marginally. Oxytocin strongly affected the 
amplitude and frequency of contractions in the outer layer of postpartum 
myometrial strips. From these observations, de Koning Gans et al. (1975) 
suggested that methylergometrine affects the inner layer {archemyometrium) of 
the uterus in contrast to ОТ and prostaglandins (PGs) which are said to affect 
the outer muscle layer {neomyometrium) (Daels 1974; de Koning Gans et al. 
1975; Saameli 1976). 
Studies in the rabbit with concomitant medication showed antagonistic 
effects after administration of dihydroergotoxine, piperoxane, and phenoxy-
benzamin, but not after the administration of hexamethonium or atropine. This 
inhibitory action of the concomitant drugs was explained as being an a-receptor 
blockade of the medication (Saameli 1976). Saameli (1976) supports the concept 
that the oxytocic effect of ergot alkaloids and of (nor)epinephrine is due to 
stimulation of the same a-adrenoreceptors in the inner myometrial layer. 
(Methyl)ergometrine is said to enhance the muscle tone of the uterus (van 
Dongen et al. 1991). De Koning Gans et al. (1975) suggested that the amplitude 
(A) and frequency (F) of contractions occur in the outer layer (the new uterus) 
while the (methyl)ergometrine affects the basal tone (ВТ) of the inner layer (old 
uterus). This might explain a certain constancy in the relation amplitude and 
frequency: a decrease of amplitude causes an increase of frequency (Chapter 5). 
Intensity (I) seems to have a maximum level. This maximum level can be 
described by maximum relaxation and maximum contraction of the uterine 
muscle. If the maximum level is changed by alterations in basal tone, 
adaptations in frequency seem a logical consequence. 
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(Methyl)ergometrine increases the basal tone. If an intensity-maximum exists, 
the amplitude of contraction has to decrease when basal tone increases. To 
explain it differently, an increase in basal tone, caused by (methyl)ergometrine, 
implies that the maximum contraction will be reached earlier than without the 
drug, which will lead to an increase in frequency of the contractions. This is 
exactly the pharmacological action ascribed (formerly) to (methyl)ergometrine. 
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2.4 Adverse Drug Reactions* 
Adverse drug reactions (ADR) of ergot alkaloids especially of 
(methyl)ergometrine are reviewed. Many side effects after administration of 
ergot alkaloids have been described (Table 2.4.1). Ergot poisoning or ergotism 
(depression, nausea, slight giddiness, as well as pains in limbs and lumbar 
region) has mostly been observed within one hour of an intravenous injection 
of 0.5 mg ergotamine (Adair et al. 1935). Because of its severe vasoconstrictive 
component, ergotamine is contra-indicated during pregnancy and the active 
management of the third stage. 
Nausea and vomiting occur quite frequently after administration of oral 
ergometrine (Mäntylä et al. 1978; Garcia et al. 1987; van Dongen et al. 1991). 
Cardiovascular side effects (brady- or tachycardia and hypertension) after both 
intramuscular and intravenous administrations of ergometrine are known 
(Browning 1974; Dukes 1991). Its vasoconstrictive effect is even used as a 
provocation test for coronary artery spasm susceptible patients (Goldberg 1983). 
One case of postpartum myocardial infarction probably induced by 
administration of 0.2 mg ergometrine maléate intravenously has been reported 
(Taylor & Cohen 1985). Bronchoconstriction (Louie et al. 1985), renal artery 
spasm (Fedotin & Hartman 1970), and segmental stenosis of a cerebral artery 
(violent headaches, convulsions, and mental confusion) (Henry et al. 1984) have 
been reported after intravenous administration of (methyl)ergometrine in 
postpartum women. Simultaneous intravenous administration of methylergo-
metrine and oxytocin has been reported to result in severe postpartum 
hypertension, cerebral edema, and convulsions (Abouleish 1976). Puerperal 
psychosis has been described after both oral and intravenous administrations of 
ergometrine as a possible idiosyncratic reaction (Iff et al. 1989). Some authors 
claim that methylergometrine has less hypertensive side-effects and less 
influence on (not proven) decrease of postpartum prolactin levels than er-
gometrine, but the number of women examined in these studies are too small 
to draw any such conclusions (Del Pozo et al. 1975; Symes 1984). 
Modified from De Groot ANJA, van Dongen PWJ, van Roosmalen J, Eskes TKAB. 
Ergotamin-induced fetal stress: review of side effects of ergot alkaloids during 
pregnancy - a case report- Eur J Obstet Gynec Reprod Biol 1993b; 51: 73-77. 
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Table 2 4 1 Adverse drug reactions of ergot alkaloids 
Ergometrine 
• orally 
intravenously/ 
intramuscularly 
neonate 
ergotism 
nausea, vomiting 
puerperal psychosis 
asthmatic attack 
fetal death 
ergotism 
bradycardia, tachycardia 
hypertension 
coronary artery spasm 
postpartum myocardial infarction 
renal artery spasm 
puerperal psychosis 
hypertonia, convulsion, 
hyperthermia, respiratory failure 
Methylergometrine 
• orally 
• intravenously/ 
intramuscularly 
+ oxytocin 
Other ergot alkaloids 
Ergotamine ergotism, hypothermia (adult) 
reversible cerebral artenopathy, claudication 
placental abruption, fetal distress, fetal death 
Methysergide damaging of heart valves 
ergotism 
ergotism 
hypertension 
cerebral edema 
artenopathy 
convulsion 
Injections of ergometrine given inadvertently in neonates caused respiratory 
failure, hypertonia, and hyperthermia (Whitfield & Salfield 1980, Hirasing & 
Berger 1983) Fetal deaths are described after ingestion of ergometrine tablets 
and after administration of ergotamine (Treffers & Becker-Bloemkolk 1976, van 
Aken et al 1982, Au et al 1985), possibly in relation with placental abruption 
(Cattor & Wilkin 1966) If an ergot alkaloid is given during pregnancy, the 
administration of a ß-sympaticomimetic drug may prevent fetal stress or fetal 
death (Treffers & Becker-Bloemkolk 1976, Wong & Paul 1979) Ergot alkaloids 
should be handled with great care in obstetrics and only be used postpartum (de 
Groot et al 1993b) 
Prophylactic use of ergometrine (injection) in the management of third stage 
was criticized by Ringrose (1962) In 1993, we also reported numerous side-
effects for (methyl)ergometnne (de Groot et al 1993b) Due to its serious and 
unpredictable side-effects, its place among the oxytocics is controversial in 
prevention of postpartum blood loss 
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3 Stability under simulated tropical conditions' 
Postpartum haemorrhage (PPH) is still one of the most common causes of 
maternal death, especially in third world countries (van Roosmalen 1988; 
Royston & Armstrong 1989; van Dongen et al. 1991). As in these countries 
emergency referral in case of severe bleeding is difficult to arrange, prevention 
and management of PPH at all levels of obstetric care is mandatory. For 
prevention and management of PPH the routine use of oxytocics in the 
postpartum period is advocated (Prendiville et al. 1988a). Drugs have to be 
stable to be used in tropical climates and the route of administration should be 
simple when used by untrained people. 
The route of choice is by mouth. Among all oxytocic drugs only the ergot 
alkaloids are suitable for oral administration. Therefore, oral ergometrine and 
methylergometrine with favourable effects on both blood loss and maternal 
morbidity and mortality were regarded as possible treatments for use in tropical 
countries. Manufacturers usually do not investigate the stability of preparations 
under tropical conditions. They usually perform their tests in temperate climates. 
In third world countries, it is often practically and/or economically not possible 
to protect pharmaceutical preparations from the harmful effects of high tem-
peratures and high relative humidity during transportation, storage and use. 
Recent stability studies of both ergometrine and methylergometrine injectable 
solutions show high extents of deterioration upon exposure to elevated tempera-
tures and to light (L) (Walker et al. 1988; Hogerzeil et al. 1991; Hogerzeil et 
al. 1992). Moreover, large differences in potency and stability between the 
various brands and formulations seem to be more important than the differences 
between ergometrine or methylergometrine (Hogerzeil et al. 1994). 
The aim of this investigation was to examine the stability of ergometrine and 
methylergometrine tablets to determine whether it is feasible to replace the 
parenteral route of oxytocics by orally administered drugs. The stability of the 
compounds have been assessed by using "shelf life" methodology to demon-
strate whether the drugs can be transported and stored without loss of potency. 
de Groot ANJA, Hekster YA, Vree TB, van Dongen PWJ. Ergometrine and 
methylergometrine tablets are not stable under simulated tropical conditions. J Clin 
Pharm Ther 1995b; 20: 109-113. 
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3.1 Material and methods 
Study design 
Definitions used in the study are given in Table 3.1.1. In the design of this 
study the recommendations laid down in "Protocol of the research of the 
stability of drugs in aqueous solutions" by the Dutch Society of Hospital 
Pharmacists (Anonymous 1992) have been used. We simulated 7 tropical 
conditions (Table 3.1.2). 
Taking into account the known vulnerability of ergometrine and methyl-
ergometrine on exposure to light, all tablets were tested for light-induced 
degradation (Hartmann et al. 1982). 
The following tablets were examined: ergometrine maléate 0.2 mg tablets 
BP88; batchnumber: 91 I 02/590E and containing 147μg free base and methyl-
ergometrine maléate 0.125 mg tablets; batchnumber: 2003; 95μg free base. 
Tablets were received in closed tins. During the storage tests the tablets were 
exposed to the intended conditions, in identical transparent tins. Each tin 
contained four tablets. For each sampling period (weeks 0-52), a different tin 
was used. One batch from each manufacturer was examined. To achieve 
acceptable statistical power, 4 tablets were assayed per storage condition per 
manufacturer. At weeks 0 and 52, 20 tablets per storage condition per 
manufacturer were investigated to improve the statistical power of the analysis. 
Tablet weight, integrity and colour were assessed prior to assay of drug content. 
Table 3.1.1 Definitions used in the study 
• Stability The extent to which a product retains, within specified limits, and 
throughout its period of storage and use, (i.e. its shelf life) the same 
properties and characteristics it possessed at the time of its manu­
facture (USP 1994) 
• Shelf life The period of time during storage and use, at which the expected 
amount of active ingredient remains in the product 
• Batch A homogeneously produced number of drugs 
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Table 3.1.2 Definitions of simulated tropical conditions 
Test 
I 
II 
III 
IV 
V 
VI 
VII 
Storage condition 
Light exposure 
dark (D) 
dark (D) 
dark (D) 
dark (D) 
dark (D) 
dark (D) 
light (L) · " 
Temperature 
6-10°C 
20°C' 
30°C* 
30°C* 
40°C* 
40°C" 
20-25°C 
Relative humidity (RH) 
83-85%· ambient 
75%" 
4 5 % " 
75%" 
12-28%: ambient 
75%" 
20-35%: ambient 
Notation 
D6/83 
D20/75 
D30/45 
D30/75 
D40/25 
D40/75 
L20/30 
Specified within ± 2°C, 
Room temperature 
Specified within ± 5%, ' " Fluorescent white light, 450-650 nm, 1000 Lux, 
Assay method 
High Performance/Pressure Liquid Chromatography (HPLC) was used in 
preference to a radio-immunoassay. This method can differentiate between the 
active principle and its degradation products. The Radio Immuno Assay method, 
an other assay method is unable to make this distiction (Koskinen & Kleimola 
1976; Sondack 1978; Tokunaga et al. 1983; de Groot et al. 1993a; de Groot et 
al. 1994c). In short the HPLC analysis that was used in this study was as 
follows. The column was 25 cm χ 4.6 mm ID packed with Spherisorb 5-ODS 
(particle size 5 μιη; Chrompack, Middelburg, Netherlands) with a guard column 
(75mm χ 2.1 mm ID) packed with 10 μτη pellicular reversed phase (Chrompack, 
catalogue no 028653). An injection loop of 100 μΐ was used. The mobile phase 
consisted of a mixture of acetonitrile as solvent A and 0.067 M monobasic 
KH,P04: 0.05% diethylamine H20 buffer as solvent B; The mixture consisted 
of 60% of A and 40%) of B. All reagents were of analytical grade 
(Merck,Darmstadt,Germany). The flow rate was 1.2 ml.min'. Detection 
wavelength was 240 nm. The retention time was 6.8 min, the capacity factor 
was 3.24; the analysis was carried out at room temperature. The detection limit 
of ergometrine and methylergometrine in water was 0.55 ng both at a signal to 
noise ratio of three. The inter-day variation was 1.2% for ergometrine and 2.2% 
for methylergometrine and the intra-day variation was 1.73% for ergometrine 
and 5.07%) for methylergometrine. The data were analysed using a general 
linear model and a logistic regression model for ordinal response variables. 
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3.2 Results 
The raw data are published in the World Health Organisation/Drug Action 
Programme WHO/DAP-research series (de Groot et al. 1994c). At t=0, the 
initial drug content of 20 tablets of each brand fulfilled the pharmaceutical 
requirements. The results of test I (least extreme condition) and test VI (most 
extreme condition) for both ergometrine and methylergometrine tablets are 
shown in Figure 3.2.1. 
Ergometrine 
The level of active ingredient in the product declines when stored under all 
conditions studied. Under refrigerated storage (D6/83), the least extreme 
condition, ergometrine remained stable for 3 weeks (content was 100.7% of 
stated amount; 0.148±0.014 mg/tablet) but at 7 weeks only 85.1%; 0.125+0.005 
mg/tablet of the stated amount remained. When stored at 40°C and 75%RH in 
the darkness (D40/75), the most extreme condition, ergometrine was unstable 
with only 26.5% (0.039±0.008 mg/tablet) of the stated amount left after 3 
weeks, and < 1% (0.001±0.001 mg/tablet) after 52 weeks of exposure (Figure 
3.2.1). 
The influence of humidity was shown in the combination of test IV (D30/75), 
very humid, and test V (D40/25), hot and dry. At 30°C and 75%RH in the 
darkness (D30/75), only 23% (0.034±0.002 mg/tablet) of the stated amount 
remained after 21 weeks. At 40°C and 25%RH in the darkness (D40/25), 44.9% 
(0.066±0.010 mg/tablet) of the stated amount was left after 52 weeks. In these 
tests humidity had a greater influence on stability than temperature. 
The influence of light was shown in combination of test II (D20/75) and test 
VII (L20/30). At 3 weeks of exposure the influence of light was stronger than 
of humidity with only 61.2% (0.090±0.010 mg/tablet) of the stated amount 
left test VII whereas test II showed still 70.7% (0.104±0.008 mg/tablet) of the 
stated amount. However, over a period of a year the influence of light was 
weaker than that of humidity showing only 15.6 % at 52 weeks in test II 
(D20/75) and still 44.2% in test VII (L20/30). 
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Figure 3 2 1 Stability of oral ergometnne and methylergometnne exposed to least 
(I) and most (VI) extreme conditions 
E Ergomelnne 
ME Methylergometnne 
D6/83 test I 6°C, 83% RH and darkness 
D40/75 test V! 40°C, 75% RH and darkness 
Methylergometnne 
The drug was unstable under all conditions studied. Under refrigerated 
storage (D6/83), the least extreme condition, methylergometrine was stable for 
21 weeks (92.6% of stated amount; 0.088±0.003 mg/tablet) but after 30 weeks 
it no longer fulfilled the pharmaceutical requirements (52.6%; 0.050±0.002 
mg/tablet). At 40°C and 75%RH in the darkness (D40/75), the most extreme 
condition, the methylergometrine was unstable, with 63.2% (0.06010.003 
mg/tablet) of the stated amount left after 21 weeks, and < 50% (0.040±0.002 
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mg/tablet) after 52 weeks (Figure 3.2.1). 
Hardly any difference between test IV (D30/75) and test V (D40/25) was 
seen with respectively 49.5% (0.047±0.003 mg/tablet) and 51.6% (0.049±0.002 
mg/tablet) of the active ingredient left after 52 weeks of exposure. 
Under all conditions, the uncoated ergometrine tablets were far less stable 
than the coated methylergometrine ones. Instability rises with humidity (D30/75 
or D40/75) and temperature (D40/25), for both ergometrine and methyl-
ergometrine. In the least extreme condition the coating did not seem to protect 
the compounds anymore from week 31 onwards (Figure 3.2.1). 
During the tests, no differences in weight larger than 0.1 mg were noticed. 
Discolouration occurred in the tablets especially when stored under humid 
conditions. Growth of mould was observed on some tablets stored in humid 
conditions (tests II, IV and VI). 
3.3 Discussion 
Tablets 
Drug stability is dependent on many product-related factors (Barends 1990; 
van der Vaart et al. 1990), i.e. the active ingredient, the excipients, the dosage 
form, the manufacturing process and the nature of the packaging. Methylergo-
metrine tablets were included in our investigation because of the claims that 
methylergometrine shows less hypertensive side-effects and less influence on 
postpartum prolactin levels than ergometrine (Del Pozo et al. 1975; Symes 
1984). When supplied by Unicef methylergometrine tablets are as cheap as 
ergometrine. The choice of manufacturer was made on ready availability of 
their products. Although ergometrine and methylergometrine are supposedly 
being produced on "market demand", in practice they are produced only once 
a year. Only one batch was available from each manufacturer. As only one 
brand of ergometrine and methylergometrine are generally distributed 
comparison between brands as recommended by Hogerzeil et al. (1994) was not 
possible in this study. 
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Sampling points in time 
Long-term stability studies under "temperate climate" conditions normally last 
5 years (Hartmann et al. 1982). The tablets in this study have been subjected 
to conditions that are more extreme. A shorter period of investigation 
(accelerated stability study) has been accepted as deterioration of tablet quality 
will appear sooner. The stability test was performed for a period of one year 
only as in actual practice in tropical countries tablets should not be stored after 
opening of the box for longer periods. Loss of potency by water absorption was 
expected to occur early (Bos 1990). Therefore, the sampling in the beginning 
of the experiment was done more frequently and eight samplings were done 
over the first 21 weeks (Anonymous 1992). 
Under the least harmful storage conditions (D6/83) ergometrine and methyler-
gometrine were not stable for more than 7 and 21 weeks, respectively. The 
results are alarming, indicating that careful storage of those products is critical 
when used in tropical conditions. Refrigerated storage may be necessary. 
Protecting the tablets from humidity by coating or special packaging may help 
as humidity seems to be more harmful than temperature. Light is not as 
damaging on tablets as on ampoules of the drugs (USP 1994). 
Methylergometrine is substantially more stable than ergometrine even under 
test VI (D40/75). 
Conclusion and recommendations 
Both ergometrine and methylergometrine tablets are not stable under 
simulated tropical conditions. These tablets are the only oxytocic drugs given 
by mouth and therefore easy to administer when used by untrained people. 
However, because of their strong instability under the conditions studied, those 
preparations are not suitable for use as prophylactic agents of PPH. Moreover, 
pharmacokinetic data suggest that their absorption is also unreliable (de Groot 
etal. 1994a; 1994b). 
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4 Pharmacokinetics and bioavailability' 
The most recent publications concerning the pharmacokinetic properties of 
(methyl)ergometrine and its degradation products date from the late seventies 
(Mäntylä et al. 1978; Mäntylä & Kanto 1981). These studies showed a 
favourable bioavailability (F^60%) and a fast absorption in male volunteers. 
They did not show any correlation between the plasma level and the clinical 
effect of methylergometrine in postpartum women. In those studies a radio-im-
muno-assay (RIA) was used to establish the concentration and the absorption 
time of (methyl)ergometrine with its metabolites in both serum and urine. 
Metabolites in both plasma and urine could not be found via radio-immuno 
assay (RIA) due to the low concentrations. Because high performance liquid 
chromatography (HPLC) offers greater possibilities, a sensitive and selective 
HPLC analysis was developed to allow the pharmacokinetics of ergometrine to 
be followed. Ergometrine is the drug most often distributed in developping 
countries. Slight changes were made in the HPLC procedure in order to analyze 
the pharmacokinetics of methylergometrine. 
First the drug assay will be described (Chapter 4.1). In Chapter 4.2, the 
various experiments of ergometrine and methylergometrine in men are described 
and data for methylergometrine in men and non-pregnant women are compared. 
Excerpted from the following papers 
de Groot ANJA, Vree TB, Hekster YA, van den Biggelaar-Martea M, van Dongen 
PVV J High performance liquid chromatography of ergometrine and prelimary 
pharmacokinetics in plasma of men. J Chromatogr Biomed Appi 1993a; 613: 158-161. 
de Groot ANJA, Vree TB, Hekster YA, van den Biggelaar-Martea M, van Dongen 
PW J, van Roosmalen J. Pharmacokinetics and bioavailability of oral ergometrine in 
male volunteers. Biopharm Drug Dispos 1994a; 15: 65-73. 
de Groot ANJA, Vree TB, Hekster YA, van den Biggelaar-Martea M, van Dongen 
PWJ, van Roosmalen. Large variation in bioavailability of oral methylergometrine in 
human male volunteers. Drug Invest 1994b; 8(6): 345-361. 
de Groot ANJA, Vree TB, Hekster YA, van den Biggelaar-Martea M, van Dongen 
PWJ, van Roosmalen J. Identical large variation in bioavailability of oral 
methylergometrine and ergometrine in male volunteers. J Appi Ther: accepted for 
publication 1995c. 
de Groot ANJA, Vree TB, Hekster YA, van den Biggelaar-Martea M, van Dongen 
PWJ, van Roosmalen J. Comparison of bioavailability and pharmacokinetics of oral 
methylergometrine in men and women. Int J Clin Pharm Ther. 1995f; 33: 328-332. 
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4.1 Drug assay 
The prophylactic use of oxytocic drugs such as oxytocin, ergometrine and 
methylergometrine reduces the risk of postpartum haemorrhage (PPH) as well 
as the need for further oxytocic therapy in the puerperium (van Dongen et al. 
1991). The wide use of injectable ergometrine has become a point of discussion 
as the ampoule proves to be unstable under tropical conditions (Walker et al. 
1988; Hogerzeil et al. 1991; 1992). Therefore, a project, supported by the 
World Health Organisation (WHO), has been started to assess the place of oral 
ergometrine in the prevention of PPH in third world countries. 
Pharmacokinetic data for the pharmacologically similar ergot alkaloids 
ergometrine and methylergometrine are scarce (Rail & Schleifer 1985; 
Anonymous 1988a) and those which do exist are found in publications from the 
late seventies (Mäntyla et al. 1978; Mäntyla & Kanto 1981). In these studies, 
measurement of the compounds took place according to a Radio Immuno Assay 
method. The few studies dealing with the determination of ergot alkaloids in 
plasma employing HPLC either do not include ergometrine (Koskinen & 
Kleimola 1976; Edlund 1981; Smith & Molinaro 1988) or were developed to 
analyze the pharmaceutical formulation (Sondack 1978; Tokunaga et al. 1983). 
The aim of this investigation was to develop a sensitive and selective HPLC 
analysis which could be used for a pharmacokinetic analysis of ergometrine. 
4.1.1 Experimental 
Drugs 
Ergometrine maléate 0.2 mg (tablet = 0.147 mg free base) was obtained from 
Wolfs (Antwerpen, Belgium; batchnumber 91102). Ergometrine maléate 0.15 
mg/ml FNA (injectable solution) was obtained from Medisch Spectrum Twente 
(Enschede, The Netherlands; batchnumber 93125020). The ergometrine batches 
fulfilled the requirements of a content uniformity test according to standard 
quality control criteria. 
70 
Chemicals 
Analytical grade potassium dihydrogenphosphate and diethylamine were 
obtained from Merck (Darmstadt, Germany). Acetonitrile was obtained from 
FSA Laboratory supplies (Loughborough, UK). 
HPLC analysis 
The HPLC system consisted of a Spectra Physics SP 8775 autosampler 
(Spectra Physics, Eindhoven, The Netherlands), a SP 8800 Ternary HPLC pump 
(Spectra Physics), a fluorescence spectrophotometer F-1050 Hitachi (Merck, 
Amsterdam, The Netherlands), and an SP 4290 integrator (Spectra Physics). The 
column (25 cm χ 4,6 mm ID ) was packed with Spherisorb 5-0DS (Chrompack, 
Middelburg, The Netherlands), a guard column (75 mm χ 2,1 mm ID) was 
packed with 10 μτη pellicular reversed phase (Chrompack, Cat. no. 028653). An 
injection loop of 100μ1 was used. The mobile phase consisted of a mixture of 
0.067M KH2P04, 0.5 ml diethylamine in water (1:1) as solvent A and 
acetonitrile as solvent B. The mixture consisted of 65% A and 35% B. All 
reagents were of analytical grade. The flow rate was 1.2 ml/min. 
Fluorescense detection was achieved at 315 nm excitation and 430 nm 
emission. The retention time was 5.26 min, the capacity factor was 4.54, and 
the analysis was carried out at room temperature. 
Sample preparation 
Plasma samples of 300 μΐ were deproteinated by acetonitrile 1:1 and centri-
fuged at ll,000g during 4 minutes. Of the clear supernatant, 100 μΐ was 
injected onto the column. 
Calibration curves 
Standard solutions were freshly made before each new set of runs. They were 
stable during a period of 14 days when kept at 4"C in the refrigerator. 
Calibration curves were constructed by adding variable quantities of the 
standard solution to blank plasma. The correlation coefficient was 0.99949 for 
ergometrine, and the equation y = 33.32* + 0.408 in the concentration range 
of 0.075 ng/ml to 5.0 ng/ml, where χ is the concentration and y is peakheight, 
was used. 
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Concentration 
The concentration of ergometrine was measured using a calibration curve 
where peak, heights of the compound (y) were expressed versus spiked 
concentrations in plasma (x). 
Quantitation limit, validation 
The quantitation limit of ergometrine in plasma was 50 pg/ml at a signal-to-
noise ratio of 3. The intra-day variability and inter-day variability are given in 
Table 4.1.2.1. 
Subject 
One male (45 year) volunteered for a pilot pharmacokinetic analysis of the 
oral and intravenous administration of ergometrine. The volunteer was screened 
for possible contra-indications (cardio-vascular disease and chronic obstructive 
lung disease). Bodyweight, height, blood pressure, haemoglobin level as well 
as liver and renal functions were recorded. During the experiments the blood 
pressure was monitored. 
This study was approved by the Committee Experimental Research Involving 
Human Subjects (CEOM) of the University Hospital of Nijmegen. 
Dosage 
A single oral dose of ergometrine maléate 0.200 mg (=0.147 mg base; Wolfs) 
was given after a standard breakfast consisting of two sandwiches, no cheese, 
and unrestricted amounts of coffee or tea. For all tests, the time between the 
intake of breakfast and administration was at least one hour. One month later, 
0.075 mg ergometrine maléate (=0.055 mg base; Medisch Spectrum Twente) 
was injected i.v. during one minute in the same volunteer. 
Sampling procedures 
Oral administration of ergometrine 
Five ml blood samples were collected using an intravenous cánula (Venflon 
R
 1.0 mm 0D) at 0, 10, 20, 30, 60, 90, 180, 270, 360, 450 and 540 minutes 
after ergometrine administration. 
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Intravenous administration 
In addition to the sampling times as described under oral administration, two 
extra samples were taken 3 and 5 minutes after the start of the injection. 
After centri fugation of the blood samples, plasma samples were stored at 
- 20°C pending analysis. 
4.1.2 Results 
The intra- and inter-day variations are given in Table 4.1.2.1. Figure 4.1.2.1 
shows the chromatograms of two plasma samples containing ergometrine 
concentrations of 1.95 ng/ml and 0.70 ng/ml as well as the chromatogram for 
blank plasma. Ergometrine is shown to be separated from endogenous com­
pounds. Ergometrine in plasma 
ergometrine 
1.95 ng/ml 
Vp| 
asma 
ι — ι — ι — Γ -
0 10 min 
ergometrine 
0.70 ng/ml 
4 p| 
asma 
Blank plasma 
ι — ι — ι — Γ -
0 10 min 
Figure 4.1.2.1 Chromatograms in human plasma samples 
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Table 4 12 1 Inter-day and ïntra-day coefficient of variation of ergometnne in 
human plasma 
concentration Coefficient of variation (%) (n=4) 
(ng/ml) Inter-day Intra-day 
3 76 
1 89 
0 43 
0 10 
1 68 
2 11 
5 14 
6 10 
2 99 
2 68 
1 96 
3 05 
Figure 4.1.2.2 shows the ergometrine plasma concentrations (ng/ml) versus 
time after oral administration of 0.2 mg ergometrine maléate and after 
intravenous administration of 0.075 mg ergometrine maléate in one male volun-
teer. 
__ Ergometrine plasma cone, ng/ml 
0.055 mg ι v. 0.147 mg p.о. 
I I I Г 0 2 4 - [ — ι 1 1 I 6 8 10 h 
Figure 4 12 2 Ergometnne plasma concentration vs time curves of ergometrine after 
administration of an intravenous dose of 0 055 mg ergometrine base 
and after oral administration of 0 147 mg ergometnne base to the same 
male human subject 
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After oral administration, the compound is rapidly absorbed with a lag time 
of 5 minutes. A maximum plasma concentration of 1.32 ng.ml"1 was reached 
after 12 minutes. The half-life of ergometrine is 1.4 hours in this volunteer. 
After the intravenous administration, the half-life was similar compared to the 
oral administration. The relative bioavailability of the oral administration was 
calculated to be 1.00. During the experiments no change in bloodpressure was 
observed. 
4.1.3 Discussion 
Ergometrine concentrations in plasma could be accurately measured using a 
HPLC method with fluorescence detection. With this analytical method, proper 
pharmacokinetics of oral and parenteral ergometrine can be described. The 
method is comparable to those reported for methylergometrine but avoids the 
extraction step (Edlund 1981). The limit of quantitation of 50 pg/ml is 
comparable to that of methylergometrine [20 pg/ml (Smith & Molinaro 1988) 
and 100 pg/ml (Edlund 1981)] and sufficient to carry out pharmacokinetic 
studies. The volunteer in this study took also part in the pharmacokinetic study 
of ergometrine with six male volunteers, the results of which are given in 
chapter 4.2. 
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4.2 Pharmacokinetic experiments 
Ergometrine and methylergometrine belong to the group of oxytocic drugs 
which enhance uterine motility. As mentioned earlier (chapter 1.2.3) prophylac-
tic use of such drugs in the third stage of labour reduces the risk of PPH and 
the need for further oxytocic therapy in the puerperium. The use of oxytocics 
in the postpartum period is advocated for the prevention and the management 
of PPH (Prendiville et al. 1988). 
Because pharmacokinetic data for ergometrine and methylergometrine were 
scarce (Rail TW & Schleifer 1985; Anonymous 1988a) and mainly concerned 
methylergometrine (Mäntylä et al. 1978, Mäntylä & Kanto 1981), male 
volunteers were first studied to determine the pharmacokinetics for the oral 
administration of ergometrine. After the pharmacokinetic data of ergometrine 
in male volunteers showed a large variation in bioavailability (de Groot et al. 
1994a), a comparable study was performed for methylergometrine in both men 
and (non-pregnant) women to investigate and compare the results with the 
previous data. When unfavourable pharmacokinetic results in men and non-
pregnant women were found, no pharmacokinetic study in postpartum women 
was performed. 
Thus we performed three series of experiments: 
1. kinetics and bioavailability of oral ergometrine in male volunteers 
2. kinetics and bioavailability of oral methylergometrine in male volunteers 
3. kinetics and bioavailability of oral methylergometrine in non-
pregnant female volunteers. 
4.2.1 Methods 
Drugs 
Pure methylergometrine (reference substance 108) and ergometrine (reference 
substance 086) were obtained from Sandoz (Basel, Switzerland). 
Methylergometrine maléate as a 0.125 mg tablet MetherginR (equivalent to 
0.095 mg free base) was obtained from Sandoz (Nürnberg, Germany, batch 
number 3001). 
Methylergometrine maléate 0.20 mg/ml (injectable solution; equivalent to 0.152 
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mg free base) was obtained from Sandoz (Uden, The Netherlands; batch number 
475MFD920812). The injectable solution contained 93.3±6.5% of the claimed 
content (n=20). 
Ergometrine maléate as a 0.2 mg tablet (equivalent to 0.147 mg free base) 
was obtained from Wolfs (Antwerpen, Belgium; batch number 91102). 
Ergometrine maléate 0.15 mg/ml FNA (injectable solution; equivalent to 0.110 
mg free base) was obtained from Medisch Spectrum Twente (Enschede, The 
Netherlands; batch number 93125020). The injectable solution contained 
99.2%±0.15 (n=20) of the claimed content. 
The methylergometrine and ergometrine batches fulfilled the requirements of 
a content uniformity test according to standard quality control criteria. 
Subjects 
Twelve males and six non-pregnant women volunteered for the phar-
macokinetic study. The subjects were screened for possible contra-indications 
(cardio-vascular disease and chronic obstructive lung disease). Bodyweight, 
height, blood pressure, haemoglobin level as well as liver and renal functions 
were recorded. Demographic data of the volunteers did not differ (Table 
4.2.2.la/b). They all had normal liver and renal functions. During the 
experiments, blood pressure was monitored. This study was approved by the 
Committee Experimental Research Involving Human Subjects (CEOM) of the 
Academic Hospital Nijmegen, Sint Radboud, The Netherlands. 
Dosage 
The oral and intravenous dosages of both drugs were administered according 
to a randomized cross-over design with an interval of at least 2 weeks between 
the administrations. Ergometrine and methylergometrine were administered to 
two different groups, each group contained six male volunteers. Only 
methylergometrine was administered to the six non-pregnant women. 
A single oral dose of ergometrine maléate 0.200 mg was given. For the i.v. 
administration, 0.075 mg ergometrine maléate was injected. A single oral dose 
of methylergometrine maléate of 0.125 mg was given and for the i.v. 
administration 0.200 mg methylergometrine maléate was injected. Each 
volunteer received the drug in both forms of administration. 
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For all tests, the time between the intake of breakfast and dosing was at least 
one hour. The standard breakfast consisted of two sandwiches, no cheese, no 
butter and unrestricted amounts of coffee or tea. 
Sampling procedures 
Oral administration: Five ml blood samples were collected through an i.v.-
canula (VenflonR 1.0 mm OD) in tubes containing 0.5 mg Li+ heparin at 0, 10, 
20, 30, 60, 90, 180, 270, 360, 450, and 540 minutes after administration. 
Intravenous administration: Intravenous injection took place during one 
minute in the arm which did not have the i.v. cánula. In addition to the 
sampling times as described under oral administration, two extra samples were 
taken at 3 and 5 minutes after the start of the injection. 
After centrifugation of the blood samples at 11,000 g for 4 min, plasma 
samples from both the oral and intravenous groups were stored at -20°C 
pending analysis. Care was taken that all of the intravenous dose was admi-
nistered by cleaning the iv dosage line with 2 ml of 0.9% saline. 
Drug assay 
Methylergometrine and ergometrine in plasma was measured using an HPLC 
assay with fluorescence detection (Chapter 4.1). 
Pharmacokinetic analysis 
The pharmacokinetic parameters after intravenous administration were 
calculated using a two compartment model. After oral administration, it was not 
possible to calculate the distinct "distribution phase"; therefore, a one 
compartment model with lag-time was used for the oral data [MW\Pharm 
computer program MediwareR, Groningen, the Netherlands] (Proost & Meyer 
1992). 
Cmjx is the maximum plasma concentration read from the fitted plasma 
concentration-time curve (r2>0.98), and tmax the time at which Cmjx occurs. The 
t|/2ß values were calculated from ln(2)/ß, where ß is calculated by log-linear 
regression analysis of the terminal log-linear phase. The t,/2ab5orptl0n and \.
υ1α were 
obtained by line feathering and linear regression analysis. Mean Absorption 
Time (MAT) was used as a measure of the rate of absorption and calculated 
as the difference between [MRTpo-tlag] and MRT„. A U C ^ is the area under the 
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plasma concentration-time curve and was calculated using the linear trapezodial 
rule with extrapolation of t=oo, using Ct/ß with Ct being the last measured 
concentration. Total body clearance CL=Dose/AUC0.oo. 
The bioavailability (F) is AUCoral. Doselv/ AUClv.Doseora,. 
V5S is the volume of distribution in steady state (ν^ΟοΒε.ΑυΜΟο,ο,/ΑυΓο.^2). 
Analysis of variance was conducted according to standard procedures. The 
level of significance was defined at p>0.05. The coefficient of variation (CV) 
was calculated as SD/mean χ 100%. 
4.2.2 Results 
The mean demographic data of the volunteers are shown in Tables 4.2.2. la/b. 
Individual values are presented in Appendix 1: Tables IV.1-IV.4, ρ 150-153. 
The only significant difference is the bodyweight for men and women in the 
methylergometrine study. 
Table 4.2.2.2 summarizes the mean pharmacokinetic parameters after intrave­
nous and oral administrations of methylergometrine in six male volunteers. 
There is no statistically significant difference in intrinsic pharmacokinetic 
parameters such as t,/2D, CL and Vss. 
Table 4.2.2.1a Mean demographic data ± SD for the two groups of male volunteers 
for ergometrine and methylergometrine (n=6). 
age (years) 
weight (kilograms) 
height (cm) 
blood pressure 
systolic 
diastolic 
Ergometrine 
41.3+7.1 
72.3±4.0 
179±4.4 
122±2.6 
80 ± 5.8 
Methylergometrine 
35.7112.5 
74.7±3.7 
181+7.9 
119+4.9 
78 ± 7.1 
Significance(p) 
0.36 
0.32 
0.57 
0.30 
0.67 
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Table 4 2.2.1b Mean demographic data ± SD of six male and female volunteers for 
methylergometnne (n=6). 
Male Female Significance(p) 
age (years) 
weight(kilograms) 
height (cm) 
blood pressure 
systolic 
diastolic 
35.7+12.5 
74.7±3.7 
181+7.9 
119+4.9 
78 ± 7 . 1 
41.2+5 3 
60.5±6.0 
167±7.4 
114+10 
71+7.0 
0 34 
0.001 
0.009 
0.31 
0 11 
Table 4.2.2.2 Mean pharmacokinetic parameters ± SD of intravenous (0.152 mg 
base) methylergometrine and oral (0.095 mg base) in male volunteers 
(n=6). 
Intravenous Oral Significance (p) 
Dose (mg) 
F (%) 
t,
ag (h) 
i™ (h) 
С™ fog.L ' 
tabs' (h) 
t 
t|, 
MRT (h) 
MAT" (h) 
A U C 0 . „ - fog.h.L ') 
CL (L.h·1) 
V
ss
 (L) 
l/2o (h) 
• (h) 
0.152 
100 
0.1910.27 
1.85+0.28 
2.2510.44 
4.8211.82 
32 2111.80 
71 5125.9 
0.095 
84.9+37.2 
0.3310 09 
0 6810.22 
0.7710.34 
0.0810.08 
2.0810.43 
3.4510.56 
0 87+0.72 
2.17+0.80 
31.1110.3 
94.4138.9 
0.31 
0.0014 
0.17 
0 50 
0.11 
- - not detected, ' model independent, " one compartment model, "" calculated data, uncorrected for the dose 
Bioavailability (F) AUC„„, Doselv/AUC,v DoseorII sec also ρ 84-86 
t l l t (h) lag time 
tm„ (h) the time at which Cm l < occurs 
C„„ (μξ L ') the maximum plasma concentration read from the plasma-concentration-time curve 
tIbs (h) the half-life of absorption, calculated by least-square linear regression analysis 
t„2 a (h) the half-life of distribution, calculated by least-square linear regression analysis 
t|,2n (h) the half-life of elimination, calculated by least-square linear regression analysis 
MRTp,, (h) the mean residence time AUMC/AUC after oral administration 
MAT (h) the mean absorption time [MRTpo-t, ] and MRT,„ 
AUC0 1 ^ g h L ') the area under the plasma-concentration-time curve extrapolated to infinite time 
CL (L h " total body clearance = Dose/AUCo., 
и
(|_) the volume of distribution in steady state (V
u
= Dose AUMC0l/AUC„ ,
2) 
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Figure 4.2.2.1 shows the ergometrine plasma concentrations (ng/ml) versus 
time curves after oral administration and after intravenous administration of 
ergometrine maléate in one representative male subject. After oral 
administration, the compound is rapidly absorbed after a lag-time of less than 
0.5 minute. A maximum plasma concentration of 0.61 ng.ml"1 was reached 
after 85 minutes. The half-life of oral ergometrine is 2.0 hours in this volunteer. 
After the intravenous administration, the half-life was 1.6 hours. In this subject 
the relative bioavailability (F%) of the oral administration was calculated to be 
103.8 (=103.8%). 
10-
1-
Ergometnne plasma cone ng/ml 
0.1-
0 01-
• 0"-.. ye 
\ 
©•·. 
'··©. 
\ 
0.055 mg i.V. 
t l / 2 1 . 6 h 
©··. 
0.147 mg ρ о. 
t1 / 2 2.0 h 
~Г 
4 
~Г 
6 т 
8 
10 2 12 h 
Figure 4 2 2 1 Ergometrine plasma concentrations (ng/ml) versus time curves after 
oral administration of 0 200 mg ergometrine maléate (=0 147 mg free 
base) and after intravenous administration of 0 075 mg ergometrine 
maléate (=0 055 mg free base) in one male subject 
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Figure 4.2.2.2 shows the methylergometrine plasma concentrations (ng/ml) 
versus time curves after oral administration and after intravenous administration 
of methylergometrine maléate in one representative male subject. After oral 
administration, the compound is rapidly absorbed after a lag-time of 10 minutes. 
A maximum plasma concentration of 0.67 ng.ml"1 was reached after 24 minutes. 
After the intravenous administration, the half-life of methylergometrine is 2.31 
hours. The half-life was similar to that of the oral administration, 2.7 (h). In this 
subject the relative bioavailability (F%) of the oral administration was calculated 
to be 0.80 (=80%). 
10-
1-
0 .1 -
0.01-
Methylergometrine plasma cone, ng/ml 
0.095 mg p.o. 
t1/2 2.7 h 
0.152 mg i.v. 
t1/2 2.3 h 
Τ 
6 
О 
τ 
2 
10 12 h 
Figure 4.2.2.2 Methylergometrine plasma concentrations (ng/ml) versus time curves 
after oral administration of 0.125 mg methylergometrine maléate 
(=0.095 mg free base) and after intravenous administration of 0.200 
mg methylergometrine maléate (=0.152 mg free base) in one 
representative male subject. 
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Figure 4.2.2.3 shows the methylergometrine plasma concentrations (ng/ml) 
versus time curves after oral administration and after intravenous administration 
of methylergometrine maléate in one representative female volunteer. In that 
female volunteer, a maximum plasma concentration of 1.28 ng.ml"1 was reached 
after 38 minutes with a lag-time of 7 minutes. The half-life of oral 
methylergometrine was 1.5 hours. After the intravenous administration the half-
life was 2.1 h. In this subject, the relative bioavailability (F%) of the oral 
administration was calculated to be 0.73 (73%). 
10-
Ι ­
Ο 1 -
0.01· 
Methylergometrine plasma cone, ng/ml 
ƒ \* 
f 4 
r
-x. 
' \ 
'·©.. 
'•0 
0.095 mg p o . 
t 1 / 2 1.5 h 
0.152 mg ι.ν. 
t 1 / 2 2.1 h 
Τ 
6 
Τ 
θ 
Τ " 
10 1 2 h 
Figure 4 2 2.3 Methylergometrine plasma concentrations (ng/ml) versus time curves 
after oral administration of 0.125 mg methylergometrine maléate 
(=0.095 mg free base) and after intravenous administration of 0.200 
mg methylergometrine maléate (=0 152 mg free base) in one 
representative female volunteer. 
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Table 4.2.2.3a summarizes the pharmacokinetic parameters in men for 0.055 
mg ergometrine (base) and 0.152 mg methylergometrine (base). After 
intravenous administration, the pharmacokinetic profile can be described with 
a two-compartment model. As can been seen, there are no significant 
differences in these values. 
Table 4.2.2.3a Mean pharmacokinetic parameters ± SD of intravenous administration 
for the two groups of male volunteers for ergometrine (0.055mg base) 
and methylergometrine (0.152mg base) (n=6). 
Ergometrine Methylergometrine Significance (p) 
>0.8 
0.80 
0.30 
>0.8 
0.40 
Dose (mg) 
t„2« (h) 
I,™ (h) 
MRT (h) 
CL (L.h 1) 
ViS (L) 
V
s s
.kg' (L.kg ') 
0.055 
0 16+0.20 
2.5711.05 
2.9011.38 
32.6112.0 
82.0114.5 
-.-
0.152 
0.19+0.27 
1.85+0.28 
2.25+0.40 
32.2+11.8 
71.5125.9 
0.96+0.36 
Abbreviations under Table 4 2 2.2 ρ 80 
Table 4.2.2.3b Mean pharmacokinetic parameters 1 SD of intravenous methyl­
ergometrine (0.152mg base) of six male and female volunteers (n=6). 
Male Female Significance(p) 
0.46 
0.64 
>0.8 
0.073 
0.091 
0.43 
Dose (mg) 
t,/2a (h) 
t|/2B (h) 
MRT (h) 
CL (L.h1) 
V
ss
 (L) 
V
s
,kg ' (L.kg ') 
0.152 
0.19+0.27 
1.85+0.28 
2.25+0.40 
32.2+11.8 
71.5+25.9 
0.96+0.36 
0.152 
0.10+0.04 
1.9410.34 
2.31+0.31 
22.2+3.10 
50.8+8.23 
0.84+0.12 
Abbreviations under Table 4 2 2 2 p80 
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In Table 4.2.2.3b the same pharmacokinetic parameters for 0.152 mg 
methylergometrine (base) in the six female and six males are given. Again the 
pharmacokinetic profile following intravenous administration can be described 
with a two-compartment model. As can been seen, there is no significant 
difference except for trends in CL and V
ss
. 
Table 4.2.2.4a summarizes the pharmacokinetic parameters in men for 0.095 
mg oral methylergometrine (base) and 0.147 mg ergometrine (base). After oral 
administration, the pharmacokinetic profile can be described with a one 
compartment model. The biovailability (F%) is subject dependent with the 
assumption that the total body clearance is similar after intravenous and oral 
administration. The lag-time 0.11±0.10 h for ergometrine, was significantly 
shorter than 0.33 ±0.09 h for methylergometrine 
Table 4 2 2 4a Mean pharmacokinetic parameters ± SD of oral administration for the 
two groups of male volunteers for ergometrine (0.147mg base) and 
methylergometrine (0 095 mg base) (n=6) 
Dose (mg) 
F (%) 
t,aB (h) 
tm., (h) 
C^OtgL') 
l ! 2atK* ( h ) 
W (h) 
t, 2» (h) 
MRT^ (h) 
MAT" (h) 
A U C 0 o / " ^ g h L ' ) 
CL (L h ') 
V„ (L) 
V
sb kg • (L kg ') 
Ergometrine 
0 147 
80 7±34 5 
0 11+0 10 
0 69±0 59 
1 07±0 29 
0 20±0 22 
1 91±0 15 
3 08±0 53 
1 26±0 90 
3 00±0 89 
36 5+12.1 
98 9±36 6 
Methylergometrine 
0 095 
84 9±37 2 
0 33±0 09 
0 68±0 22 
0 77±0 34 
0 08±0 08 
--
2 08±0 43 
3 45±0 56 
0 87±0 72 
2 17+0 80 
31 1 + 10 3 
94 4+38 9 
1 26+0 50 
Significance(p) 
>0 8 
0.003 
>0 8 
0 13 
0 25 
0 39 
0 27 
0 43 
-
041 
>0 8 
-
Abbreviations under Table 4 2 2 2 ρ 80 
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In Table 4.2.2.4b the same pharmacokinetic parameters for 0.095 mg oral 
methylergometrine (base) in the six female and six males are given. Again the 
pharmacokinetic profile following oral administration can be described with a 
one compartment model. The elimination half-life (t,/2ß) was significantly longer 
in men than in women (p=0.0123). The lag-time for methylergometrine was 
significantly longer in men 0 33±0.09 h than in women 0.0910.07 h (p=0.0004). 
The total body clearance was with 31.Ш0.3 L.h ' and 23.6+4.01 L.h"1 similiar 
for men and women, respectively. The volume of distribution was significantly 
larger in men than in women, 94.4±38.9 L vs 47 0±6.05 L (p=0.01). 
Side-effects 
After intravenous administration of 0.2 mg methylergometrine maléate, two 
men experienced a "weird" sensation, and another nausea Three women became 
dizzy after the methylergometrine injection, after oral dosing none of them 
experienced side-effects. Only one volunteer experienced nausea after 
administration of oral 0.2 mg ergometrine maléate. 
Table 4 2 2 4b Mean pharmacokinetic parameters ± SD of oral methylergometrine 
(0 095 mg base) of six male and female volunteers (n=6) 
Female 
0 095 
96 4±27 5 
0 09±0 07 
0 97+0 74 
1 21±0 40 
0 50±0 55 
1 42±0 31 
2 87+0 56 
0 57+0 34 
3 49±0 70 
23 6±4 01 
47 0±6 05 
0 78±0 05 
Signifn 
0 56 
0.0004 
0 39 
0 064 
0 10 
0.0123 
0 10 
0 38 
-
0 13 
0.01 
0 039 
Abbreviations under Table 4 2 2 2 ρ 80 
Dose (mg) 
F (%) 
t,
ae
 (h) 
t™, (h) 
C
m a x
 (μ
β
 1 ') 
Ws' О1) 
t,
 2a (h) 
t„2ß (h) 
MRT (h) 
M A T ' (h) 
AUC0o/*'^ghL') 
CL (L h ') 
V„ (L) 
Vss kg ' (I kg ') 
0 095 
84 9±37 2 
0 33±0 09 
0 68±0 22 
0 77+0 34 
0 08±0 08 
2 08+0 43 
3 45±0 56 
0 87+0 72 
2 17±0 80 
31 1±103 
94 4±38 9 
1 26±0 50 
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4.2.3 Discussion 
Oral methylergometrine has been proposed to be used in postpartum women. 
The aim of this study was to examine whether oral methylergometrine could be 
a possible alternative to injectable oxytocics used in the third stage of labour. 
Unexpectedly large variations in bioavailability and pharmacokinetics of oral 
ergometrine in male volunteers were found (de Groot et al. 1994a). The vast 
variability of pharmacokinetic parameters reported for ergometrine (de Groot 
et al. 1994a) was not reported in literature for methylergometrine (Rail & 
Schleifer 1985; Anonymous 1988a). These studies reported that methyler-
gometrine had a fast gastro-intestinal absorption, and that about 60% of the 
orally administered dose reaches the systemic circulation (Mäntylä et al. 1978). 
The information was based on only two subjects. 
However, this present study has shown an identically large variation in 
bioavailability of methylergometrine in men as for ergometrine. In men, the 
overall bioavailability was 80.7±34.5 % and 84.9±37.2% for ergometrine and 
methylergometrine, respectively. The variation was «40% CV. An identical 
variation in bioavailability was seen after oral administration of 
methylergometrine in women. After intravenous administration, the pharmaco-
kinetic parameters of methylergometrine did not show any difference between 
men and women except for the Vss, which was larger in men (p=0.091). This 
effect was more pronounced after oral administration of the drug (p=0.01). The 
oral administration showed more differences between the pharmacokinetic 
parameters in men and women. Men showed a longer lag-time (p=0.0004), a 
larger volume of distribution (p=0.001), and a longer t1/2D (p = 0.0123). The 
mean body weight of the men was significantly larger than that of the women 
(p=0.0010). Corrected for the body weight, the Vss did not differ between men 
and women after an intravenous administration of 0.2 mg methylergometrine 
maléate: 0.84±0.12 L.kg"' for women and 0.96±0.36 L.kg"' for men 
(p=0.4).However, after oral administration of 0.125 mg methylergometrine 
maléate, the Vss.kg"1 remained larger in men 1.26±0.50 L.kg"1 than in women 
0.77+0.05 L.kg1 (p=0.0393). 
After oral administration of the drug, absorption is subject dependent. The 
half-life of absorption (t1/2abs) is the result of absorption and distribution 
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processes. Because it was not possible to calculate the "distribution phase" after 
oral administration, the one-compartment model was used for the data. 
Calculated by a one-compartment model t,/2abs data are underestimated as this 
model neglects the distinct distribution phase. Therefore we also calculated the 
mean absorption time (MAT). MAT is an alternative method to measure the rate 
of absorption and is model independent. MAT can be calculated from [MRTpo -
tlag] -MRT,V. The MAT neither differed significantly in men between 
methylergometrine and ergometrine (p=0.43) nor between men and women 
(p=0.38) for methylergometrine. The intrinsic pharmacokinetic parameters such 
as t,/2ß, CL and Vss in men and women depend on the drug and not on the route 
of administration (Table 4.2.2.4b). 
In short, no real differences in pharmacokinetics were found in men between 
ergometrine and methylergometrine nor were differences between men and 
women for methylergometrine shown in this study. All these experiments 
showed large variations in bioavailability and pharmacokinetics. 
As instability of (methyl)ergometrine tablets could influence the 
pharmacokinetic results, the drugs used in the experiments were tested for 
stability. The batches from which the tablets were taken fulfilled the content 
uniformity test's requirements. Therefore, instability of the used tablets was 
ruled out as a possible explanation for the large interindividual variations of 
bioavailability and lag time, after oral administration. The intravenous drug was 
stable and care had been taken that all of the dose was administered by cleaning 
the syringe with 2 ml of 0.9 % saline. 
However, the purpose of administration of oral (methyl)ergometrine is to 
reduce postpartum blood loss. Therefore, a randomized trial has been set up to 
show whether a clinical effect despite possible varying pharmacokinetics could 
be demonstrated. 
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5 Pharmacodynamics' 
Uterine activity can be stimulated during menorrhagia or the postpartum 
period. Ergot alkaloids were one of the earliest stimulants in obstetrics, applied 
as treatment or prevention of postpartum haemorrhage first noticed by Caspar 
Schwenkfeldt in 1600 (Barger 1931). In contrast to oxytocin and prostaglandins, 
ergot alkaloids can be given orally which has the advantage of easy drug 
administration. Pharmacokinetic and pharmacodynamic data on oral ergot 
alkaloids are, however, sparse. 
Postpartum haemorrhage is responsible for 150,000 deaths worldwide a year 
(Kwast 1991b). About ninety-eight percent of which occur in developing 
countries (Royston & Armstrong 1989). In these countries active management 
of the third stage of labour with oxytocics is particularly advocated (WHO 
1990). Intramuscular oxytocin, the standard care in the third stage, is not 
available to all women. Although not recommended by the manufacturer, oral 
use of methylergometrine maléate may be considered as an easy alternative. 
Before starting worldwide distribution of these tablets extensive study on the 
stability, pharmacokinetic and pharmacodynamic parameters and clinical effect 
had to be performed. 
This study assessed simultaneously pharmacodynamic and pharmacokinetic 
parameters of oral and intravenous methylergometrine maléate on uterine muscle 
in six non-pregnant women at the second day of the menstrual cycle (CD 2) 
because at CD 2 the menstruating uterus resembles the uterus in the postpartum 
period (Hendricks 1966). 
5.1 Material and methods 
Subjects 
Six non-pregnant women with regular menstrual cycles volunteered for the 
Based upon the paper: de Groot ANJA, van Dongen PWJ, Vree TB, Eskes ТКАВ. Oral 
administration of methylergometrine shows a late and unpredictable effect on the non­
pregnant human menstruating uterus. Eur J Obstet Gynecol Reprod Biol 1995d; 
2: 101-107. 
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pharmacokinetic and pharmacodynamic studies with methylergometrine maléate. 
They were screened for possible contra-indications such as cardio-vascular 
disease, chronic obstructive lung disease, fibroids or uterine surgery, and should 
have had a tubal ligation to prevent any negative interaction with fertility. 
This study was approved by the Committee Experimental Research Involving 
Human Subjects (CEOM) of the University Hospital Sint Radboud, Nijmegen, 
the Netherlands. 
Intra-uterine pressure (IUP) recordings 
Intra-uterine pressure was recorded using a fluid-filled sponge-tipped catheter 
(Hendricks 1966; Bengtsson 1968). 
The portio vaginalis was cleansed and disinfected with iodine. The open-tip 
sponged catheter was inserted over a guiding tube. The uterus was manipulated 
as less as possible in order not to cause any interference with the uterine 
contractility pattern. A gauze (10x1 Ocm) was left in the vagina while the 
catheter was fixed on the upper leg to prevent expulsion. The catheter was 
connected to a pressure-transducer, which was connected to a computer. The 
woman was in supine position during the registration. The pressure-transducer 
was fixed on the mattress being the level of the surface supporting the supine 
volunteer. Zero pressure was set at atmospheric pressure at this "mattress"-level 
(Faber 1992). The location of the catheter was controlled by asking the 
volunteer to cough. Proper intra-uterine position showed than a pressure 
elevation (about 10 mmHg). 
Because presence of any foreign body in utero causes an increase of basal 
pressure level for at least 20 minutes (Braaksma 1970), we waited thirty 
minutes to allow the "cyclic-specific" pattern to develop and then started the 
study. After recording uterine activity at least 60 minutes after the insertion of 
the sponge-tipped catheter, methylergometrine maléate was administered either 
intravenously or orally. The registration ended when the catheter was expelled. 
If the catheter remained its position, it was removed after 5 h. 
A transurethral catheter was inserted to provide continuous bladder drainage 
because filling of the bladder was reported to effect IUP (Braaksma 1970). 
Digitalization of the signal (IUP) 
The intra-uterine pressure signal was filtered by 0.65 Hz. Total noise with 
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shortened impulse was measured over 15 min (mean+SD = 0.442+0.084), which 
did not disturb the general activity pattern. 
To obtain an accurate signal, the range of the mercury scale has been set on Ο­
Ι 50 mmHg. 
Measurements were made using the DTX/plus pressure-transducer (Viggo-
spectramed, Oxnard, California, USA) and a special developed amplifier before 
the signal was fed to a personal computer (DASH-8, Metrabyte). Special care 
has been taken for patient safety by a safety-chart. The software has been 
developed with Borland C++ (Scotts Valley, California, USA). Events were 
marked by special keys. Recordings were stored in files which were Microsoft 
Excel compatible. The resolution of the whole system was about 0.5 mmHg. 
The system was calibrated electronically and mechanically (mmHg). 
Pharmacodynamics 
Mechanical uterine activity was measured by IUP-recordings. Contractions 
were expressed in IUP-cycles. An IUP-cycle was defined as a transitory rise 
above the basal tone. To describe uterine activity, IUP-cycle specific parameters 
were distinguished: frequency (F), basal tone (BT), intensity (I) and amplitude 
(A=I-BT). The number of IUP-cycles in a 5 minutes' period were recorded and 
the mean value of F, BT and A of the IUP-cycles in each 5 minutes' period was 
calculated. 
The mean values of these parameters (F, BT and A) during the thirty 
minutes' registration of the "cyclic-specific" pattern were regarded as base-line 
values and set at 100%. For each parameter the relative increase in a 5 minutes' 
period was expressed as percentage of base-line value and plotted versus time. 
For each IUP-recording, the area under the curve (AUC) was calculated in 
time-intervals of 30 minutes and from the time of drug administration till 90 
minutes after administration. 
IUP-recordings 
Registration took place at the 2nd day of the cycle (CD 2) of two subsequent 
menstrual cycles to rule out a possible refractory period, i.e. uterine insensitivity 
to methylergometrine maléate. In addition four women were also examined 
when 0.2 mg methylergometrine maléate was injected on the third day of the 
menstruation of the second cycle (CD 3), i.e. 24 h after the oral test. 
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Drugs 
Pure methylergometrine (reference substance 108) was obtained from Sandoz 
Pharma AG (Basel, Switzerland). Methylergometrine maléate (0.125 mg tablet 
MetherginR; equivalent to 0.095 mg free base) was obtained from Sandoz 
Germany, Nürnberg; batch number 3001. 
Methylergometrine maléate (0.20 mg/ml injectable solution; equivalent to 0.152 
mg free base) was obtained from Sandoz, Uden, The Netherlands; batch number 
475 MFD 920812. 
These methylergometrine maléate batches fulfilled the requirements of 
standard quality control criteria. 
Dosage 
• For the assessment of the biovailability of methylergometrine maléate a 
cross-over design was used for the intravenous and oral administrations of 
methylergometrine maléate. An intravenous dose of 0.2 mg methylergometrine 
maléate was injected at CD 2 after a standard breakfast containing two sandwi-
ches, no cheese and unrestricted amounts of coffee or tea by all subjects. The 
drug was administered at least one hour after insertion of the IUP-catheter. Care 
was taken that all of the intravenous dose was administered by cleaning the 
intravenous dosage-line with 2 ml 0.9% saline. 
An oral dose of 0.5 mg methylergometrine maléate was given after a 
standard breakfast on the second day of the next menstrual cycle. 
• An additional intravenous administration was administered in four women on 
CD 3, 24h after oral administration at CD 2. 
Sampling 
Oral administration 
Blood samples of 5 ml were collected through an intravenous (i.v.) internal 
catheter (Venflon R 1.0 mm OD) in tubes containing 0.5 mg Li heparin at times: 
0, 10, 20, 30, 60, 90, 180, 240 minutes. 
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Intravenous administration 
Intravenous administration of methylergometrine maléate took place during 
one minute in the opposite arm where the Venflon was located. In addition to 
the sampling times as described under oral administration, two extra samples 
were taken at 3 and 5 minutes after the start of the injection. 
After centrifugation of the blood samples at 11,000 g for 5 min, plasma 
samples from both the oral and intravenous groups were stored at - 20°C 
pending analysis. 
Drug analysis 
Drug analysis was performed by High Pressure Liquid Chromatography 
(HPLC) according to de Groot et al. (de Groot et al. 1994b). 
Pharmacokinetic analysis 
The pharmacokinetic parameters were calculated from a two-compartment 
model after intravenous administration and from a one-compartment model with 
a lag-time fitted to oral data [MW/Pharm computer program MediwareR, 
Groningen, the Netherlands] (Proost & Meijer 1992). Cmax is the maximum 
plasma concentration read from the fitted plasma concentration-time curve 
(r2>0.98), and tmay the time at which Cmj4 occurs. The t1/2B values were 
calculated from ln(2)/ß, where ß is calculated by log-linear regression analysis 
of the terminal log-linear phase. The tl/2jbsorpllon and t1/2a were obtained by line 
feathering and linear regression analysis. 
Mean Absorption Time (MAT) was used as a measure of the rate of absorp-
tion and calculated as the difference between [MRT -t, ] and MRT]V. 
АиС0.и is the area under the plasma concentration-time curve and was 
calculated using the linear trapezodial rule with extrapolation of t=oo, using Ct/ß 
with Ct being the last measured concentration. The bioavailability (F) is 
AUCoral. Dose,,/ AUC„.Dose„rjl. Total body clearance CL = F.Dose/AUC0.œ. Vss 
is the volume of distribution in steady state (Vss = F.Dose.AUMCo^/AUCo^2). 
Analyses of variance were conducted according to standard procedures. The 
level of significance was defined at ρ = 0.05. 
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5.2 Results 
Subjects 
Six women entered the study. Their mean age was 38±5 year, mean weight 
59±5 kg and a mean length of 167+6 cm (mean±SD). The blood pressure 
ranged between normal values; mean systolic pressure 113±11 mmHg, mean 
diastolic pressure 73±8 mmHg. They all had an normal sized uterus in a 
position of anteversion-anteflexion. 
Pharmacokinetic results 
Table 5.2.1 summarizes the mean pharmacokinetic parameters of 0.2 mg 
methylergometrine maléate after intravenous administration and of 0.5 mg after 
oral administration in the six women at CD 2. After intravenous administration 
the distribution half-life (t,/2cl) was 0.09±0.04 h. The elimination half-life (t,/2ß) 
was 2.0±0.3 h. The total body clearance (CL) amounted to 22.012.7 L.h"1 and 
the steady state volume of distribution (Vss) was 50.5±5.8 L.h"1. After oral 
administration of methylergometrine maléate the lag time was 0.30±0.08 h, the 
absorption half-life (t1/2jbs) was 0.14±0.12 h, the mean absorption time (MAT) 
was 0.40+0.35 h and the elimination half-life (t1/2D) was 1.59±0.32 h. Total body 
clearance was 30.0+8.8 L.h'1 and the volume of distribution was 68.6+24 L. 
The biovailability (F) was subject dependent and ranged between 47.7 and 
94.6%, with the assumption that the total body clearance is similar after 
intravenous and oral administration. Large interindividual differences in Cma4 
(53%CV), tmjv (56%CV) and t,/2jhs (85%CV) after oral administration were 
recorded. Two volunteers showed prolonged absorption and were left out in the 
calculation of the means. 
Table 5.2.2 summarizes the pharmacokinetic parameters after additional 
intravenous administration of 0.2 mg methylergometrine maléate in four women 
when it was injected on CD 3 of the second cycle, i.e. 24 h after the oral 
administration. There is no difference in pharmacokinetic parameters after the 
intravenous dosage at CD 2 of the first menstrual cycle and at CD 3 of the 
second cycle (p>0.05). The individual pharmacokinetic parameters of 
methylergometrine maléate following intravenous and oral administrations are 
shown in appendix 2 Table V.l, ρ 154. 
94 
Table 5.2.1 Pharmacokinetic parameters (mean ± SD) of methylergomelrine maléate 
after intravenous 0.2 mg (0.152 mg base) and oral 0.5 mg (0.380 mg 
base) administration in six female volunteers. 
Dose (mg) 
F (%) 
t,aB (h) 
t™, (h) 
Cmax ^g.L'') 
1
І/2аЬ5 ( h ) 
t, J n*(h) 
t|/2B О») 
MRT (h) 
MAT" (h) 
AUC0.„ fog.h.L"
1) 
CL (L.h1) 
V
ss
 (L) 
Intravenous 
0.152 
0.09±0.04 
2.0 ±0.3 
2.3 ±0.4 
6.2 ±0.57 
22.0±2.7 
50.5+5.8 
Oral 
0.380 
74.2±18.5 
0.30±0.08 
0.75±0.40 
3.88±2.19 
0 1410.12 
-.-
1.6 ±0.3 
2.8 ±0.4 
0.40±0.35 
9.6 ±4.8 
30.0+8.8 
68.6124.0 
Significance (ρ) 
0.0855 
0.0855 
-
0.0607 
0.1048 
Bioavailability (F) AUC^.Dose.yAUC,. Dose
or 
4 (h) 
t
m
„ (M 
C
m
„ ( H g L ' ) 
t,™» (h) 
W(h) 
t„2B (h) 
MRT„ (h) 
MA Г (h) 
A U C 0 l U i g h L ' ) 
CL ( L h " 
V„ (L) 
lag time 
the time at which C
m
„ occurs 
the maximum plasma concentration read from the plasma-concentration-time curve 
the half-life of absorption, calculated by least-square linear regression analysis 
the half-life of distribution, calculated by least-square linear regression analysis 
the half-life of elimination, calculated by least-square linear regression analysis 
the mean residence time AUMC/AUC añer intravenous administration 
the mean absorption time [MRTpo-t,ae] and MRT,V 
the area under the plasma-concenlration-time curve extrapolated to infinite time 
total body clearance = Dose/AUC0 l 
the volume of distribution in steady state (
 и
 = Dose AUMC0JA\JC„1. ) 
one-compartment, " model independent; -.- not detected 
Table 5.2.2 Pharmacokinetic parameters (mean±SD) in four females 
A Intravenous methylergometrine maléate (ME) (0.2 mg) without 
preceding oral ME 
В Intravenous ME (0.2 mg) with preceding oral ME (0.5 mg). 
1.2« (h) 
t,
 : л
 (h) 
MRTI4 (h) 
AUCüa№g. 
CL (L.h') 
V„ (L) 
h.L"') 
A 
0.09+0.04 
2.0 ±0.3 
2.3 ±0.4 
6.2 ±0.6 
22.0±2.7 
50.5±5 8 
В 
0.05+0.02 
1.9 ±0.5 
2.2 ±0.6 
7.0 ±3.1 
24 0±9.3 
49.8+15.9 
Significance (ρ) 
0.14 
0 78 
0.65 
0.55 
0.63 
>0 8 
Abbreviations see Table 5 2 I 
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Pharmacodynamic results, effect of methylergometrine maléate on IUP 
When 0.2 mg methylergometrine maléate was injected intravenously on CD 
2 of the first menstrual cycle, the frequency of uterine contractions and basal 
tone increased in all six women while the amplitude of the uterine contractions 
decreased. This effect lasted at least 90 minutes with a maximum effect at 30 
minutes. The effect of 0.5 mg oral methylergometrine maléate on uterine 
activity on CD 2 of the second menstrual cycle in the same woman was much 
less marked than after the intravenous administration. 
Figure 5.2.1 and 5.2.2 show an uterus well responding to both routes of 
administration and a uterus responding to intravenous but hardly to oral 
administration respectively. The best (volunteer 1) and worst (volunteer 2) 
responding registrations are shown. 
Figure 5.2.1 shows the effect of methylergometrine maléate on IUP in 
volunteer 1. At the top of the figure the IUP-recordings after intravenous {left 
panel) and oral {right panel) administrations are given. At the bottom the mean 
values of F, BT and A of the IUP-cycles over 5 minutes' periods are shown. 
The left panel shows the fast increase in frequency, basal tone and decrease 
in amplitude of uterine contractions after intravenous administration of 0.2 mg 
methylergometrine maléate. Within three minutes after the injection, the 
frequency of contractions increased with 350% to a maximum of 650% as 
percentage of the baseline frequency value. After 35 minutes the increase of 
frequency was reduced to 200% of the baseline value. The basal tone showed 
a fairly identical pattern with a maximum increase of 700% within 10 minutes 
after drug administration. Basal tone remained increased till 550% of its 
baseline value till 70 minutes after drug administration. The amplitude 
decreased to 30% of its baseline value within 10 minutes and remained reduced 
during further recording. 
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Figure 5 2 1 
Top-trace 
Bottom-trace 
Effect of methylergometnne maléate (ME) after intravenous (0 2 mg) 
[left] and oral (0 5 mg) [right] administration in volunteer 1 At t=0, 
ME was administered. 
Effect on intra-uterine pressure 
Effect on frequency (F), basal tone (BT) and amplitude (A) The mean 
values of F, В and A during thirty minutes before drug administration 
were regarded as baseline values and set at 100%, the increase in a 5 
minutes' period was expressed as % or baseline value and plotted 
versus time after intravenous (0 2 mg) ME and oral (0 5 mg) ME 
administrations 
The right panel shows the late and less marked effect after oral adminis­
tration of 0.5 mg methylergometrine maléate. An increase in frequency of 240% 
occurred 35 minutes after drug administration. A maximum increase of 320% 
of the baseline value was reached after 50 minutes. An increase in basal tone 
was seen after 30 minutes with maximum values of 700% after 50 minutes. The 
basal tone remained elevated compared to the baseline values. The amplitude 
decreased to 17% after 55 minutes, but returned to its baseline value 80 minutes 
after drug administration. 
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Intravenous Oral 
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Figure 5.2.2 Effect of methylergometrine maléate (ME) after intravenous (0.2 mg) 
[left] and oral (0.5 mg) [right] administration in volunteer 2. At t=0, 
was administered. 
For explanation of tracings, see Figure 5.2.1. 
Figure 5.2.2 shows the effect of methylergometrine maléate on IUP in 
volunteer 2: she responded well to the intravenous dose but badly to the oral 
dose compared to volunteer 1. At the top of the figure the IUP-recordings after 
intravenous (left panel) and oral (right panel) administrations are given. At the 
bottom the mean value of F, BT and A of the IUP-cycles over 5 minutes' 
periods are shown. 
The different responses to oral administration in volunteer 1 and 2 is shown 
clearly in the bottom-tracings (effect on F, BT and A) of Figures 5.2.1-2. 
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Figure 5.2.3 Effect of methylergometrine maléate (ME) after intravenous (0.2 mg) 
administration without preceding oral ME [left] and with preceding oral 
ME (0.5 mg) [right] in volunteer 1. At t=0, methylergometrine maléate 
was administered. For explanation of tracings, see Figure 5.2.1. 
Figure 5.2.3 shows the effects of the intravenous dose on IUP without and 
with preceding oral methylergometrine maléate (0.5 mg) in volunteer 1. When 
0.2 mg methylergometrine maléate was injected 24 h after the oral test, hardly 
any changes in BT, F and A of intra-uterine pressure were recorded. 
Figure 5.2.4 illustrates the mean basal tone, mean frequency and mean 
amplitude in 5 minutes' periods after oral and intravenous administrations 
(A: left panel) and after intravenous administration at CD 2 and the day after 
an oral test CD 3 (B: right panel). The values used in the figure are the mean 
values of the 6 different volunteers. The figure clearly illustrates the different 
patterns in F, BT and A after intravenous or oral administrations (left panel). 
It shows also that there is hardly any uterine response to a 0.2 mg intravenous 
dose if this is preceded by an oral dose of 0.5 mg methylergometrine maléate 
24 h before (right panel). The graphs are derived from the individual data 
shown in appendix 2 Tables V2-V5, ρ 155-158. 
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Figure 5 2 4 Mean basal tone (ВТ), mean frequency (F) and mean amplitude (A) of intra-utenne 
pressure (lUP)-cycles in a 5 minutes' period versus time At t=0, MF. was 
administered 
A left panel The effect of intravenous (0 2 mg) and oral (0 "> mg) administrations of ME on mean 
BT (mmHg), mean F (number of IUP/5 minutes' period = IUP пЛтіп) and A 
(mmHg) of IUP-cycle in a 5 minutes period, in menstruating women (n=6) 
В right panel The effects of 0 2 mg ME on the same parameters are shown without (n~6) and with 
(n=4) 0 5 mg ME given orally 24 h before the intravenous administration 
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Table 5.2.3 shows the AUC of the individual IUP-recordings. When AUC 30 
minutes before drug-administration (AUC ,„_„) is compared to AUC 30 minutes 
after drug administration (AUC0^30), a marked increase in AUC is seen after 
intravenous administration and hardly any after oral administration. After oral 
administration a (slight) change in AUC was seen in the period between 30 and 
60 minutes after the intake of 0.5 mg methylergometrine maléate. When 0.2 mg 
methylergometrine maléate was injected 24 h after the oral test, the AUC was 
less marked than after the injection of 0.2 mg methylergometrine maléate at CD 
2 of the first menstrual cycle and even less than after the oral administration of 
0.5 mg methylergometrine maléate (Table 5.2.3). Table 5.2.3 has been derived 
from appendix V.6 (p 159-164). 
Table 5.2.3 Area under the curve of IUP (AUC) during several time-periods in relation 
to intravenous (0.2 mg) and oral (0.5 mg) administrations of methylergo-
metrine maléate (ME) 
Volunteer 
A 
• Intravenous 
AUC 
AUC 
AUC 
AUC 
AUC 
• Oral 
AUC 
AUC 
AUC 
AUC 
AUC 
В 
-30->0 
0->30 
30->60 
60->90 
0^90 
-30->0 
0->30 
30->60 
60->90 
0^90 
• Intravenous 
AUC 
AUC 
AUC 
AUC 
AUC 
-30->0 
0->30 
3 0 ^ 6 0 
60->90 
0->90 
1 
Without 
726 
2163 
1829 
1725 
5717 
640 
857 
1857 
1358 
4072 
2 3 4 
preceding oral ME 
843 
1329 
1352 
1311 
3992 
1209 
1240 
1307 
1330 
3883 
With preceding 
365 
111 
719 
541 
2037 
414 
384 
460 
426 
1270 
1456 
2042 
1119 
857 
3018 
1077 
1018 
1205 
1216 
3439 
oral ME 
872 
805 
731 
719 
2255 
1320 
2384 
1479 
1764 
5627 
1420 
1320 
1851 
1944 
5115 
* 
971 
782 
984 
1294 
3060 
5 
339 
580 
651 
236 
1467 
1062 
953 
1249 
1244 
3446 
-
-
-
-
-
6 
682 
943 
914 
650 
2507 
1453 
998 
736 
1627 
3361 
-
-
-
-
-
AUCO-ИО ALT (mean IUP multiplied b\ a defined time-period) over a lime-period from 0 minutes till 30 
minutes after drug administration, 'Oral ME (0 5 mg) 24h before intravenous administration 
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Side effects 
Three women experienced dizziness after intravenous injection, while all 
experienced abdominal cramps within 5 minutes after intravenous administra-
tion. After an oral dose three out of six experienced abdominal cramps 
approximately one hour after drug administration. 
5.3 Discussion 
This study demonstrates the feasability to assess the effects of uterine 
stimulation during human menstruation together with pharmacokinetic data. 
Although uterine stimulation is not frequently used to treat menorrhagia, this 
model may provide indirect evidence for the more important issue of 
postpartum haemorrhage. It is likely that the human uterus functions alike 
during menstruation and labour, i.e., to provide expelling force. This can be 
demonstrated by the intra-uterine pressure patterns which are similar in both 
situations (Hendricks 1966; 1968; Hein 1972). The same holds true for 
coagulating and fibrinolytic properties within the uterine cavity (Gerbasi et al. 
1990; Yoshimura et al. 1992). 
It is also our experience that the method used in this study, i.e. the sponge-
tipped fluid filled catheter, is more reliable in the non-pregnant uterus than in 
the postpartum uterus because of increased degree of expulsion in the latter. In 
the postpartum uterus only transabdominal placed open-tip catheters provide 
reliable information. This procedure, however, encounters medical-ethical 
contra-indications when used just for research purposes. Micro-transducers at 
the catheter tip were not used because of possible artifacts (Âckerlund et al. 
1978) and the impossibility of calibration during the recording (Braaksma 
1971). 
The most striking observation was the wide variation of bioavailability of 
oral methylergometrine maléate, which corresponds with the recently published 
data found in male volunteers (de Groot et al. 1994b); former data on 
methylergometrine (Saameli 1976) described only a fast absorption of 
methylergometrine tablets. 
Uterine motility was reflected in basal tone, frequency, amplitude and AUC 
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of the IUP-cycle. The values of two AUC.10_0 in the same volunteers in different 
tests were not similar which makes it irrational to compare AUC0^,0 after 
intravenous and after oral administrations within the same volunteer (e.g. 
volunteer 5). In one and the same volunteer F, BT and A showed quantitative 
variations at CD 2 of two subsequent menstrual cycles before drug 
administration took place. This explains why in one volunteer differences in 
AUC.,0_„ existed in the subsequent menstrual cycles. Volunteers 3, 5 and 6 
(Table 5.2.3) had a higher BT before oral administration than before the 
injection of methylergometrine maléate. This explains why AUC„_>W orally is 
larger than intravenously. The changes in BT, F, A and AUC after oral ad-
ministration of methylergometrine maléate show a rather late and unpredictable 
stimulating effect on uterine motility. They reflect the same wide variation as 
observed in the pharmacokinetic data after oral administration. 
The observation of the strongly diminished effect of intravenously 
administered methylergometrine maléate 24 h after oral administration suggests 
a long-lasting receptor blockade. It seemed as if the uterus was insensitive to 
the methylergometrine maleate-dose. The first dose may affect and change the 
uterine receptors for methylergometrine maléate. This could explain the insen-
sitivity to the second dose of 0.2 mg methylergometrine maléate in postpartum 
uteri lasting 3 h, measured by external tocography, as reported by Müller & 
Stoker (1959) and observed in our experiments even 24 h after oral 
administration of 0.5 mg methylergometrine maléate. Methylergometrine 
maléate probably blocks α-receptors in the inner layer, specifically affecting the 
basal tone of this layer (Daels 1974; de Koning Gans et al. 1975; Saameli 
1976). 
Conclusion 
Oral administration of methylergometrine maléate shows a late and 
unpredictable effect on the menstruating uterus in contrast to the fast and 
predictable effect of an intravenous dose. 
A relation between plasma concentration and pharmacodynamic effect could 
not be demonstrated after oral administration. Therefore oral ergot alkaloids can 
not be advocated either for the treatment of menorrhagia or for postpartum 
haemorrhage. 
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6 Clinical effects 
6.1 Survey of the management of the third 
stage of labour in the Netherlands' 
The World Health Organization (WHO) advocates prophylactic oxytocic 
drugs to be administered to all women in the third stage of labour to reduce 
postpartum blood loss (WHO 1990). A survey in the United Kingdom in 1984 
showed that the active management with Syntometrine and controlled cord 
traction is universal in those units with a third stage management policy, i.e. 
98% of all units (Garcia et al. 1987; Prendiville et al. 1989). 
The situation in the Netherlands is different in that there exists a strong belief 
that expectant management in low risk women is not worse than active manage-
ment. Also, studies in Ireland (Begley 1990) and the United Kingdom (Thila-
ganathan et al. 1993) suggest that there still exists a need for a trial of oxytocin 
versus placebo in women at low risk for postpartum haemorrhage. One such 
study is in progress at present and conducted by Dutch midwives who are used 
to expectant management of the third stage. 
We report here the results of a questionnaire sent to Dutch midwives and 
obstetricians to investigate the practices followed during the third stage of 
labour. 
6.1.1 Methods 
A questionnaire was mailed to Dutch midwives and obstetricians by a 
pharmaceutical industry (Ferring Ltd) making use of their mailing database. 
The respondent was asked whether he/she was a midwife or an obstetrician. 
Information was collected regarding the annual number of births in his/her 
practice and the number of colleagues in his/her practice. 
The four questions are given in Table 6.1.1.1. 
Based upon: de Groot ANJA, van Roosmalen J, van Dongen PWJ. Survey of the 
management of the third stage of labour in the Netherlands. 1995h; submitted. 
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Table 6 1 1 1 Questionnaire 
1 Do you actively manage the third stage of labour? 
as a routine 
on indication 
never 
2 If you actively manage the third stage, which oxytocic do you use9 
oxytocin Is', 2nd, or 3rd choice9 
ergomelnne Is', 2nd, or 3rd choice9 
prostaglandin Γ, 2nd, or 3rd choice9 
3. Which dose of oxytocin do you use9 
1,5, or 10 IU 9 
4 Which route of administration do you use9 
intravenous, intramuscular, or intramyometrial9 
In analyzing the results, each question was considered separately This means 
that percentages mentioned have been calculated from all those who responded 
the specific question. 
6.1.2 Results 
Of 1394 midwives, 406 (29%) returned the questionnaire. For the 
obstetricians, the response rate was higher: 47% responded (401) of the 855. 
The overall response rate was 35%, which is considered fairly good for a 
pharmaceutical mailing. 
Fifty-five percent of the obstetricians used prophylactic oxytocics in the third 
stage as a routine; the other 45% only do so when indicated. As shown in Table 
6.1.2.1 for the obstetricians, the drug of first choice was oxytocin (98.5%); 
ergometrine was used as second choice (49%), and prostaglandins was the third 
choice (29%). Only 10% of the midwives use prophylactic oxytocics in the third 
stage as a routine. As shown in Table 6.1.2.1, 98.5% of the midwives use 
oxytocin as the drug of first choice; ergometrine is the second choice (46%), 
while prostaglandins were used by 2% as the third choice 
The most frequent route of administration was intramuscular; 80.5% of the 
obstetricians and 99% of the midwives prefer this route. The most frequent used 
dose was 5 IU of oxytocin; 75% of the obstetricians and 70% of the midwives 
administered this dose. Routine use of prophylactic oxytocics in the third stage 
of labour is not the standard of practice in the Netherlands as is shown in 
Figure 6.1.2.1. 
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Table 6.1.2.1 Management of the third stage of labour by Dutch midwives and 
obstetricians 
Addressed 
Responded to 1 or more questions 
Question 1 
• Active management of third stage 
- as a routine 
- on indication 
- never 
Question 2 
• Choice of oxytocic 
- Oxytocin 
- Ergometrine 
- Prostaglandin 
Is' choice 
2nd choice 
3 rd choice 
P1 choice 
2nd choice 
3rd choice 
1st choice 
2nd choice 
3 rd choice 
Midwives 
1394 
406 
397 
39 
357 
1 
394 
390 
2 
-
4 
181 
4 
0 
0 
8 
% 
(29.1) 
(9.8%) 
(89.9%) 
(0.3%) 
(98.5%) 
(0.5%) 
-(0%) 
(1%) 
(46%) 
(1%) 
(0%) 
(0%) 
(2%) 
Obstetricians 
855 
401 
392 
216 
174 
2 
390 
384 
4 
1 
6 
192 
3 
0 
29 
112 
% 
(46.9) 
(55.1%) 
(44.4%) 
(0.5%) 
(98.5%) 
(1%) 
(0.3%) 
(1.5%) 
(49.2%) 
(0.7%) 
(0%) 
(7.4%) 
(28.7%) 
( ): percentage calculated on the number of answers to the specific question 
As a routine 10% As a routine 55% 
On indication 90% 
Midwives 
On indication 45% 
Obstetricians 
Figure 6.1.2.1 Use of oxytocic drugs in the third stage of labour in the Netherlands. 
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6.1.3 Discussion 
The overall response rate of 35% is fairly good for pharmaceutical mailing, 
but selection of responders might take place. It is unknown which obstetricians 
or midwives responded and therefore bias may have occurred. The difference 
in management of 55% for obstetricians and 10 % for midwives with respect 
to use of prophylactic oxytocics as a routine is so striking, however, that the 
survey supports the statement that there are big differences between 
obstetricians and midwives in the management of the third stage of labour. 
Fifty-five percent of the obstetricians in the Netherlands tend to use prophylactic 
oxytocics as a routine as compared to only 10% of the midwives. But also 
among the obstetricians, no consensus exists as a large minority (45%) uses 
active management only on indication. 
We conclude that in the Netherlands, routine prophylactic oxytocics is not the 
standard practice as is the case in the United Kingdom. The Netherlands, 
therefore, is one of the few places where one can still conduct randomized trials 
of oxytocics with a placebo. A placebo-controlled trial of oral ergometrine to 
reduce postpartum haemorrhage is presented in chapter 6.2. 
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6.2 A placebo-controlled trial of oral 
ergometrine to reduce postpartum 
haemorrhage* 
PPH claims the lives of 150,000 women annually (Kwast 1991a). It is one 
of the most frequent causes of maternal mortality in the developing world 
(Kwast 1991b; Royston 1989). The prophylactic use of oxytocic drugs is gen­
erally advocated to prevent these tragedies (WHO 1990). At present, the best 
choice for prophylactic use in the third stage of labour is oxytocin (van Dongen 
et al. 1991; Mc Donald et al. 1993). On a world-wide basis, however, this 
standard of care is not available for all women who give birth. Not only are 
there logistic problems in some obstetric care settings in administering 
injections, such as oxytocin, there is also ample evidence that ampoules of 
oxytocin lack stability under tropical conditions (Walker et al. 1998; Hogerzeil 
et al. 1994). Stimulation of oxytocin by early breast suckling has been investi­
gated as an alternative, but did not show reduction of postpartum blood loss 
(Bullough et al. 1989). 
For prophylaxis, the only oral drugs available are ergometrine and 
methylergometrine. As described in Chapter 3, a world-wide distribution of 
(methyl)ergometrine tablets would entail logistical problems as the oral 
medication must be stable under tropical conditions. This issue has not yet been 
satisfactorily settled (de Groot et al. 1995b). Before the stability question is 
studied further, the prophylactic effectiveness of the oral ergometrine in 
reducing blood loss postpartum must be estabilished. We here report a 
randomized trial in which our primary hypothesis was that oral ergometrine will 
reduce postpartum blood loss by 30% as compared to a placebo. A lesser 
reduction of blood loss was considered to be of little use as its effects on 
maternal mortality and on the need for blood transfusions are probably negli­
gible (Newton et al. 1961). 
de Groot ANJA, van Roosmalen J, van Dongen PWJ, Borm GF. A placebo-controlled 
trial of oral ergometrine to reduce postpartum haemorrhage. 1995І; submitted. 
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6.2.1 Subjects and methods 
Design 
Basically the study is a double-blind multicentre trial of oral ergometrine 
versus placebo. Assuming a lognormal distribution for blood loss, it was 
estimated that a sample size of 140 per group was required to show a clinically 
relevant 30% reduction of blood loss with an error rate of 0.05 (two-sided) and 
a power of 0.80. To allow comparison with a standard prophylactic regimen, a 
third group receiving the standard intramuscular oxytocin was added, but for 
obvious reasons this could not be conducted in a blind manner. Thus, formal 
randomisation was conducted in a 2:2:1 design. 
Randomization 
The hospital pharmacy of the University of Nijmegen supplied numbered 
boxes containing 0.4 mg ergometrine maléate tablets, placebo tablets, or 5IU 
oxytocin according to a computer-generated randomisation list. Care was taken 
that no difference could be seen or heard between the packages of the tablets 
(whether ergometrine or placebo) and the oxytocin ampoules. 
Recruitment 
Two university hospitals (in Leiden and Nijmegen), a midwifery school (in 
Kerkrade) and independent midwives with a practice in the area of the 
university hospital of Nijmegen participated in the study. The study was 
approved by the medical ethical committees of the hospitals and the midwifery 
school. Informed consent was asked in early labour. Only women who did not 
develop exclusion criteria (Table 6.2.1.1) participated in the trial. They were 
assigned to either one of the groups just before the delivery of the baby's head. 
The same procedure was followed in home births. 
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Table 6 2 11 Exclusion criteria for participation in trial 
1 The woman refuses to take part 
2 Any cardiovascular disease (hypertension) 
3 Multiple pregnancies 
4 Non-cephalic presentation 
5 Polyhydramnios 
6 Tocolysis 2 hours prior to delivery 
7 Anticoagulant therapy 
8 Stillbirth 
9 Antepartum haemorrhage 
10 Chemical induction or augmentation (oxytocin, prostaglandins) 
11 Instrumental/ Operative delivery 
12 Anaemia Hb <6.8 mmol/L 
13 Previous complication in the third stage 
Management of the third stage was prescribed as follows: 
(Prendiville et al. 1988a;b; Elboum & Harding 1991) 
1 Give tablets or injection immediately after birth. 
2 When the mother feels contractions or when there are signs of separation, 
encourage maternal effort to adopt a position aiding gravity, i.e. standing 
upright, kneeling, squatting, or sitting on a bedpan. If necessary, place a 
flat hand on the mother's abdomen to act as a brace to aid pushing. 
3 If the placenta does not deliver spontaneously, wait and reattempt the 
second step. 
4 If haemorrhage occurs, administer additional oxytocics and remove 
placenta by other means, such as controlled cord traction. 
Outcomes 
Primary outcome of the study was the mean blood loss. PPH was defined 
as a loss of >500 ml blood loss (WHO 1990); and severe PPH as >1000 ml. 
Further use of oxytocics or other interventions were secondary outcomes of 
the study. 
I l l 
Assessment of blood loss 
Measurement of blood loss by the gravimetric method (Wilcox et al. 
1959) started immediately after birth. A "fresh" perineal pad was placed 
under the perineum to absorb blood or fluid. All gauzes and pads were 
collected in the hour following the delivery of the placenta and were 
weighed at the end of this period. The difference in weight of the material 
before and after the hour was calculated. A 100 gram increase in weight was 
considered to be equivalent to 100 ml blood (i.e. specific gravity is 1 g/ml). 
At delivery, some blood was usually spattered on the drapes and on the 
gowns of the attendants although attempts were made to minimize such 
losses. This gave a constant error of approximately 10% (Newton 1961). In 
addition, the placental interstices contain maternal blood (about 9% of 
placental weight). As systematic overestimations (amniotic fluid) and 
underestimations (blood loss) are likely to be distributed equally among the 
groups, no corrections have been made for them. In the midwifery school 
and in the hospitals, blood pressure was recorded just before birth and again 
15, 30, 45, and 60 minutes after the delivery of the placenta. 
6.2.2 Results 
During the study period from July 1993 to July 1994, 371 women were 
assigned to the study: Kerkrade 61, Leiden 69, Nijmegen 23, and home 
births 218. Four women with exclusion criteria were entered erroneously 
(three forcipal extractions, one augmentation). They are considered as non-
participants, leaving 367 women in the study (Table 6.2.2.1). Not all eligible 
women entered the trial. The main reason was that the woman wished a 
"natural childbirth" which would be disturbed by the prophylactic use of any 
drug. Age, parity, and labour characteristics of the parturients are comparable 
among the three groups (Table 6.2.2.1). 
Blood loss, percentage of PPH, and the need for further oxytocics among 
the ergometrine, placebo, and oxytocin groups were not significantly 
different (Table 6.2.2.2). 
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Table 6 2 2 1 Details of parturients 
• Demographic variables 
Mean maternal age, years (SD) 
Pnmiparous women (%) 
• Labour 
Length 1st stage, hours (range) 
Length 2nd stage, minutes (range) 
Length 3rd stage, minutes (range) 
Episiotomy (%) 
Birthweight, gms (SD) 
Ergometrine 
(n=146) 
30(4) 
48 (33%) 
64(1-164) 
22 (1-119) 
15 (2-90) 
40 (27%) 
3519 (443) 
Placebo 
(n=143) 
30(4) 
46 (32%) 
6 8(1-16 7) 
23 (2-90) 
14 (3-55) 
47 (33%) 
3498 (444) 
Oxytocin 
(n=78) 
30(4) 
27 (35%) 
6 8(1 5-16 7) 
25 (2-100) 
11 (4-90) 
23 (29%) 
3534 (410) 
Table 6 2 2 2 Primary and secondary outcomes 
• All parturients 
Mean blood loss, ml (SD) 
> 500 ml 
>1000 ml 
Use of further oxytocics 
Third stage complications 
manual removal of placenta 
requiring blood transfusion 
• Primiparous women 
Mean blood loss, ml (SD) 
> 500 ml 
>1000 ml 
Use of further oxytocics 
• Multiparous women 
Mean blood loss, ml (SD) 
> 500 ml 
>I000 ml 
Use of further oxytocics 
Ergometrine 
n=146 
476(340) 
54(37%) 
12 (8%) 
21(14%) 
2 
1 
n=48 
585(417) 
25(52%) 
7(15%) 
12(25%) 
n=98 
423(321) 
29(30%) 
5(5%) 
9(9%) 
Placebo 
n=143 
520(419) 
55(38%) 
16(11%) 
26(18%) 
0 
3 
n=46 
657(442) 
26(57%) 
9(20%) 
9(20%) 
n=97 
455(394) 
29(30%) 
7(7%) 
17(18%) 
Oxytocin 
n=78 
499(454) 
25(32%) 
7(9%) 
14(18%) 
1 
2 
n=27 
562(459) 
12(44%) 
3(11%) 
6(22%) 
n=51 
465(452) 
13(25%) 
4(8%) 
8(16%) 
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Table 6.2.2.3 Change in amount of blood loss compared to placebo group 
' All parturients 
• Primiparous women 
• Muciparous women 
Ergometrine Oxytocin 
-5% (-20% to +13%)' -9% (-26%) to +12%) 
-8% (-32% to +25%) -20%> (-44%) to +15%) 
-5% (-22% to +19%) -3% (-25% to +25%) 
95% confidence intervals 
Blood loss (ml) 
J 5 0 0 -
J 0 0 0 -
1500 -
iOOO -
5 0 0 -
0 -
* 
* 
* P100 
P95 
P75 
M 
P25 
P5 
* PO * * 
Figure 6.2.2.1 
Ergometrine Placebo Oxytocin 
Effect of treatments on the amount of blood loss postpartum (ml) 
Abbreviations M = median, Ρ = Percentile (Box-plot) 
114 
The percentage of PPH (>500 ml) amounted to 37%, 38%, and 32% 
among the three groups (Table 6.2.2.2) Ergometrine reduced blood loss by 
5% (CI:-20% to +13%) as compared with placebo (Table 6.2.2.3). Oxytocin 
gave a reduction of 9% (CI:-26% to +12%). 
Figure 6.2.2.1 shows the estimates for the effect of the treatments on the 
amount of blood loss. Blood pressure measurements were only recorded for 
the institutional births (n=149). Oral ergometrine showed no significant 
elevation of blood pressure. 
6.2.3 Discussion 
Routine use of oxytocics and active management of the third stage in low-
risk women remains a controversial issue (Inch 1985; Anonymous 1986; 
Begley 1990; Thilaganathan et al. 1993) although WHO has recommended 
that the third stage should be managed actively in countries where access to 
hospital services is difficult or time consuming (WHO 1990). Easy alterna-
tives to intramuscular oxytocin as early breast suckling have been examined 
but proved not effective (Bullough et al. 1989). 
In the Netherlands, active management of the third stage of labour and 
routine use of oxytocics are not standard practice, especially not among 
midwives who attend most low risk pregnancies (de Groot et al. 1995h). The 
use of placebo was, therefore, not considered unethical. A study comparing 
oxytocin versus placebo is currently being conducted in Dutch midwifery 
practices. 
Remarkable is the high rate of PPH in about one third of all three groups 
compared to 10% in Gilbert's study (Gilbert et al. 1987). This unexpected 
high rate of PPH was also noticed by McDonald et al. (1993) in their study 
on the effect of oxytocin alone versus Syntometrine. Part of the high inci-
dence may relate to a study-induced higher accuracy in measuring blood loss. 
It is noteworthy that Gilbert (1987), but also McDonald et al. (1993) did not 
measure blood loss but only estimated the amount. 
In our study, oral ergometrine gave only a small reduction in blood loss 
(5%). Especially in multiparous women, virtually no difference in blood loss 
was recorded among the three groups. Oral ergometrine does not seem to 
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reduce the frequency of severe PPH (>1000 ml) contrary to McDonald's 
suggestion that this may be the main effect of prophylaxis (McDonald et al. 
1987). Even the use of oxytocin intramuscularly showed little or no advan-
tage in women at low risk for PPH. We could not confirm the reduction of 
blood loss by oxytocin im (5IU) in low risk women as described in the small 
study of Poeschmann et al. (1991). 
As reported by others (Prendiville et al. 1988a; Poeschmann et al. 1991), 
parity and the presence of an episiotomy are determining factors in the 
amount of blood loss. These factors were equally divided among the three 
groups. Including these factors in the analysis did not change our results. 
Conclusion 
On the basis of our study, there is no reason to recommend oral 
ergometrine as an easy alternative to parenteral prophylactic drugs in the 
third stage of labour. It had too little demonstrable effect on blood loss after 
childbirth as compared to placebo. Until now, no other oral oxytocics are 
available for this purpose. Recently Irons et al. (1994) suggested nipple 
stimulation postpartum as an easy alternative to parenteral oxytocics for the 
third stage of labour. A reduction-trend in the amount of blood loss 
compared to placebo, was seen, but the difference was not significant. There 
is still a need for research into easy alternatives for active management of the 
third stage of labour. 
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7 Summary and conclusions 
7.1 Summary 
The objective of this thesis was to investigate the possibility of using oral 
ergometrine or methylergometrine to prevent postpartum haemorrhage (PPH) 
as an easy alternative to prophylactic parenteral drugs in the third stage of 
labour. 
PPH is defined and its essentials in prevention and management are 
described (Chapter 1). Primary prevention of PPH is advocated at all levels 
of obstetric care. Intramuscular oxytocin as a prophylactic oxytocic drug has 
disadvantages in the active management of the third stage of labour. Oral 
medication is preferable to injections when world-wide use is contemplated. 
Only ergot alkaloids are suitable for oral administration for this purpose. The 
history of ergot alkaloids, which supplied the first uterotonics, is described. 
Their chemical background and pharmacological properties are summarized, 
and their adverse reactions to these drugs are reviewed (Chapter 2). 
To be an alternative to prophylactic parenteral oxytocics, tablets should 
fulfill pharmaceutical, pharmacological, and clinical requirements. Data for 
these drugs had not yet provided conclusive evidence of their suitability. 
Therefore ergometrine and methylergometrine tablets were examined with 
regard to their stability under tropical conditions (Chapter 3), 
pharmacokinetics (Chapter 4), and pharmacodynamics (Chapter 5), and 
clinical effects (Chapter 6). 
Chapter 1 
Primary prevention of PPH is advocated at all levels of obstetric care. 
This implies that active management of the third stage is also recommended 
at the first, most peripheral, levels of obstetric care. Active management 
includes use of an oxytocic, early cord clamping, and active expulsion of the 
placenta. The oxytocic drug of choice is oxytocin, 5 IU, given intramuscu-
larly. 
Women with high risk factors for PPH ( e.g. polyhydramnios, previous 
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complications in third stage, antepartum haemorrhage, prolonged labour, 
multiple pregnancies) should deliver in hospital. Timely ante partum referral 
is necessary. In these women, prevention and anticipatory management 
includes availability of intravenous treatment as well as active management 
with an oxytocic. 
Evidence for the effectiveness of active management of the third stage in 
women at low risk for PPH is still not conclusive. Whether women 
delivering at home with easy accessability to hospital or those at low risk 
delivering in hospital should be actively managed remains controversial and 
is not supported by us until a clinical trial in this particular group of women 
has shown the effectiveness of active management. Guidelines for clinical 
practice are shown in the flow chart (Figure 1.2.4.1). 
Because the menstruating uterus was used as model to simulate the 
process of placental separation in the pharmacodynamic study, Chapter 1.3 
discusses our hypothesis that menstrual bleeding and placental separation are 
comparable. The endometrium, blood vessels, myometrium, and the 
coagulation factors are compared during menstruation and placental 
separation. There are no great differences between the non-pregnant 
endometrium and the decidua (postpartum). The differences in spiral arteries 
between the non-pregnant and pregnant state are striking. During 
menstruation, uterine contractions have probably no major role in 
haemostasis, whereas uterine retraction postpartum plays an important role in 
haemostasis postpartum. At local uterine level, changes in coagulation 
factors, increasing fibrinolytic capacity, and the function of platelets in 
haemostatic plug formation are comparable. 
Chapter 2 
Epidemics of ergotism occurred frequently in the Middle Ages. They were 
source of inspiration for artists and popularly known as "St. Anthony's Fire", 
resulting in gangrene, neurological disease, and death. It was caused by 
eating rye bread contaminated with the fungus Claviceps purpurea. In 1582 
it was described that birth could be hastened by administering a few spurs of 
the secale comutum. The dosage was, however, very inaccurate resulting in 
frequent uterine ruptures. The nickname of the preparation of "pulvis ad 
partum" was changed to "pulvis ad mortem". Therefore, after 1828 the ergot 
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alkaloids were no longer used during delivery but only as a measure to 
prevent postpartum haemorrhage. 
From 1875 onwards, many derivatives of ergot alkaloids were found. 
Dudley and Moir isolated ergometrine in 1932. It proved to have a very 
specific uterotonic action. However, because of severe and unpredictable 
side-effects and the instability of the drug (this thesis), oral ergometrine is 
not the drug of choice for prevention of postpartum haemorrhage. 
Chemical background and pharmacological properties are summarized and 
a review of adverse drug reactions is given. 
Chapter 3 
The stability of oral preparations of the two ergometrine compounds 
methylergometrine and ergometrine under tropical conditions was unknown 
and was, therefore, examined in this study. 
The "shelf lives" of ergometrine and methylergometrine tablets were 
examined by exposing these to seven artificially controlled conditions. 
Samples were analysed by High Performance Liquid Chromatography at nine 
different sampling times over a period of one year to determine the content 
of ergometrine and methylergometrine. Under refrigerated storage (test I), 
less than 90% of the stated amount of active ingredient was found in the 
tablets after 14 weeks for ergometrine and 21 weeks for methylergometrine. 
When stored in the dark at 40CC with 75% Relative Humidity, the tablets fell 
below accepted specification criteria (= 90-110% of stated amount of active 
ingredient) within three weeks for ergometrine and 21 weeks for the coated 
methylergometrine tablets. 
The stability of uncoated ergometrine was far less than that of coated 
methylergometrine tablets. Instability worsened under extreme humid and hot 
conditions, for both ergometrine and methylergometrine. From week 31 
onwards, the coating did not seem to protect the compound anymore, 
irrespective of the condition of exposure. 
Tropical conditions make the tablets unstable with humidity as the main 
adverse factor. Under all simulated conditions, both ergometrine and 
methylergometrine tablets were unstable. 
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Chapter 4 
In 4.1 the assay method to measure (methyl)ergometrine in plasma is 
described. An isocratic high-performance liquid chromatographic method with 
fluorescence detection has been developed for the measurement of ergometrine 
in human plasma. The quantitation limit in plasma was 50 pg.ml"'. An 
example of the plasma concentration-time curves after oral and intravenous 
administration of ergometrine in one volunteer is shown. This HPLC method 
makes it feasible to describe pharmacokinetic parameters for oral ergometrine. 
In 4.2 the experiments are described. The aim of these experiments was to 
assess the pharmacokinetics and bioavailability of comparable doses 
methylergometrine and ergometrine (parallel design) in six male volunteers 
after an intravenous dose and an oral dose of the maléate (cross- over design). 
Further the pharmacokinetics and bioavailability of methylergometrine in six 
non-pregnant women were assessed and compared to the methylergometrine 
values in men (parallel design in gender). 
After intravenous administration, the pharmacokinetic profile of 
methylergometrine and ergometrine can be described by a two-compartment 
model. No statistical differences between the pharmacokinetic parameters of 
both compounds in men were observed. 
For methylergometrine and ergometrine the distribution half-life tu2a is 
0.19±0.27 h, and 0.16+0.20 h (p>0.8), respectively; the elimination half-life 
(t1/2ß) is 1.85±0.28 h and 2.57+1.05 h (p=0.80), respectively; the total body 
clearance (CL) amounts to 32.2+11.8 L.h"1 and 32.6±12.0 L.h"1 (p>0.8); the 
steady state volume of distribution (Vss) is 71.5+25.9 L. and 82.0±14.5 L. 
(p=0.40), respectively. In women, after intravenous administration of 
methylergometrine the distribution half-life t,/2n is 0.10+0.04 h (p=0.46), the 
t,/20 is 1.94+0.34 h (p=0.64), the CL amounts to 22.2+3.10 L.h-1 (p=0.073); 
and the Vss is 50.818.23 L (p=0.091). The p-values between brackets show 
that the intrinsic pharmacokinetic parameters for methylergometrine were not 
statistically different between men and women. 
After oral administration, the pharmacokinetic profile can be described with 
a one-compartment model. Except for the lag-time (t,ag), no statistical 
differences between the pharmacokinetic parameters of the compounds 
methylergometrine and ergometrine were present in men. The tlag of 
methylergometrine and ergometrine after oral administration was subject 
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dependent. The average values for the two compounds were respectively 
0.3310.09 h and 0.11+0.10 h (p=0.003). For methylergometrine and 
ergometrine a large variation of bioavailability was observed 84.9±37.2% 
(43.8% CV) and 80.7±34.5% (42.7 %CV) (p>0.8), respectively. 
However, differences, in the following intrinsic pharmacokinetic parameters 
for methylergometrine were noted between men and women. The tlag in 
women was also subject dependent and was significantly shorter than the tlag in 
men with a mean value of 0.09±0.07 h (p=0.0004). The t1/2B in women was 
shorter 1.42±0.31 h vs. 1.85 ± 0.28 (p=0.0123) and the steady state volume of 
distribution was smaller 47.0+6.05 L vs. 71.5 ±25.9 1 (p=0.01). The mean 
tI/2ilbs was not significantly different 0.5010.55 h (p=0.10). 
In women mean value of bioavailability of methylergometrine was 96.4-
+27.5% ranging from 63% and 138%, it was not significantly different from 
the value in men (p=0.56). 
The experiments with oral administrations for both men and women show a 
large inter-individual variability in bioavailability. 
From a pharmacokinetic point of view, the oral route of administration does 
not seem the most reliable way for accurate dosing to prevent postpartum 
haemorrhage. 
Chapter 5 
The objective was to study the pharmacodynamic and pharmacokinetic 
effect of oral and intravenous methylergometrine upon uterine motility during 
menstruation. Intra-uterine pressure was measured in six volunteers with a 
fluid- filled sponge-tipped catheter during menstruation. Methylergometrine 
maléate was given orally (0.5 mg) or intravenously (0.2 mg) in a cross-over 
design. 
After intravenous administration, a fast increase of the frequency of uterine 
contractions and basal tone occurred with a decrease of amplitude, lasting at 
least 30 minutes. Oral administration had a longer latency time and a less 
marked effect on uterine motility. Pharmacokinetic data, such as the maximum 
plasma concentration (Cmax), the time at which Cmax is reached (tmax), and the 
half-life of absorption (t|/2abs) also showed large individual variation after oral 
administration. 
Oral administration of methylergometrine had an unpredictable and a late 
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effect on uterine motility in the menstruating uterus probably due to an 
unpredictable bioavailability in contrast with the fast and predictable effect 
after intravenous administration. 
Chapter 6 
Active management with oral ergometrine maléate 0.4 mg was compared 
with expectant management for the control of blood loss in the third stage of 
labour in women at low risk for postpartum haemorrhage (PPH). 
The design of the study was a three-arm randomized trial in which 0.4 mg 
ergometrine maléate (2 tablets à 0.2 mg) was set off against a placebo, and 
both groups were compared to a standard oxytocin regimen of 5IU. The 
participants were women at low risk, for PPH. 
Of 367 parturients, 146 were randomized to ergometrine maléate 0.4 mg, 
143 to the placebo and 78 to intramuscular oxytocin in a 2:2:1 design. 
Compared with the placebo, ergometrine reduced blood loss by 5% (-5%; 
Confidence interval: -20% to +13%). Oxytocin reduced blood loss by 9% (-
9%; Confidence interval: -26% to +12%) as compared to the placebo. 
Conclusion: Oral ergometrine has too little effect on blood loss after child-
birth in order to be a good alternative to parenteral prophylactic management. 
In short 
• Primary prevention of PPH is advocated at all levels of obstetric care. This 
implies active management of the third stage of labour at the first and most 
peripheral levels of obstetric care where access to hospital services is 
difficult. 
• Tropical conditions make (methyl)ergometrine tablets unstable. 
• Pharmacokinetic experiments with oral (methyl)ergometrine show a large 
inter-individual variability in bioavailability for both men and women. 
• Oral administration of methylergometrine had an unpredictable and late 
effect on uterine motility in the menstruating uterus probably due to 
inefficient bioavailability. 
• Oral ergometrine has too little effect on blood loss after childbirth to be a 
good alternative for parenteral prophylactic management. 
122 
7.2 Conclusions 
Oral (methyl)ergometrine is not an alternative to parenteral prophylactic 
oxytocic drugs in the active management of the third stage of labour. It is 
instable, its pharmacokinetic and pharmacodynamic properties are 
unpredictable and no clinical effect has been shown. All in all, the negative 
outcomes of the three studies on oral (methyl)ergometrine strengthen each 
other. To ameliorate a product's stability seems unlogical, if the same product 
shows unfavourable pharmacokinetics. All the more so, since the tablets do 
not show the wanted clinical effects. 
Throughout history ergot alkaloids are known as powerful drugs. Epidemics 
of ergotism were frequently encountered in the Middle Ages; in obstetric 
practice their nickname has been "pulvis ad mortem" when used for 
augmentation or induction of labour (1928). Nowadays, the side effects of 
(methyl)ergometrine can still be severe. From the point of view of the 
(medical) adage "Primum non nocere", the use of (methyl)ergometrine as 
prophylactic drug is disputable. 
It seems that the time has come to abandon oral ergometrine from obstetrics. 
However, there is still no suitable alternative for the active management of 
the third stage of labour for women in developing countries. The research 
quest for easy alternatives should be continued. If not, maternal mortality will 
remain a catastrophai problem, costing 1,500 lives a day. 
The conclusion drawn from our research project is two-fold: 
• There is still no easy alternative for the active management of the third 
stage of labour. 
• Because of unfavourable pharmaceutical and pharmacokinetic properties 
oral (methyl)ergometrine should be excluded from the medication list. 
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Samenvatting en conclusies 
Samenvatting 
De doelstelling van dit proefschrift was te onderzoeken of het gebruik van 
ergometrine en methylergometrine tabletten een eenvoudig alternatief zou zijn 
voor de profylactisch gebruikte parenterale medicatie in het derde tijdperk van 
de bevalling om fiuxus of haemorrhagia postpartum (HPP) te voorkomen. 
HPP wordt gedefinieerd en aandachtspunten voor de preventie en het beleid 
worden beschreven (Hoofdstuk 1). Er wordt toegelicht waarom primaire 
preventie van HPP op elk niveau van verloskundige zorg wordt bepleit. 
Intramusculaire toediening van Oxytocine als profylactisch oxytocicum kent 
zijn nadelen bij gebruik in het actieve beleid van het derde tijdperk van de 
bevalling. Voor wereldwijd gebruik verdienen tabletten de voorkeur boven 
injecties. Van de oxytocica zijn alleen de ergot alkaloïden geschikt voor orale 
toediening. Ergot alkaloïden zijn de oudste uterotonica. De geschiedenis van 
de ergot alkaloïden wordt beschreven in Hoofdstuk 2.1. Hun chemische 
structuur, farmacologisch eigenschappen en bijwerkingen worden samengevat 
in Hoofdstuk 2.2-4. 
Om als alternatief voor de parenterale profylactische oxytocica te kunnen 
dienen, moeten de tabletten voldoen aan farmaceutische, farmacologische en 
klinische eisen. Over deze gegevens was onvoldoende informatie. 
Om deze reden werden (methyl)ergometrine tabletten onderzocht op 
stabiliteit onder tropische omstandigheden (Hoofdstuk 3), farmacokinetiek 
(Hoofdstuk 4), farmacodynamiek (Hoofdstuk 5) en klinisch effect (Hoofdstuk 
6). 
Hoofdstuk 1 
Primaire preventie van HPP wordt bepleit op elk niveau van verloskundige 
zorg. Dit houdt in dat het derde tijdperk actief wordt geleid, ook in de eerste 
lijn en op de meest perifere niveaus van verloskundige zorg. Actief leiden van 
het nageboorte tijdperk houdt in dat profylactisch een oxytocicum wordt 
gebruikt, er vroeg wordt afgenaveld en de placenta aktief geboren wordt. Het 
te verkiezen oxytocicum is op dit moment Oxytocine 5 IU intramusculair. 
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Vrouwen met hoge risico-factoren op het ontwikkelen van HPP 
(Polyhydramnion, voorgaande complicaties van het nageboorte tijdperk, 
antepartum bloedingen, meerling zwangerschappen) dienen te bevallen in een 
ziekenhuis. Vroegtijdige antepartum verwijzing is noodzakelijk. Preventie en 
anticiperend beleid omvat bij deze vrouwen zowel actief leiden van het derde 
tijdperk als inbrengen van een infuus. 
Tot op heden is het niet aangetoond dat actief leiden van het derde tijdperk 
bij vrouwen met een laag risico op het ontwikkelen van HPP nuttig is. Het 
blijft dan ook controversieel of vrouwen die thuis bevallen en voor wie een 
ziekenhuis makkelijk bereikbaar is, actief moeten worden geleid in het derde 
tijdperk. Actief leiden in een dergelijke situatie wordt door ons althans niet 
bepleit totdat een klinisch studie de effectiviteit van een dergelijke behandeling 
heeft aangetoond. Richtlijnen voor de praktijk van preventie van HPP worden 
gegeven in Figuur 1.2.4.1. 
In Hoofdstuk 1.3 wordt de hypothese besproken waarbij de menstruele 
bloeding vergeleken wordt met de loslating van de placenta. Wij gebruikten de 
menstruerende uterus namelijk als model om de loslating van de placenta te 
simuleren in de farmacodynamische studie. Het endometrium, de bloedvaten, 
het myometrium en de stollingsfactoren worden tijdens menstruatie en 
loslating van de placenta vergeleken. Er zijn geen opvallende verschillen 
tussen het niet-zwangere endometrium en de decidua (postpartum). De 
verschillen in spiraal-arteriën in een niet-zwangere en zwangere uterus zijn 
daarentegen erg groot. Tijdens de menstruatie spelen uteruscontracties 
waarschijnlijk geen rol in de hémostase, terwijl retractie van de uterus 
postpartum wel essentieel is voor een goede hémostase. Op niveau van de 
uterus zijn veranderingen in stollingsfactoren, toenemende fibrinolytische 
activiteit en de functie van bloedplaatjes in de hemostatische prop-vorming 
vergelijkbaar. 
Hoofdstuk 2 
Ergotisme epidemieën kwamen frequent voor in de middeleeuwen. Ze 
golden als inspiratie bron voor kunstenaars en stonden bekend onder de naam 
"Het Antoniusvuur" of "Het Heilig vuur" leidend tot gangreen, neurologische 
ziekten en de dood. Antoniusvuur werd veroorzaakt door het eten van besmet 
(rogge-)brood met de schimmel Claviceps purpurea. In 1582 werd beschreven 
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dat de bevalling kon worden bespoedigd door toediening van enkele korreltjes 
van het secale cornutum. Onnauwkeurige dosering leidde echter tot vele uterus 
rupturen. Dit was dan ook de reden dat na 1828 de ergot alkaloïden slechts in 
het derde tijdperk ter preventie van HPP werden gebruikt en niet voor inductie 
of bespoediging van de baring. 
Vanaf 1875 werden diverse derivaten van Ergot alkaloïden ontdekt. In 
1932 werd door Dudley and Moir ergometrine geïsoleerd. Het bleek een zeer 
specifieke uterotone werking te bezitten. Echter, vanwege de ernstige en 
onvoorspelbare bijwerkingen en instabiliteit van de medicatie (dit proefschrift) 
is ergometrine niet het middel van voorkeur in de preventie van postpartum 
bloedingen. 
De chemische structuur, farmacologische eigenschappen en bijwerkingen 
van ergot alkaloïden worden beschreven in Hoofdstuk 2.2-4. 
Hoofdstuk 3 
De stabiliteit onder tropische omstandigheden van ergometrine en 
methylergometrine tabletten was onbekend en werd daarom onderzocht. 
De "shelf lives" van ergometrine en methylergometrine tabletten werden 
bepaald door de tabletten aan zeven kunstmatige omstandigheden bloot te 
stellen. De monsters werden geanalyseerd met behulp van High Performance 
Liquid Chromatography (HPLC) op negen verschillende bemonsterings 
tijdstippen gedurende een periode van een jaar. Daarbij werd de nog aktief 
werkzame hoeveelheid ergometrine of methylergometrine gemeten. Na 
veertien weken bewaard te zijn geweest in een gekoelde omgeving, werd 
minder dan 90% van de gemeten werkzame hoeveelheid teruggevonden bij de 
ergometrine tabletten, voor de methylergometrine tabletten was dit na 21 
weken. Bewaard in het donker bij 40°C en 75% relatieve vochtigheid 
(Relatieve Humidity RH) voldeden de ergometrine tabletten na 3 weken al niet 
meer aan de farmaceutisch eisen (= 90-110% van de vermelde actieve 
component moet in het preparaat aanwezig zijn) en na 21 weken voldeden ook 
de "coated" methylergometrine tabletten niet meer aan deze eisen. 
De stabiliteit van de non-coated ergometrine tabletten was duidelijk minder 
dan van de coated methylergometrine tabletten. Instabiliteit trad het sterkst op 
onder extreem vochtige en hete omstandigheden, zowel voor ergometrine als 
methylergometrine. Eenendertig weken na blootstelling aan een kunstmatige 
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bewaaromstandigheid leek de coating de methylergometrine tabletten niet meer 
te beschermen onafhankelijk van de specifieke kenmerken van deze 
bewaaromstandigheid. 
Tropische omstandigheden leidden tot instabiliteit van de tabletten, waarbij 
de vochtigheid de meest schadelijke factor was. De coated methylergometrine 
tabletten waren stabieler in vochtige en hete omstandigheden dan de non-
coated ergometrine tabletten. Onder alle gesimuleerde omstandigheden waren 
zowel de ergometrine als methylergometrine tabletten niet stabiel. 
Hoofdstuk 4 
Hoofdstuk 4.1 beschrijft de analyse methode voor de bepaling van (methyl-
ergometrine in plasma. Een ¡socratisch HPLC methode met fluorescentie 
detectie werd ontwikkeld voor de meting van ergometrine in humaan plasma. 
De detectie grens in plasma was 50 pg. ml"1. Een voorbeeld van een 
plasmaconcentratie versus tijd-curve na toediening van orale en intraveneuze 
ergometrine wordt beschreven bij één vrijwilliger. De HPLC-methode maakte 
het mogelijk (methyl)ergometrine in humaan plasma aan te tonen. 
Hoofdstuk 4.2 beschrijft de afzonderlijke experimenten. De doelstelling van 
de studies was om van methylergometrine en ergometrine (parallel design) de 
farmacokinetische eigenschappen te bepalen bij 6 mannen na orale en 
intraveneuze toediening in vergelijkbare doseringen (cross-over design). 
Daarnaast werden farmacokinetische eigenschappen en de biologische 
beschikbaarheid van methylergometrine bij zes niet-zwangere vrouwen bepaald 
en vergeleken met de waarden bij de mannen (parallel design in geslacht). 
Na intraveneuze toediening kon het farmacokinetisch profiel van 
methylergometrine en ergometrine beschreven worden met een twee-compar-
timenten systeem. Er werden geen verschillen tussen farmacokinetische 
parameters van methylergometrine en ergometrine geconstateerd. Voor 
methylergometrine resp ergometrine was de distributie halfwaarde tijd t1/2a 
0.19+0.27 u, 0.16±0.20 u (p>0.8); de eliminatie halfwaarde tijd (t1/2ß) was 
1.85±0.28 u, resp. 2.57±1.05 u (p=0.80); De totale klaring (CL) bedroeg 32.2-
±11.8 L.u"', resp. 32.6±12.0 L.u"' (p>0.8); het steady state verdelings volume 
(VJ bedroeg 71.5±25.9 L. resp. 82.0+14.5 L. (p=0.40). Bij vrouwen was na 
intraveneuze toediening van methylergometrine de distributie halfwaarde tijd 
tl/2„ 0.10±0.04 u (p=0.46), de tI/2B 1.94±0.34 u (p=0.64), de lichaamsklaring 
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CL 22.2±3.10 L.u·1 (p=0.073), en het verdelingsvolume Vss 50.8+8.23 L 
(p=0.091). De p-waarden tussen haakjes laten zien dat de intrinsieke 
farmacokinetische parameters niet statistisch significant verschillend zijn tussen 
mannen en vrouwen. 
Na orale toediening kon het farmacokinetisch profiel beschreven worden 
door een één-compartiment systeem. Bij mannen werden geen verschillen 
geconstateerd tussen methylergometrine en ergometrine behalve in de lag-tijd 
(t, ). De t]ag van methylergometrine en ergometrine bleek persoons-afhankelijk 
te zijn na orale toediening; 0.33±0.09 u, resp 0.11+0.10 u (p=0.003). De 
verschillen in farmacokinetische eigenschappen tussen mannen en vrouwen 
waren echter wel groter. De t, bij vrouwen was eveneens persoonsafhankelijk 
en was significant korter dan tlag bij mannen, gemiddelde waarde 0.09±0.07 u 
(p=0.0004). De t,/2D bij vrouwen was korter 1.42+0.31 u (p=0.0123) en het 
verdelingsvolume was kleiner 47.0±6.05 L (p=0.01). De gemiddelde t,/2abs was 
0.50±0.55 u (p=0.10). Een grote variatie in biologische beschikbaarheid voor 
zowel methylergometrine als ergometrine werd aangetoond, namelijk 
84.9+37.2% (43.8% CV) and 80.7±34.5% (42.7 %CV) (p>0.8). Bij vrouwen 
was de gemiddelde waarde van biologische beschikbaarheid van methyl-
ergometrine 96.4±27.5% variërend tussen 63% en 138%; dit was niet signi-
ficant verschillend van de waarde bij mannen (p=0.56). De experimenten met 
orale methylergometrine en ergometrine lieten een grote interindividuele 
variatie in biologisch beschikbaarheid zien bij mannen voor beide preparaten. 
De experimenten met orale methylergometrine bij vrouwen toonden een 
vergelijkbare variatie in biologische beschikbaarheid aan. Uit farmacokinetisch 
oogpunt is de orale toedieningsweg geen betrouwbare route om (methyl)er-
gometrine nauwkeurig te doseren. 
Hoofdstuk 5 
De doelstelling van de studie was de farmacodynamische eigenschappen van 
intraveneus en oraal toegediende methylergometrine op de uterusactiviteit 
tijdens de menstruatie te bekijken, in combinatie met de farmacokinetiek. 
Hiertoe werd bij zes vrijwilligsters de intra-uteriene druk gemeten met een met 
vloeistof gevulde "sponge-tipped" druk-catheter tijdens de menstruatie. 
Methylergometrine maleaat werd oraal (0.5 mg) en intraveneus (0.2 mg) 
toegediend in een cross-over design. 
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Na intraveneuze toediening werd een snelle toename in frequentie en basale 
tonus van de uteruscontracties waargenomen terwijl de amplitude van de 
contracties verminderde. Deze verandering van farmacodynamische parameters 
duurde minimaal 30 minuten. Farmacokinetische gegevens, zoals de maximum 
plasma concentratie (С
тах
), de tijd waarop de C
max
 werd bereikt en halfwaarde 
absorptie tijd lieten sterke individuele variaties zien na orale toediening tussen 
de proefpersonen. 
Men zou mogen concluderen dat orale toediening van methylergometrine 
een onvoorspelbaar en laat effect heeft op de uterusactiviteit van de 
menstruerende uterus, mogelijk door een onvoorspelbare biologische beschik­
baarheid van het orale preparaat. Dit in tegenstelling tot het snel en 
voorspelbare effect dat na intraveneuze toediening van methylergometrine 
gezien wordt. 
Hoofdstuk 6 
Actief leiden van het derde tijdperk met orale ergometrine maleaat 0,4 mg 
werd vergeleken met het expectatieve beleid ter controle van het bloedverlies 
in het derde tijdperk van de bevalling van vrouwen met een laag risico op het 
ontwikkelen van haemorrhagia postpartum (HPP). 
De studie werd opgezet als een drie-armige gerandomiseerde trial, waarbij 
0,4 mg ergometrine maleaat (2 tabletten à 0,2 mg) werd vergeleken met een 
placebo en deze beide groepen een vergelijk mogelijk maakten met de 
standaard medicatie Oxytocine 5 IU intramusculair. 
Van de 367 deelneemsters werden 146 gerandomiseerd voor ergometrine 
maleaat 0.4 mg, 143 voor placebo en 78 voor intramusculaire Oxytocine in een 
2:2:1-design. Vergeleken met placebo, reduceerde ergometrine het bloedverlies 
met 5% (-5%; betrouwbaarheidsinterval: -20% tot +13%) Oxytocine 
reduceerde het bloedverlies met 9% (-9%; Betrouwbaarheidsinterval: -26% tot 
+ 12%) ten opzichte van placebo. 
Conclusie Orale ergometrine heeft een te gering effect op het bloedverlies 
postpartum om een goed alternatief te zijn voor profylactisch parenteraal 
beleid. 
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Resumerend 
• Primaire preventie van HPP wordt op elk niveau van verloskundig zorg 
bepleit. Dit impliceert actief beleid van het derde tijdperk in de eerste lijn 
en de meest perifere niveaus van obstetrische zorg, waar toegang tot 
ziekenhuis faciliteiten moeizaam is. 
• Tropische omstandigheden leiden tot een instabiliteit van (methyl)-
ergometrine tabletten. 
• Farmacokinetische studies met orale (methyl)ergometrine tonen een grote 
interindividuele variatie in biologische beschikbaarheid aan voor zowel 
mannen als vrouwen. 
• Orale toediening van methylergometrine gaf een onvoorspelbaar effect op 
uterusactiviteit, mogelijk door een inefficiente biologische beschikbaarheid. 
• Orale ergometrine heeft een te gering effect op het bloedverlies postpartum 
om een goed alternatief te zijn voor de momenteel gebruikte profylactische 
parenterale medicatie. 
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Conclusies 
Orale (methyl)ergometrine is geen alternatief voor parenteraal toegediende 
profylactische oxytocica in het actieve beleid van het derde tijdperk, door 
aangetoonde instabiliteit, onvoorspelbare farmacokinetische en farmacody-
namische eigenschappen en door afwezigheid van klinisch effect. De negatieve 
resultaten van de studies afzonderlijk versterken elkaar alleen nog maar in 
deze conclusie. Het heeft namelijk geen zin de stabiliteit van een middel te 
verbeteren als de farmacokinetiek te wensen overlaat. Temeer nu blijkt dat de 
tabletten ook niet het klinisch beoogde effect geven. 
Door de geschiedenis heen staan de ergot alkaloïden bekend als zeer 
krachtige middelen. Heden ten dage kunnen de bijwerkingen van 
(methyl)ergometrine nog steeds zeer ernstig zijn. Vanuit het medisch adagium 
"Primum non nocere", is het gebruik van ergot alkaloïden als profylactisch 
middel discutabel. 
Misschien is het tijd om orale ergometrine te schrappen uit het medisch 
verloskundig arsenaal? 
Helaas is er nog steeds geen geschikt alternatief voor gebruik in het nage-
boortetijdperk voor vrouwen in ontwikkelingslanden. Onderzoek naar 
eenvoudige alternatieven zal gecontinueerd moeten worden. Anders zal 
moedersterfte een catastrofaal probleem blijven, dat dagelijks 1.500 levens 
kost. 
De conclusie van de gehele studie is tweeledig: 
• Er is nog steeds geen eenvoudig alternatief voor het gebruik van Oxytocine 
bij het aktief leiden van het nageboortetijdperk. 
• (Methyl)ergometrine tabletten voldoen vanwege onvoorspelbare stabiliteit 
en ongunstige farmacokinetische eigenschappen niet aan de huidige 
farmaceutisch eisen. 
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Appendix 1. Tables concerning chapter 4: Pharmacokinetics 
Table IV.l.a Demographic data of six male volunteers for ergometrine 
Subject 1 
age (years) 
weight (kg) 
height (cm) 
BP' (mmHg) 
33 33 45 41 50 46 
73 70 72 67 79 73 
181 184 178 175 173 183 
120/70 120/80 120/80 125/88 120/82 125/80 
'BP = blood pressure 
Table IV.l.b Demographic data of six male volunteers for 
methylergometrine 
Subject 
age (years) 
weight (kg) 
height (cm) 
BP" (mmHg) 
1 
24 
75 
180 
120/80 
2 
53 
79 
173 
120/80 
3 
27 
79 
194 
125/80 
4 
49 
73 
183 
120/88 
5 
26 
72 
173 
110/70 
6 
35 
70 
184 
120/70 
*BP = blood pressure 
Table IV. 1.с Demographic data of six female volunteers for 
methylergometrine 
Subject 
age (years) 
weight (kg) 
height (cm) 
BP' (mmHg) 
1 
45 
61 
162 
100/60 
2 
47 
70 
172 
120/80 
3 
32 
60 
165 
130/75 
4 
39 
65 
176 
110/75 
5 
43 
55 
156 
110/65 
6 
41 
52 
171 . 
115/70 
"BP = blood pressure 
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Table IV.2.a Pharmacokinetic parameters of ergometrine after an intravenous dose of 
0 055 mg (base) in six male volunteers 
Subject 
Ί 2a 
'l m 
MRT^ 
AUC0„ 
CL 
v
s s 
h 
h 
h 
цдЫ.' 
Lh 1 
I 
1 
0 093 
1 830 
1 986 
1 34 
35 5 
70 4 
2 
0 561 
2 180 
2 177 
1 68 
29 9 
64 8 
3 
0 080 
1 587 
1 524 
0 98 
50 4 
76 87 
4 
0016 
3 53 
4 436 
1 75 
23 0 
102 0 
5 
0 100 
2 103 
2416 
1 14 
39 7 
96 0 
6 
0 157 
4213 
4 825 
2 49 
170 
82 1 
Tabic IV.2.b Pharmacokinetic parameters of ergometrine after an oral dosis of 0 147 mg 
(base) in six male volunteers 
Subject 
Dose 
F 
llag 
с 
tabi 
MRT^ 
MAT" 
AUC„„ 
CL 
v,
s 
mg 
% 
h 
h 
μβί' 
h 
h 
h 
h 
h 
HghL' 
Lh' 
L 
1 
0 147 
116 
0 147 
0 84 
1 16 
0 18 
2 10 
3 43 
1 297 
4 17 
38 70 
1169 
2 
0 147 
54 3 
0 008 
0 11 
0 93 
0015 
1 87 
2 72 
0 593 
2 44 
30 65 
82 63 
3 
0 147 
103 8 
0 007 
1 41 
061 
0 55 
1 99 
3 66 
2 129 
2 70 
53 78 
154 5 
4 
0 147 
80 1 
0 28 
1 34 
0 99 
0 36 
1 93 
3 58 
1 136 
3 76 
29 10 
81 2 
5 
0 147 
103 6 
0 151 
0 23 
1 34 
0010 
1 66 
2 56 
0 007 
3 15 
46 10 
1101 
6 
0 147 
26 3 
0 084 
021 
1 39 
0 087 
1 92 
2 52 
2 389 
1 75 
20 8 
48 23 
not detected 
one compartment 
independent of model 
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Table І .З.а Pharmacokinetic parameters of methylergometnne (0 152 mg ι v) in male 
volunteers (Table 4 3 2-3) 
Subject 
t , 20. 
t i 2ß 
MRT1V 
AUC0„ 
CL 
vss 
h 
h 
h 
με, hL-l 
Lh-l 
L 
1 
0 076 
1 84 
2 30 
4 74 
30 4 
69 9 
2 
0 74 
1 96 
2 54 
8 11 
17 65 
44 8 
3 
0 04 
1 63 
1 87 
2 96 
49 7 
92 7 
4 
0 09 
231 
2 92 
4 07 
33 9 
99 1 
5 
0 14 
1 52 
1 70 
4 05 
21 5 
36 5 
6 
0 041 
1 88 
2 17 
3 63 
39 8 
86 1 
Table І .З.Ь Pharmacokinetic parameters of methylergometnne (0 095 mg oral) in male 
volunteers (Table 4 3 2 4) 
Subject 
Dose 
F 
^ 
г 
tabs 
tl/2a 
tl/2B 
MRT 
M A T ' 
AUC„„ 
CL 
v
ss 
mg 
% 
h 
h 
μgL·f 
h 
h 
h 
h 
h 
ц і
п Ь ' 
L h ' 
L 
1 
0 095 
103 6 
0 24 
0 99 
1 00 
0 23 
1 62 
2 91 
0 37 
3 07 
29 5 
69 1 
2 
0 095 
22 2 
0 35 
0 54 
0 50 
0 033 
1 87 
3 09 
0 20 
1 13 
14 6 
39 3 
3 
0 095 
81 9 
0 26 
0 59 
0 47 
0 06 
2 28 
3 64 
1 51 
1 52 
45 6 
153 3 
4 
0 095 
80 0 
0 32 
0 40 
0 67 
0010 
2 69 
4 22 
0 98 
2 03 
28 7 
111 7 
5 
0 095 
85 4 
0 29 
0 90 
0 65 
0 14 
2 37 
391 
1 92 
2 16 
30 5 
103 9 
6 
0 095 
136 
0 50 
0 67 
1 35 
0 03 
1 65 
2 91 
0 24 
3 10 
37 5 
89 2 
not detected 
one compartment 
independent of model 
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Table IV.4.a Pharmacokinetic parameters of methylergometrine (0 152 mg ι ν) in 
female volunteers 
Subject 
Ί 2a 
Ί 2ß 
MRT1V 
A U C 0 „ 
CL 
vSi 
h 
h 
h 
μ
Ε
Η ί ' 
L h ' 
L 
1 
0 035 
2 17 
2 67 
5 86 
22 7 
60 6 
2 
0 13 
1 66 
2 12 
5 30 
26 6 
56 5 
3 
0 10 
2 14 
2 80 
681 
176 
49 4 
4 
0 12 
2 38 
2 55 
5 97 
20 5 
52 1 
5 
0 14 
1 52 
1 70 
6 72 
21 5 
36 5 
6 
0 077 
1 78 
2 04 
5 43 
24 2 
49 4 
Table IV.4.b Pharmacokinetic parameters of methylergometrine (0 095 mg oral) in 
female volunteers 
Subject 
Dose 
F 
ti* 
с 
'abs 
t|/2a 
11/2Ι> 
MRTp, 
MAT" 
AUC 0„ 
CL 
v„ 
mg 
% 
h 
h 
μ g L , 
h 
h 
h 
h 
h 
ц
ё
Ь Ь ' 
L h 1 
L 
1 
0 095 
98 6 
0 063 
1 88 
0 76 
1 26 
1 26 
3 70 
0 967 
361 
25 0 
45 
2 
0 095 
138 
0 14 
1 25 
1 36 
0 49 
1 29 
2 71 
0 45 
4 39 
28 6 
53 0 
3 
0 095 
73 1 
0 11 
0 64 
1 28 
0 14 
1 54 
2 55 
0 36 
3 11 
19 3 
42 9 
4 
0 095 
63 0 
0 17 
0 25 
1 05 
0010 
1 96 
3 00 
0 28 
2 36 
199 
56 2 
5 
0 19 
90 5 
0016 
0 12 
3 83" 
0016 
1 40 
2 06 
0 344 
7 61"" 
21 1 
42 7 
6 
0 19 
115 
0 119 
1 65 
1 91" 
1 06 
1 06 
3 19 
1 031 
7 81«" 
27 5 
42 2 
For abbreviations see chapter 4 
one compartment 
model independent 
" "" corrected for the dose 
not delected 
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Appendix 2. Tables concerning chapter 5: pharmacodynamics 
Table V.l.a Pharmacokinetic parameters of methylergometnne maléate (0 2 mg ι ν") in 
='v females six 
Subject 
' l 2α 
' l 2ß 
MRTIV 
AUC0œ 
CL 
ν« 
h 
h 
h 
μ 8 Γ . υ 
L h ' 
L 
0 035 
2 17 
2 67 
5 86 
22 7 
60 6 
0 065 
1 61 
1 95 
611 
24 87 
48 6 
0 13 
2 14 
2 80 
681 
176 
49 4 
0 10 
2 38 
2 55 
5 97 
20 5 
52 1 
0 061 
1 69 
1 96 
6 90 
22 04 
43 14 
0 14 
1 78 
2 04 
5 43 
24 2 
49 4 
Table V.l.b Pharmacokinetic parameters of methylergometnne maléate (0 2 mg ι ν) in 
four females 24h after the oral (0 5mg ME) test 
Subject 1 
t.>« 
t|/20 
MRT]V 
AUC 0„ 
CL 
V« 
h 
h 
h 
ц е
ь ь ' 
L h ' 
L 
0 065 
2 29 
2 16 
3 72 
34 1 
73 1 
0 047 
1 79 
2 10 
8 48 
17 93 
37 65 
0 064 
2 22 
2 92 
105 
14 44 
42 12 
0 034 
1 27 
1 58 
5 17 
29 41 
46 40 
Table V.l.с Pharmacokinetic parameters of methylergometnne (0 380 
substance) in woman 
mg oral pure 
Subject 
Dose 
F 
' lat 
с 
'abs
 t 
'ΐ/2α 
Ί/2Β 
MRT,,, 
MAT" 
AUC 0„ 
CL 
v. 
mg 
% 
h 
h 
H g L ' 
h 
h 
h 
h 
h 
M g h L ' 
L h ' 
L 
0 380 
75 4 
0 32 
1 12 
2 04 
0 24 
1 73 
3 17 
1 01 
7 00 
40 85 
102 2 
0 380 
89 9 
0 16 
0 24 
6 12 
0010 
1 97 
3 01 
1 06 
156 
192 
54 4 
0 380 
92 6 
031 
0 80 
6 38 
0 15 
1 10 
2 11 
0 44 
13 82 
25 47 
40 41 
0 380 
47 7 
0 39 
0 45 
2 75 
0 007 
1 63 
2 75 
0 79 
5 45 
27 5 
64 4 
0 380 
60 0 
0 28 
4 46 
4 13 
4 24 
421 
12 48 
9 68 
10 22 
3 12 
19 0 
0 380 
94 6 
0 43 
2 94 
4 98 
1 73 
1 73 
5 44 
3 40 
11 76 
10 54 
26 88 
one compartment," model independen! ' " absorption too long outliers9, 
• · not detected For abbreviations see chapter 5 
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Stellingen 
behorende bi| het proefschrift 
"Safe motherhood - the role oí oral (methyl)ergomelnne 
in the prevention of postpartum haemorrhage" 
A N J A de Groot 
1 Het derde tijdperk moet actief geleid worden, tenzij tweede-lijns 
zorg binnen 20 minuten bereikbaar is (dit proefschrift) 
2 Ondanks het adagium in de geneeskunde "pnmum non noccre" is 
intraveneuze (methyl)ergometrine met haar mogelijk incidenteel 
dodelijke bijwerkingen nog steeds als profylactisch geneesmiddel 
geregistreerd (dit proefschrift) 
3 Glucuronidase is een aannemelijke metabole route van 
(methyl)ergometrine (dit proefschrift) 
4 (Methyl)ergometrme lijkt zijn werkzaamheid uil te oefenen via een 
nog onbekende receptor op het archemyometnum (dit proelschnfl) 
5 Na een eerste dosering (mcthyl)ergometrine lijkt de receptor 
ongevoelig te worden voor een tweede dosering (dit proefschrift) 
6 Nederland blijft een unieke locatie vanuit mondiaal verloskundig 
perspectief (dit proelschrift) 
7 Objectieve beoordeling van wetenschappelijk versus ethisch belang 
is essentieel voor wetenschappelijk onderzoek 
8 Patiënt-gebonden onderzoek dient te volgen op onderzoek bi| 
vrijwilligers, waarbij de hoofdonderzoeker de eerste proefpersoon 
behoort te zijn 
9 Goed klinisch onderzoek vraagt een leger van doorzetters 
10 If you steal from another, it*s plagiarism, il you steal from many 
it is research (Wilson Mizner) 
11 Soms 1 ij let promoveren sneller te gaan dan het behalen van een 
golfvaardigheidsbewijs 
12 Eskes knipt navelstrengen door maar knoopt enkele later weer aan 
onderzoek vast 



